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Based on statistics from the World Health Organization, cancer is among the top killers 
in the world. Metastasis, which is the process of cancer cells leaving their primary location and 
forming secondary tumor(s) in remote places in the body, is responsible for the majority of 
cancer-related deaths. The current anti-metastasis treatments are rarely effective, therefore, this 
dissertation aims at developing new techniques of using gold nanoparticles (AuNPs) for cancer 
treatments and inhibiting metastasis. Chapter 1 introduces the general background of gold 
nanoparticles including their synthesis, physical and optical properties, their usage in cancer 
treatment and their biocompatibility. In Chapter 2, we introduce the AuNPs to cancer cells, and 
use their optical properties as sensing and imaging probes in order to study their impact on 
cancer cells for diagnosis and treatment. Chapter 3 focuses on the impact of AuNPs on the 
mechanical properties of cancer cells for inhibiting cancer cell migration and invasion. Chapter 
4 studies the molecular mechanism of AuNPs treatments in inhibiting cancer cell migration and 
invasion. After studying the AuNPs impact on cells, the purpose of Chapter 5 is to check the 
feasibility of utilizing AuNPs treatments for the inhibition of cancer metastasis in animals. This 
work differs from the previous studies in two major aspects: 1) Rational designs of AuNPs to 
achieve high specificity for inhibiting cancer cell migration and invasion, with a greatly reduced 
effective AuNP concentration to enhance biocompatibility; 2) Use of state-to-the-art high 
resolution microscopy imaging techniques and systematic mass spectrometry-based proteomics 
to gain deep understanding of the underlying principles involved. Biomechanical properties 





Recent advancements in nanomedicine provide new opportunities to avoid some 
drawbacks of commonly used cancer drugs. Due to their unique properties, nanoparticles can 
cross biological barriers, enter targeted cells with high selectivity, and function inside cells in a 
controlled manner. Nanoparticles have shown promise as anti-metastasis drug delivery vehicles 
targeting invasive or metastatic cancer cells, and they could function as anti-metastatic drugs 
even without drug loading. The photothermal, optical and mechanical properties of gold 
nanoparticles (AuNPs), as well as their excellent biocompatibility, make them very useful in 
cancer treatment. Several groups have studied and observed the AuNPs’ effect in attenuating 
cancer metastasis, however, the development of the AuNPs for effective anti-metastasis effect 
and the mechanism of how AuNPs treatments inhibit cancer cell migration remains largely 
unexplored. Therefore, this dissertation is devoted to develop effective therapeutic treatment for 
cancer and inhibiting metastasis using AuNPs, and to address some fundamental questions of 
how AuNPs inhibit metastasis.  
1.1 Introduction of Gold Nanoparticles  
Gold has been a mainstay of science and technology for thousands of years. Gold is a 
rather non-reactive metal, but when the size is reduced to the nanometer scale, its properties 
completely change due to the drastic changes in its electron behavior at this length scale [1]. 
Colloida AuNPs are one of the most stable nanoparticles and present fascinating properties. The 
use of AuNPs possibly dates back to the 4th or 5th century B.C. in Egypt and China for 
decoration and medical treatment purposes [2]. One famous example in history is the Roman 
Lycurgus Cup, which appears green when exposed to reflected light and red to transmitted light 
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due to the unique properties of AuNPs embedded within the glass. In a well-known lecture by 
Faraday in1857, a ruby solution of colloidal gold was prepared by reduction of ionic gold in an 
aqueous solution, and the interaction between AuNPs and light was explored [3]. In the last 
decade, various methods have been developed for synthesizing AuNPs with different shape and 
sizes and their optical properties have been extensively explored [4-7]. With the development of 
gold nanotechnology, AuNPs play important roles in a wide range of fields, from catalysis and 
energy to biology and medicine [6, 8-10].  
    The unique properties of AuNPs originate from surface plasmon resonance (SPR). 
When light is applied to AuNPs at the specific wavelengths, electrons begin to oscillate in 
resonance with the frequency of light due to the interaction between the electromagnetic field of 
light and the conduction electrons of AuNPs [11]. The SPR gives AuNPs unique optical properties 
including their large absorption and scattering cross-sections. The SPR wavelengths of AuNPs 
are dependent on their size, shape, and local dielectric surroundings. In addition, AuNPs can be 
easily surface-modified with proteins, peptides, oligonucleotides, and many other compounds, 
while still maintaining their optical properties. The easy surface modification of AuNPs enables 
their targeting of specific subcellular locations [12]. Furthermore, one of the greatest attributes of 
AuNPs that has set them above their metallic particle counterparts is their chemical inertness, 
and it is because of their low toxicity that AuNPs are often used in biological systems. The above 
properties, including plasmonic properties, targeting, and bio-compatibility have turned AuNPs 
into incredibly useful nanomaterials with a wide range of chemical and biological applications [13, 
14]. 
1.1.1 Synthesis of Gold Nanoparticles 
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AuNPs can be prepared by either “top down” or “bottom up” methods. A “top down” 
method is a procedure that Au bulk is broke down produce AuNPs with the desired sizes and 
shapes. On the other hand, a “bottom up” method is a procedure that AuNPs form from 
individual molecules, by reduction of Au precursor ions. The “bottom up” methods are the most 
popular methods for AuNPs preparation. In “bottom up” methods, the Turkevich method that 
prepares citrate-stabilized AuNPs are the most commonly recognized, which was introduced by 
Turkevich in 1951 [15]. In this reaction, the HAuCl4 solution is boiled, then the sodium citrate 
solution is quickly added. A wine-red colloidal gold nanosphere suspension is obtained after few 
minutes. By tuning the ratio of HAuCl4 and sodium citrate, different sizes of gold nanospheres 
can be prepared (15-150 nm) [16]. 
To prepare non-spherical (shape controlled, anisotropic) AuNPs, selective growth on 
specific facets are required. The most common strategy of synthesizing shape controlled AuNPs 
is based on “seed-mediated growth” [17] through a two-step process. In the first step, small Au 
seeds (1-5 nm) are generated in a condition of high chemical supersaturation, which leads to 
fastest nucleation rate to ensure the growth of all crystal facets. In the second step, the reaction 
conditions are altered to ensure the specific growth in certain facets, with templating molecules 
and much milder reduction condition, therefore the seeds can grow to large anisotropic AuNPs. 
Gold nanorods (AuNRs) draw increasing attention due to their tunable plasmonic 
propertities, which make them ideal candidates for multiple applications such as solar harvesting, 
spectroscopy and microscopes, sensing and therapies. AuNRs synthesis is one of the most 
mature and established protocol among all of the anisotropic AuNPs.  The most successful 
strategy is using a seed-mediated , wet chemical synthesis method (firstly developed by Murphy 
lab [18]), with the presence of cetyl trimethylammonium bromide (CTAB) which forms the rod-
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shaped micelles [19] and Ag+ that leads to an increase of  AuNRs yield and improves upon the 
control of the aspect ratio [17]. This method has been modified by our lab for extremely high yield 
of AuNRs (can reach 99%) by using CTAB-capped Au seeds, with the addition of  AgNO3 
[4]. In 
addition, we have developed a synthetic route for small AuNRs, a method that produces efficacy 
in heat conversion and photothermal effect [7]. 
1.1.2 Physical and Optical Properties of AuNPs 
In a metal, such as gold, the electrons are highly delocalized over the space, giving the 
metal the property of conductivity. When we decrease the size of a noble metal below the free 
electron path, the movement of the electrons are confined. In the presence of light (which is an 
oscillating electromagnetic field), the free elections of the metal nanoparticles will oscillate. This 
process is resonant at a particular wavelength of the light, which is termed from surface plasmon 
resonance (SPR, Figure 1.1). The surface plasmon oscillation decays through radiating ways by 
scattering light or non- radiating ways such as conversion to heat. Therefore, the AuNPs can act 
as excellent optical probes or an effective heat generator.  
The SPR of AuNPs can be tuned by changing the size, shape, composition and the 
dielectric constant of the environment. Spherical Au NPs have their SPR peak at about 520-540 
nm. The gold nanorods possess two SPR peaks, the transverse and the longitudinal. The 
transverse SPR peak locates at around 520 nm (Figure 1.1). The longitudinal SPR of gold 
nanorods changes from visible to near infrared (NIR) due to the change of aspect ratio (length of 
a rod divide by its width), as shown in Figure 1.2. 
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FIGURE 1.1. Gold nanoparticle and light interacting: surface plasmon resonance (SPR). 





FIGURE 1.2 Tunability of the SPR of AuNRs. (a-f) TEM images of AuNRs with different 
aspect ratios (length of a rod divide by its width). Reprinted with permission from [4]. 
Copyright 2006 American Chemical Society. (g) Tuning longitudinal SPR by synthetically 
controlling aspect ratio. Reprinted with permission from [20]. Copyright 2006 American 
Chemical Society 
AuNPs can act as excellent optical probes. AuNPs can be readily used to enhance optical 
imaging based on their absorption, scattering, fluorescence, Raman scattering, etc. The scattering 
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signal from AuNPs is usually much stronger than the scattering background from cells and 
tissues, making dark field (DF) microscopy a viable choice for reporting the existence of AuNPs 
within biological systems. A useful by-product of AuNP light scattering is the enhanced Raman 
signals for molecules [21]. AuNPs can greatly enhance the Raman signal of a molecule. The 
surface-enhanced Raman scattering (SERS) obtains more than 10 orders of signal enhancement, 
allowing for ultra-sensitive single molecule level detection (down to 10–15 M). 
In addition, the non-radiative properties of AuNPs have shown great potential in plasmonic 
photothermal cancer therapy. It is reported that gold nanospheres about 40 nm size absorb light 
105 times stronger than most strongly light-absorbing dye molecules [1]. The light absorbed  by 
nanoparticles with specific shape and size can be converted into non-radiative heat with very 
high efficiency and speed [22]. A previous study done by our lab regarding the photothermal 
process has revealed that photoexcitation of metal nanostructures can generate a heated electron 
gas that can quickly cool within ∼1 ps via transfer energy to the nanoparticle lattice, which could 
then exchange energy with the surroundings on a time scale of ∼100 ps [23, 24]. The SPR greatly 
enhanced the photothermal effect of AuNPs, by a few orders of magnitude in a short time. 
Therefore, if AuNPs are attached to or inside cancer cells and exposed to light, intensive heat can 
be generated to destroy the cells. Compared with conventional dyes absorbers, the AuNPs are 
more effective and stable without exposing them to photobleaching.  
1.2 Gold Nanoparticles for Cancer Treatment 
1.2.1 Plasmonic Photothermal Therapy  
The fact that gold is chemically inert, relatively resistant to bacteria, and biocompatible 
has made it a prime candidate in this quest to improve the human condition by finding more 
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effective ways to treat patients. There is evidence that gold was used in dental repairs over 4000 
years ago[25]. Throughout history, gold has been added to medicine to treat diseases, a practice 
demonstrated by the use of gold cordial that was used for treating ailments caused by a decrease 
in the vital spirits (melancholy, fainting, fevers, etc), by the application of or a mixture of gold 
chloride and sodium chloride to treating syphilis [26]. More recently, Robert Koch, a German 
bacteriologist, discovered that the presence of gold in compounds, specifically gold cyanide, 
inhibited the growth of tuberculosis causing bacteria in 1890, and a French scientist Jacques 
Forestier, is credited with the discovery of the anti-inflammatory properties of gold compounds 
and the manipulation those properties using them in drugs to treat rheumatoid arthritis in 1929. 
[27] Also, the qualities of gold have deemed it a great choice of metal for surgical implants and 
for wires in pacemakers or stents.  
Since its ancient usage in 1700 BC, heat has demonstrated its ability for tumor therapy 
when the glowing tip of a fire was used for treating breast cancer [28]. Photothermal therapy is a 
minimally-invasive therapeutic strategy in which photon energy from light is converted into heat 
in order to destroy cancer cells. It could avoid the severe infection complications commonly 
encountered after surgery [29], and circumvent the side effects from using toxic drugs in 
chemotherapy. Heating sources including NIR or visible light, the magnetic field, radiofrequency 
waves, microwaves, and ultrasound waves are used to induce a moderate temperature rise,  
clinically termed as hyperthermia, in a specific target region to destroy the cancer cells [30]. Due 
to the low absorption efficiency of natural tissue absorbents, photo sensitizers such as synthetic 
organic dye molecules indocyanine green and porphyrins coordinated with transition metals are 
externally injected into the tumor sites to enhance the photothermal effects when NIR light is 
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used [31]. However, the dye molecules photo bleach quickly, rendering insufficient therapeutic 
outcomes. 
As mentioned in Section 1.1, the non-radiative properties of AuNPs have shown great 
potential in plasmonic photothermal cancer therapy (PPTT). Currently, AuroLase® therapy, a 
type of  PPTT based on 150 nm silica-gold nanocoreshells (AuNCSs) coated with polyethylene 
glycol (PEG) that absorbs NIR light, was developed by Nanospectra Biosciences, Inc., and has 
been under clinical trials (ClinicalTrials.gov Identifiers: NCT00848042 for refractory and/or 
recurrent tumors of the head and neck (2008-2014), NCT01679470 for metastatic lung tumor 
(2012-2014), and currently recruiting clinical NCT02680535 for localized prostate cancer (2016 
until now)). The clinical trials of AuroLase® is based on intravenous (i.v.) injection of AuNCSs 
in the blood, and their accumulation inside tumors via the enhanced permeability and retention 
(EPR) effect due to leaky and poorly organized tumor blood vessels.  Prior to human clinical 
trials, PPTT using AuroLase® was performed in treatment of brain tumors in orthotopic canine 
model, tumor ablation was observed after PPTT (Figure 1.3 a and b)[32]. 
In addition, studies of gold nanorods (AuNRs) have been applied the treatment of 
spontaneous tumors in canine and feline patients. Cancer is very common in cats and dogs. It is 
estimated that 23% of all dogs [33] die of cancer and  the percentage of feline deaths due cancer is 
half of canine  [34]. In general, dogs and cats develop similar cancers very analogous to those in 
humans [34], such as mammary gland tumors [35]. Ali et al has performed several studies on 
treating spontaneous mammary gland tumors on cats and dogs by directly inject AuNRs to solid 
tumor (intratumoral injection, i.t.), followed by NIR irradiation. After three sessions of 
treatments, efficient tumor regression for all cases was achieved with no recurrence and 
metastasis without toxicity effects on blood profile, or liver and kidney functioning afterwards 
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(Figure 1.3 c) [9] . Abdoon et al also conducted similar studies on dogs and cats with mammary 
gland tumors. Their results showed that the treated animals had complete remission (62.5% 
(10/16)), partial remission (25% (4/16)) and no response (and 12.5% (2/16)), respectively 
(Figure 1 d) [36]. The two groups’ difference of the conditions is that Ali et al have developed 
gentle conditions to trigger apoptosis, while Abdoon et al relied on heating up the tumor harshly.  
London and coworkers used AuNRs-PTT and applied it for treating spontaneous neoplasia in 
dogs (carcinoma, sarcoma or mast cell tumor). The AuNRs were injected intravenously to seven 
canines 72 hours before using a 30 W 808 nm NIR laser to irradiate the tumor mass. At study 
end, partial or complete remission of tumors was observed and the overall response rate was 








FIGURE 1.3. (a-b) AuroLase® treatment of canine transmissible venereal tumor in brain 
of a dog. MR-DCE axial images of dog brain showing contrast enhancement of bilobed 
tumor (a) before and (b) ablation of tumor after treatment. Reprinted with permission 
from ref [32]. Copyright 2009 American Association for Cancer Research. (c) Our study 
showed the tumor regression curves from 13 mammary gland tumors in cats and dogs with 
variable volumes under multiple PPTT treatments using gold nanorods. Reprinted with 
permission from ref [9]. Copyright 2016 Dove Medical Press. (d) Abdoon et al’s study 
showing the efficacy of PPTT on 16 dogs and cats with mammary tumors using gold 
nanorods. Reprinted with permission from ref [36]. Copyright 2016 Elsevier. 
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Advantages and disadvantages of PPTT and types of cancer PPTT has been performed 
AuNP-assisted PPTT offers obvious advantages over many other types of cancer treatments. 
First, AuNPs-assisted PPTT avoids the systemic side effects associated with traditional cancer 
therapies, such as chemotherapy. The treatment is mainly designed for localized solid tumors, 
with almost no damage to healthy tissues. Second, since PPTT is a physical treatment, there is no 
restriction on the types of tumors to be treated. As usually different cancer types have their 
specific chemotherapy drugs, and many cancers develop resistance to particular drugs after a 
certain time period, however, PPTT could be a “universal” treatment for many types of cancer. 
In spite of the many advantages stated above, AuNP-assisted PPTT presents its unique 
challenges. The first issue is the biological fate of AuNPs, especially in the long-term. The 
potential applications for AuNPs are endless, but their applications in nanomedicine are 
dependent upon their toxicity level. Despite the evidence that AuNPs are biocompatible and 
chemically inert, there have also been studies with contradictory results[38]. However, for many 
cases, the toxicity does not come from the AuNPs, but from the non-biocompatible surface 
ligands [39], the high power of laser [40], or the high treatment dose of AuNPs [41, 42]. AuNPs 
accumulate mainly in liver and spleen. Many studies, however, have shown that their negative 
effect is negligible in the aforementioned organs [40, 43]. The second issue is the inconsistency of 
the treatments due to different laboratory variables such as lab personnel, types of AuNPs, 
surface modifications, laser dosage, different handling, etc. These inconsistencies will result in 
different results, which are sometimes account for high variations of PPTT. The third issue is 
that PPTT is largely limited to treating localized solid tumors. For cancers that are not localized, 
or advanced metastatic cancers, the effectiveness of PPTT might be greatly impaired. Despite 
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this, the recent advances of PPTT show the feasibility of it preventing and inhibiting cancer 
recurrence and metastasis [44]. 
Types of tumors for PPTT treatment. Due to the nature of the PPTT, localized solid 
tumors are more suitable for treatment. The PPTT has been performed in various cancer types, 
including breast[45, 46], head and neck[40, 47], [48], melanoma[49, 50], lung (ClinicalTrials.gov 
Identifiers NCT01679470), prostate (ClinicalTrials.gov Identifiers NCT02680535), liver[51], etc.  
    Gold nanoparticle types for photothermal therapy. The AuNPs that enable the 
photothermal effect generated with NIR light are more often used in photothermal therapy. NIR 
light exhibits wavelengths between 750- 1700 nm (first window NIR-I, 750-1000 nm; NIR-II, 
1000-1700 nm [52]), where the water absorption is minimal and light can deeply penetrate the 
tissues in order to reach the tumor area (several cm of tissue). Spherical Au NPs have their show 
a SPR peak at about 520-540 nm. Several Au nanostructures that absorb NIR light have been 
reported, with structure including Au nanorods [20], Au nanoshell [53] , Au nanocages [54] and Au 
nanostars [55]. It has be recently found that, other shapes of AuNPs also exhibit photothermal 
capability, such as Au bipyramids[46], Au nanoprisms [56], Au nanorings[57], and AuNP assemblies 





FIGURE 1.4. The most frequently used Au nanoparticles in photothermal therapy. 
Reprinted with permission from [59]. Copyright 2017 Wiley. 
1.2.2 AuNPs in Inhibiting Cancer Metastasis  
Metastasis enables cancer cells to migrate to distant secondary sites, which is responsible 
for 90% cancer-related deaths [60-62]. Metastasis is a multi-step process where the primary cancer 
cells migrate and invade locally, the intravasate and circulate in blood or lymphatic vessels, and 




FIGURE 1.5. A scheme of the metastatic cascade. A to F describes the process of metastasis. 
Cancer cells inside the primary tumor adopted an invasive phenotype, then locally invade 
into the surrounding stroma and reach blood vessels, enter the blood circulation (the 
cancer cells traveling in the circulation are called circulating tumor cell (CTCs), and finally 
reach the secondary site and colonize there  Reprint from reference [63].  Copyright 2011 
American Association for the Advancement of Science. 
The migration of cancer cells from one site to another requires dramatic remodeling of 
the cellular cytoskeleton[61, 62, 64, 65]. The process of cell migration can be described by four steps: 
protrusion, adhesion, contraction and retraction (Figure 1.6). The cell migration is initiated by 
polarization and extension of actin protrusions. To stabilize the protrusions, the cells generate 
adhesions which link the actin cytoskeleton to the extracellular matrix (ECM). The adhesions at 
the rear of the cell then disassembly and allow the retraction of the cell body forward [66]. Studies 
on the changes of cytoskeletal components could provide novel therapeutic approaches to 




FIGURE 1.6. The cell cytoskeleton and four steps of cell migration: protrusion, adhesion, 
contraction, retraction. Reprint from reference [66]. Copyright 2014 Wiley. 
Past attempts to develop anti-metastasis drugs have not been efficacious in clinical trials [67]. 
Moreover, in many cases, the anti-cancer drugs that target specific proteins might lose their 
efficacy after several months of treatment due to mutations of the proteins that result in the rise 
of drug resistance in cancer cells [68].  Recent advances in nano-medicine provide us with great 
opportunities to avoid the drawbacks of commonly used drugs [69, 70]. Nanoparticles are able to 
target tumors selectively [71], a lot of studies showed that nanoparticles are helpful for cancer 
diagnosis , therapy [72], and  recent discovery of their  effect on inhibiting cancer cell migration 
and/or metastasis [73-76] . AuNPs, especially, have been widely used in these studies, due to their 
unique physical, chemical properties, easy surface modification and good biocompatibility. 
Figure 1.7 shows the numbers of publications and citations related to AuNPs inhibiting 
metastasis, an area of research that started to emerge in the last decade (reach nearly 85 





FIGURE 1.7. Total publications (left) and citations (right) per year till the end of 2018, of 
the topic “AuNPs inhibit metastasis”. The figure reference to Web of Science search key 
words “gold nanoparticles” and “metastasis”.  
Generally, there are mainly three strategies for using AuNPs for inhibiting metastasis: 1) 
AuNP-based drug delivery system which delivers chemo-drugs, antibodies or siRNA to invasive 
cancer cells, cancer stem cells and tumor microenvironment (TME, since metastasis only occurs 
in a “supportive” TME, the perturbation of TME could be a good strategy for inhibiting 
metastasis), 2) the using of AuNPs itself without any drugs to inhibit metastasis, and 3) the 
combining AuNPs with near infra-red light to generate the photothermal effect in order to inhibit 
metastasis.  In the first strategy, AuNPs are usually conjugated with drugs used for targeting and 
treating invasive or metastatic cancer cells. Peptides have been used for targeting of metastatic 
breast cancer; including RGD peptides (for targeting integrin), [77] and tumor metastasis targeting 
(TMT) peptide have been used for targeting of metastatic breast cancer [78]. Beside targeting and 
treat invasive cancer cells, targeting cancer stem cell [79, 80], inducing angiogenesis [81, 82], and 
altering the tumor microenvironment [83]  could also achieve inhibiting effects on metastasis.   
   In the second strategy, AuNPs have recently shown their own ability to inhibit 
metastasis even without drug loading. AuNPs could inhibit the motility of cancer cells [84-86], 
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induce anti-cancer immune response for effective cancer therapy [87], or modulate the tumor 
microenvironment and blood vessel components [88, 89]. In 2013, Arvizo et al. reported that non-
specifically targeted AuNPs could inhibit tumor growth and metastasis by abrogating MAPK 
signaling and reversing the epithelial-mesenchymal transition. Murphy et al. reported that 
AuNPs with different surface charges and sizes can affect cancer cell migration [73]. In the same 
year, Zhou et al. showed that AuNRs coated with bovine serum albumin (BSA) exhibited 
reduced cell migration and invasion by impairing ATP synthesis, which subsequently inhibits F-
actin cytoskeletal assembly and decreases the metastatic ability of the tumor [76]. However, for 
most of the previously mentioned works, non-specific targeted nanoparticles were used. For 
instance, Zhou et al.[76] used BSA coated AuNRs that showed inhibitory effects on cancer cell 
migration, but the high concentration of AuNRs (50-200 µM) used might be an obstacle for 
clinical usage. Our lab recently discovered that nucleus-targeting of gold nanoparticles (AuNPs) 
could stimulate the overexpression of Lamin A/C, thus increasing nuclear stiffness, and greatly 
decreasing cancer cell motility (Figure 1.8). The nucleus-targeting AuNPs decrease the dose to 




FIGURE 1.8. Nuclear targeting AuNPs increase nuclear stiffness and Lamin A/C 
formation, and inhibit the ovarian cancer cell migration and invasion. Reprinted with 
permission from ref [90]. Copyright 2017 American Chemical Society.  
The third strategy is using AuNP-assisted plasmonic photothermal effect to inhibit 
metastasis. PPTT has been reported by many studies for its ability to inhibit metastasis. During 
our previous studies, we observed animals with induced or spontaneous tumors were effectively 
cured, interestingly, with no metastasis [9]. PPTT can be used to eliminate primary cancer cells 
and treat the local metastasis in lymph node [91]. Burke et al reported that the breast cancer stem 
cells, which are persist to many chemo treatment and drive tumor recurrence and metastasis, are 
sensitive to NPs-mediated PTT and lost their long-term proliferative ability[92].  Li and coworkers 
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fabricated deep tumor-penetrating polymer nanotherapeutics that loads a NIR probe for 
photothermal therapy. Although AuNPs they didn’t use AuNPs in their study, their platform 
showed inhibition of tumor growth and metastasis of breast cancer by photothermal therapy, as 
the metastasized cells decreased greatly in the lung[93].  
Although the phenomena that PPTT could inhibit metastasis is starting to uncovered by 
many animal studies, the mechanism is barely understood. Our results showed that integrin-
targeting AuNP-PPTT can cause cytoskeleton remodeling by affecting Rho GTPase and other 
pathways, causing the decreasing of cancer cell motility [10]. In addition, we also studied the 
effect of the same treatment on collective cell migration by phosphoproteomics and high-
resolution imaging, which reveals impaired cell junctions and actin cytoskeleton[94].  
Besides using this strategy alone, PPTT can also be combined with other therapies such 
as chemotherapy and radiotherapy in order to inhibit metastasis. One reports that combining 
chemotherapy and photothermal ablation using doxorubicin-loaded DNA wrapped AuNRs , 
which suppresses lung metastasis in an orthotropic 4T1 mammary tumor model[95]. In addition, 
the same group developed gold-coated nanocages, which loaded DOX, and used hyperthermia to 
trigger drug release for anti-metastasis purpose. This caused an obvious decrease in the number 
of pulmonary metastatic nodules [96]. In addition, Atkinson et al reported that gold nanoshells and 
PPTT could sensitize breast cancer stem cells to radiation therapy [97].  
 




Immunotherapy emerges as a breakthrough recently for cancer treatment. Although it 
shows a great success in several clinical cases, when giving systemically, this strategy might lead 
to many unintended side effects. Nanomedicines, due to the specific properties of nanoparticles 
such as targeting specific cells, control-release of the drug loaded, etc., are promising to avoid 
the side effects, decrease the toxicity of conventional immunotherapy[98], and stimulate the anti-
cancer immunity [99]. The cargos include tumor antigens that induce response to the effective 
cells (such as CD8+ T cells and CD4+ T cells), inhibitors of immunosuppression (i.e., CTLA‐4, 
PD‐1, PD‐L1), etc. In addition, NPs enables targeted immunotherapies when pharmacologically 
incompatible. Nanoparticles can recognize specific surface receptors and then enter DCs [100]. 
After targeting DCs, Rosalia et al. observed a further boost of tumor-specific CD8+ T cells [101]. 
Therefore, the resulting cancer cell membrane-coated NPs can be used to deliver tumor-
associated antigens to antigen presenting cells [102], offering a platform for cancer 
immunotherapy. 
Multiple evidences suggest that AuNP-PPTT could be well engaged into cancer 
immunotherapy. Zhou et al prepared AuNRs conjugated with immunoadjuvant imiquimod (R837) 
[49]. Under NIR irradiation, tumors ablation and immune responses triggering was observed in 
metastatic melanoma in mice (Figure 1.9). In addition, lung metastasis and tumor recurrence 
was prevented due to the inducing of a strong long-term antitumor immunity. Liu and coworkers 
used photothermal therapy that heated tumors and stimulate DC maturation locally. It was 
synergize with anti-CTLA-4 therapy for effective inhibition of cancer metastasis in mice [103]. In 
addition, the same group adopted a nanocomposite with R837 that showed the photothermal 
ablation could generate a “vaccine-like” immune response, inflame the tumour 
microenvironment, increase pro-inflammatory cytokine and T cell infiltration. This effect can be 
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synergized with checkpoint blockades for tumor control for achieving effective treatment for 
metastatic cancer (Figure 1.10) [104]. Zhou et al combined local phototherapy and 
immunotherapy that induces a systemic immune response against primary tumors and metastases 
in pancreatic tumor model [105]. Although some studies mentioned above used other types of 
nanoparticles than gold, the concept that photothermal therapy could effectively promote 
immunotherapy are shown. 
 
FIGURE 1.9. Schematic figure of photothermal therapy using gold nanorods loaded with 
immune-adjuvant and the mechanism of antitumor immune responses in the treatment of 







Figure 1.10. (a) Bioluminescence images for tracking breast tumor and metastasis in 4T1 
mice after various treatments (conditions # 1-6). (b) Morbidity-free survival of mice with 
metastatic 4T1 tumors after various treatments. (c) Morbidity-free survival of mice with 
orthotopic 4T1 tumors with spontaneous metastases after various (10 mice per group). 
Reprinted with permission from ref [104]. Copyright 2018 Springer Nature.  
1.2.3 Biodistribution, pharmacokinetics and toxicity of gold nanoparticles  
For PPTT to be successful, ideally the AuNPs need to accumulate in the tumor. However, 
the distribution and the pharmacokinetics of AuNPs in body are largely dependent on several 
factors: size, surface coatings, and administration routes of AuNPs.  
In general, for nanoparticles that are i.v. injected, the main pathway of clearance is 
through the reticuloendothelial system (RES) via macrophages in the liver and spleen [106]. The 
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diminished interaction between nanoparticles and the RES lengthens the blood circulation time, 
which is often associated with higher intratumoral penetration [42]. Nanoparticles show tumor 
accumulation due to the enhanced permeation and retention (EPR) effect, a phenomenon directly 
related to immature and leaky tumor blood vessels. In addition, in order for nanoparticles to get 
inside the tumor, they must first cross a barrier of high interstitial fluid pressure and dense 
stromal tissues. Smaller AuNP sizes might be more beneficial for overcoming these barriers. The 
effects of size factor on toxicity, clearance routes, heat generation efficiency, blood circulation 
time and intratumoral penetration ability are summarized in Figure 1.11. The smaller AuNPs (> 
20 nm) might be beneficial. 
Higher
toxicity










FIGURE 1.11. The sizes of the AuNPs in PTT affect their biological behaviors, concluded 
from ref [1, 107-111]. 
Effect of Size and Shape on Cellular Toxicity, pharmacokinetics and Biodistribution.  
Nanoparticles display distinctive biological behavior in the body compared to small 
molecules. Smaller size enables the AuNPs to pass through the blood brain barrier (BBB, <20 
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nm) and AuNPs with sizes below 5 nm are able to clear from kidney [108]. Fraga et al.’s study 
that utilized 20 nm AuNPs showed a lack of particles in the brain at both assessed time points, 30 
min and 28 days, indicating that the AuNPs did not cross the BBB [109]. Most of the AuNPs for 
PPTT are larger AuNPs (> 20 nm) which are usually unable to pass BBB or achieve renal 
clearance, showing accumulation mainly in the liver and spleen. There is evidence that smaller 
nanoparticles are more toxic than larger ones possibly due to their higher chance in interacting 
with their surroundings and inducing greater immune responses as a result of their high surface 
area relative to their mass[112].  Pan Y et al. reported that AuNPs with a diameter of  1.4 nm are 
much more cytotoxic than 15 nm AuNPs of similar chemical composition [113]. In another study, 
Coradeghini et al. assess the colony forming efficiency of Balb/3T3 mouse fibroblast cells 
incubated with 5 and 15 nm AuNPs for 72 hours. The results indicated that the 5 nm AuNPs at a 
concentration higher than 50 μM shows cytotoxicity, while there was no cytotoxicity found for 
the 15 nm AuNPs [114]. Low cytotoxicity was observed in 15-20 nm AuNPs despite the 
differences in cell lines and treatment time. Pattanayak et al. studied AuNPs between 15-20 nm 
in diameter in the L929 mouse cell line for 15-16 hours of treatment, and reported that there was 
no toxicity observed [115]. Murphy et al shows 18 nm AuNPs do not cause acute cytotoxicity [116].  
Khan et al. treated HeLa cells with 18 nm AuNPs before incubation for 3 and 6 hours. The 
AuNPs were not observed to enter the nuclei of the cells, as they were found to be localized 
within the cytoplasmic membranes. They generated the transcriptional profiles of HeLa cells and 
found the expression level of most of the genes remained unaltered [117].  
Li and co-workers studied the size effect on the biodistribution and pharmacokinetics of 
intravenously injected AuNPs (20, 40, and 80-nm, all coated with PEG) in mice [111]. The 20-nm 
AuNPs exhibited slowest clearance from the body and longest blood circulation time (half-life 
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clearance of particles 30-40 h), followed by the 40-nm AuNPs (half-life 10 h). The 80-nm 
AuNPs exhibited the fastest clearance (half-life < 1 h), as shown in Figure 1.12. In addition, the 
20-nm AuNPs had lower accumulation in liver and spleen than the 80-nm AuNPs, but they 
exhibited higher accumulation in the tumor due to the longer blood circulation time. Similar 
observations were reported by Cho et al., who also performed studies regarding 
pharmacokinetics and biodistribution of different sized  PEG coated AuNPs (4, 13, and 100 nm) 
when injected intravenously into mice[118]. Both of the smaller AuNPs, 4 nm or 13 nm, revealed 
longer blood circulation intervals, peaked at 24 h and cleared by day 7, while the large 100 nm 
AuNPs were cleared by 24 h. In contrast, 100 nm AuNPs rapidly accumulated (∼30 min) in the 
liver, spleen, and mesenteric lymph nodes, while small AuNPs accumulated more slowly in the 
organs (peaks at 7 days in liver and spleen; 1 month in mesenteric lymph nodes). TEM showed 
AuNPs existing in cytoplasmic vesicles and lysosomes of liver Kupffer cells in addition to 




FIGURE 1.12. Pharmacokinetics (of 20, 40, and 80-nm AuNPs) expressed as the percentage 
of the injected dose per gram of tissue in mice (%ID/g). Reprinted with permission from ref 
[111]. Copyright 2009 Elsevier.  
Effect of Surface Modifications on Toxicity and Bio distribution. Surface 
modifications have been observed to have drastic effects on the interactions between AuNPs and 
biological systems. The structures, functional groups, and charges of the surface modifications 
result in different cellular responses to the conjugated AuNPs. It is noteworthy to mention that 
the aforementioned debate over the perceived toxicity of AuNRs stems primarily from the 
surfactants of the AuNRs. Cetyltrimethylammonium bromide (CTAB) is one of the surfactants 
central to this debate since,  there have been studies that confirmed that the incomplete 
purification of AuNRs during synthesis results in free CTAB molecules that induce the observed 
cytotoxicity[39, 69, 119].   
In order to assess the toxicity of AuNPs with different surface charges, Goodman et al. 
synthesized cationic and anionic particles, and found that the toxicity of the AuNPs was related 
to their interactions with the cell membrane. The cationic AuNPs were found to be more strongly 
attracted to the negatively charged membrane than the anionic AuNPs were, as is expected given 
their electrostatic complementarity relative to the negatively charged bilayer of cell membrane 
[120]. In another work demonstrating the cellular behavior of positively charged, negatively 
charged, and neutral AuNPs, Schaeublin et al. found that charged AuNPs displayed toxicity at 
relatively low dosages (10 mg/mL), while the neutral AuNPs displayed significant levels of 
toxicity at a higher dosage of 25 mg/mL. The final results illustrated that both the positively and 
negatively charged AuNPs were toxic, with the negatively charged  AuNPs having a magnified 
response resulting in necrosis being the primary mechanism of cell death [121]. It is also worth 
noting that the physiochemical surface properties of AuNRs change after contacting with 
 
 26 
biological media, which needs to be considered when examining the biological impact of 
AuNRs[122]. 
The FDA-approved PEG-modification was achieved by adding mPEG-SH in the gold 
nanoparticles to form a nearly neutral surface, which showed little cytotoxicity in vitro and is 
currently becoming one of the most favorable surface modifications of AuNPs for in vivo usage. 
PEG-modification creates a nonspecific barrier which reduces unspecific bindings in blood 
components such as proteins and cells[123], which could greatly decrease the interaction between 
AuNPs and RES, leading to extended blood retention and increased uptake in the tumor [106]. 
Gold nanoparticle administration strategies, intravenous vs intratumoral.  In PPTT 
treatment, since the intravenous injection relies on the EPR effect, it might face challenges 
regarding the transportation of adequate amounts of AuNCSs to the tumor site. Several studies 
have showed less than 10% ID/g delivered to the tumor when administrated by intravenous 
injection[106, 124]. On the other hand, several other groups, including our lab, have been using 
intratumoral administration of AuNPs [9, 40]. The intratumoral administration showed a successful 
result when a reasonable dose was applied. The intratumoral injection could directly introduce 
AuNPs into the tumor site and therefore, provide a more favorable AuNPs concentration inside 
the tumor while decreasing the injection dose. However, i.v. injection could be more helpful in 
some cases, especially for tumors that are not accessible by direct injection of AuNPs. 
AuNRs, AuNCSs and AuNCs are separately discussed in the following contents. 
The PEG-coated AuNRs (Length x width) (65 x 11 nm) completely changed the in vivo 
pharmacokinetics of the initially CTAB coated ones, according to the report from Niidome et al. 
when using a mouse model [123]. PEG-coated AuNRs exhibited stable and an extended circulation 
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in the blood (half-life of ~ 1 h), with no accumulation in major organs (except for the liver) at 
least for 72 h. For the CTAB-coated AuNRs, fast clearance in blood and accumulation around 
0.5 h was observed, as shown in Figure 1.13. The majority of the AuNRs accumulation occurred 
in the liver. Similar observations in rats comparing CTAB and PEG coated AuNRs (55.3 × 18.5 
nm) were reported Lankveld by et al, with the conclusion that the PEGylation of AuNRs resulted 
in a prolongation of blood clearance after intravenous administration[125], and an accumulation of 
AuNRs mainly inside liver and spleen. 
Although most of the studies involving AuNRs biodistribution are performed using ICP-
MS to measure the Au content in organs, live animal imaging methods are also used. Su et al. 
used 3 dimensionnel  optoacoustic tomography imaging to map the biodistributoion of AuNRs 
coated with PEG in live mice [126]. The optoacoustic imaging was equipped with two lasers: one 
sensitive to both the AuNRs and blood (765 nm, close to the SPR of AuNRs) and the other only 
sensitive to blood (1064 nm). Maximum levels of blood AuNRs brightness were observed 24 h 
post-injection, followed by a slow clearance during the next six to seven days.  
Our study have  reported a 15-month toxicity study of AuNRs@PEG (25 x 5 nm) in mice 
[40]. To asses the toxicity, we examined the histopathology of liver, spleen, lung, and kidney 
tissues of mice 1 and 15 months after single i.v. injection of AuNRs@PEG. No histopathological 
abnormalities in the preceding organes were observed (Figure 1.14 A). No clinical signs of 
toxicity, including impeded movement, ruffled fur, signs of abnormal constitution, aberrant 
behavior, ocular or nasal discharge, loss of weight, respiratory distress, inability to walk, or 
diarrhea, were observed during the 15 months. The AuNRs were found without morphology 
changes in the liver and spleen for up to 15 months (Figure 1.14 B). Unlike the previous studies 
by Niidome et al, our results showed a higher AuNRs accumulation in spleen than liver (Figure 
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1.14 C and D). Slow AuNRs clearance was observed after 30 days to 15 months, but still Au 
content exists at 15 months (Figure 1.14 C-F). 
Furthermore, for the clinical cases of canines and felines (with mammary gland tumors 
that have been treated with AuNR-assisted PPTT), no evidence of negative impact was shown on 
their liver and spleen functions[9]. 
a b
 
FIGURE 1.13. (a) Blood clearance and Biodistribution of AuNRs in mice after intravenous 
injection. Black bars show PEG-coated AuNRs at 0.5, 3, 6, 12, 24, and 72 h after injection, 
and white bars show CTAB-coated AuNRs at 0.5 h. The CTAB-coated AuNRs were 
washed once with water to reduce toxicity to mice. Reprinted with permission from ref [123]. 
Copyright 2006 Elsevier. (b) Percentage recovery of gold in different organs at day 1 (top 





FIGURE 1.14. 15-month toxicity study of AuNRs@PEG in mice. Reprinted with 
permission from ref [40]. Copyright 2017 National Academy of Sciences. 
 
Gad et al conducted a series of studies to evaluate the toxicity of PEG-coated AuNCSs 
when injected intravenously based on the ISO-10993 standard[43]. In addition, they studied the 
biodistribution/clearance in mice, acute toxicity in rats, and acute and chronic toxicity in Beagle 
dogs for time durations of up to 404 days. This study provides an extensive description of the 
biological fate and safety of AuNCSs. Results shows that the AuNCSs were well tolerated and 
did not exhibit any toxicities. AuNCSs mainly accumulate in liver and spleen, which account for 
over 85% of the total gold measured (Figure 1.15 a). Furthermore, no variations in the mean 
body weights was reported for dogs treated with AuNCSs compared to the control in the 10-
month long-term study (Figure 1.15 b). Stern et al evaluated  the safety of AuNCSs safety in 22 
patients with human prostate cancer that  were treated using AuNCSs based PTT[127]. Results of 






FIGURE 1.15. (a) Gold content in major organs after i.v. injection of PEG coated AuNCSs 
in Balb/c mice. (b) Mean body mass for dogs in a 10-month study, no variations in body 
mass were observed for the test groups (with i.v. injection of PEG coated AuNCSs) 




FIGURE 1.16. Blood chemistry and Hematology. Only ALT, AST, WBC, and RBC are 
shown here. Reprinted with permission from ref [127]. Copyright 2016 Sage journals. 
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There is less data on the pharmacokinetics and biodistribution of gold nanocages. Xia and co-
workers evaluate the pharmacokinetics and tumor targeting ability of PEG-coated AuNCs with 
different sizes (30 vs 55 nm) in an EMT-6 mouse mammary tumor model [110]. Their results 
suggest that AuNCs of 30 nm in size had more blood retention than AuNCs of 55 nm in size, 
along with higher uptakes in tumor. 
1.3 Motivation of the Work 
Metastasis is responsible for over 90% of cancer-related deaths [62]. In order to initiate 
metastasis, cancer cells must be equipped with the ability to migrate and invade the surrounding 
tissues, then intravasate to the microvasculature of the lymph and blood stream, and finally 
translocate to distant tissues and adapt in the microenvironment [62]. However, past attempts to 
develop anti-metastasis drugs have not been very efficacious in clinical trials [128]. Recent 
advancements in nanomedicine provide new opportunities to avoid some drawbacks of 
commonly used cancer drugs, as nanoparticles can cross biological barriers, enter target cells 
with high selectivity, and function inside cell in a controlled manner [14, 129, 130]. Nanoparticles 
have shown promise as anti-metastasis drug delivery vehicles targeting invasive or metastasized 
cancer cells [79, 88, 131], and they could even function as anti-metastasis drugs without drug loading 
[85, 86, 132, 133].  
The recent discovery of nanoparticles’s effect on inhibiting cancer cell migration or 
metastasis has drawn the attention of many researchers [73-76]. The optical and mechanical 
properties, such as plasmonic photothermal effect and high mechanical strength, as well as 
excellent biocompatibility of gold nanoparticles (AuNPs) make them very useful in attenuating 
cancer metastasis [134]. However, non-specific targeting AuNPs was used in nearly all the 
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previous studies for the self-therapeutic effect of AuNPs in inhibiting cancer metastasis. To 
develop AuNPs for metastasis treatment, there are several challenges: 1) an optimized 
therapeutic method needs to be developed; 2) the mechanism of how AuNPs treatments inhibit 
cancer cell migration remains largely unexplored. 
This work differs from the previous studies in two major aspects: 1) Rational designs of 
AuNPs to high specifically inhibit cancer cell migration, with a greatly reduced effective 
concentration to enhance biocompatibility. 2) Use of the state-to-the-art high resolution 
microscopy imaging techniques and systematic mass spectrometry-based proteomics to gain 
deep understanding of the underlying principles involved. Biomechanical properties (such as cell 
stiffness) was also used for revealing the mechanisms of how AuNPs inhibit cancer metastasis. 
With optimized AuNPs-based therapy or its derived therapies, it has great potential to 
revolutionize treatment regimens by replacing them with ones that are more effective and less 
toxic, and could potentially eliminate drug resistance effects on cancer cells. The selectivity of 
optimized delivery of AuNPs to the cancer cells could minimize the side effects on healthy cells. 
Successful optimization of AuNPs-based therapy and the detailed molecular mechanism study 
will provide a unique and novel candidate for cancer treatment for the next-phase of translational 











GOLD NANOPARTICLES FOR BIOLOGICAL DIAGNOSIS AND 
IMAGING 
Summary. Due to the SPR effect, AuNPs exhibit excellent optical properties, which can 
be used for biological imaging and sensing (as shown in Figure 2.1). In general, the optical 
properties of AuNPs adds to their capacity as therapeutic agents for disease treatment (i.e. as 
theranostics agents). In this chapter, we have 1) discussed the recent advance of gold 
nanoparticles in biological optical imaging and sensing, especially using their enhanced Rayleigh 
scattering and surface-enhanced Raman scattering (SERS) properties; 2) explored the application 
of AuNPs in probing dynamic philological behaviors of cancer cell apoptosis using SERS; and 3) 
based on the strong Rayleigh scattering of AuNPs to light, we developed a new flow cytometry-
based method for the AuNP uptake by cancer cells for fast detection purpose.  
Plasmonic Photothermal
Cancer	Therapy	(PPTT)











FIGURE 2.1. Simple scheme of some of the properties of AuNPs. Due to the unique optical 
properties of gold nanoparticles (AuNPs), i.e., the surface plasmon resonance, AuNPs can 
be readily used to enhance optical imaging based on their absorption, scattering, surface-
enhanced Raman scattering, etc. The heat that generated after absorbing photon energy 
can be convert to heat. 
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1.4 Current Advance of Using Gold Nanoparticles in Biological Optical Imaging and 
Sensing [135] 
Summary. Optical imaging represents one of the most essential tools in biological studies. 
Although with great advances, bio-optical imaging still suffers from problems such as resolution, 
sensitivity, speed, and penetration depth. Due to the unique optical properties of gold 
nanoparticles (AuNPs), i.e., surface plasmon resonance, AuNPs can be readily used to enhance 
optical imaging based on their absorption, scattering, fluorescence, Raman scattering, etc. Here, 
as an introduction part, we include the most recent achievements and challenges associated with 
using AuNPs to improve resolution and sensitivity in biological imaging in vitro and in vivo. The 
application of AuNPs in the following three aspects were discussed: 1) Direct visualization of 
AuNPs inside the biosystems using i) dark field (DF) microscopy, ii) differential interference 
contrast (DIC) microscopy, and iii) other techniques, such as interferometric scattering (iSCAT) 
microscopy and photothermal imaging. 2) Monitoring of biomolecular events and physiological 
processes using surface-enhanced Raman spectroscopy (SERS). In conclusion, based on our 
literature study, AuNPs-assisted bioimaging acts as a promising tool in exploring fundamental 
biological questions and early diagnosis of diseases. 
1.4.1 Introduction 
Using a microscope, Robert Hooke (in 1665) and Anton van Leeuwenhoek (in 1674) 
observed the images of “cell”, opening the door of cell biology. The development of optical 
microscopes during the last 350 years enables us to see more microscale details in the biological 
system. One recent noteworthy progression is the development of optical super-resolution 
microscopy, which allows the observation of macromolecules in live cells down to nanoscale 
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level and was awarded the 2014 Nobel Prize in Chemistry. Although with great advances, bio-
optical imaging always has coupled strengths and weaknesses regarding resolution, sensitivity, 
speed, and penetration depth.  
Recently, there has been a great deal of research concerning the advancement of optical 
imaging using AuNPs due to their unique plasmonic properties [136]. The first question that arises 
is how to clearly “visualize” the AuNP probes inside cells [137]. The scattering signal from 
AuNPs is usually much stronger than the scattering background from cells and tissues, making 
dark field (DF) microscopy a viable choice for reporting the existence of AuNPs within 
biological systems. Differential interference contrast (DIC) microscopy uses two interference 
light beams to generate contrast for optical path differences, allowing for the simultaneous 
imaging of nanoparticles and cellular components, such as nuclei, vesicles, and microtubules. 
Interferometric scattering microscopy (iSCAT) relies on the interference between a reference 
light and light scattered by the specimen in the medium to produce a high interferometric 
contrast image that can be obtained after the removal of static imaging background, allows 
sensitive and precise imaging of AuNPs with improved spatiotemporal resolution. In addition, 
the light absorbance by AuNPs could be converted to heat, which can be used for photothermal 
imaging. 
In addition to visualizing the AuNPs inside the cells, a second question that comes to 
mind is how AuNPs could improve the detection of biological events. A useful by-product of 
AuNP light scattering is the enhanced Raman signals for molecules [21]. Raman spectroscopy is a 
powerful tool for analyzing the species within a biosystem as it provides the chemical fingerprint 
of the molecule [138]. AuNPs can greatly enhance the Raman signal of a molecule. The surface-
enhanced Raman scattering (SERS) obtains more than 10 orders of signal enhancement, allowing 
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for ultra-sensitive single molecule level detection (down to 10–15 M). Additionally, compared to 
other imaging methods, SERS can provide more chemical bond/structure information. As the 
SERS peaks appear sharper compared to other detection methods such as fluorescence, higher 
accuracy in detection can be accomplished. In vivo SERS imaging for tumor diagnosis and 
therapy is a recent trendy development, which is bringing SERS into many clinical imaging 
applications.  
1.4.2 Direct Visualization of Gold nanoparticles in Biological Systems 
Recent innovations in optical imaging, including DF, bright field, DIC microscopies, 
photothermal and photoluminescence detection methods, etc., enable the visualization of single 
AuNPs interacting with the biological systems. The development of these methods has enhanced 
our ability to detect, localize, and track the dynamics of individual AuNPs and/or their 
aggregates and has broadened the understanding of bio-nano interactions in terms of the protein 
corona formation, membrane binding and diffusion, internalization, and trafficking of 
nanoparticles within cells [139, 140]. Furthermore, AuNPs can be used as both diagnostic and 
therapeutic agents.  In this section, we will mainly focus on the recent advances in DF, DIC, 
iSCAT, and photothermal microscopies as well as their applications in the study of bio-nano 
interactions.  
1.4.2.1  Dark Field (DF) Microscopy 
AuNRs with DF microscopy, a scattering-based technique, produces a bright image of the 
specimen on a dark background. The strong scattering signal of AuNPs is attributed to their high 
scattering coefficients (∼5 orders of magnitude higher than conventional fluorescent dyes) [141].  
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Imaging gold nanoparticles inside cells  
Extensive work has been conducted regarding the use of DF microscopy to track the 
intracellular locations and behavior of AuNPs inside cells, such as the examination of AuNP 
uptake [142], the evolution of AuNP clusters in live cells (based on their color change [143, 144], 
corresponding to different cluster sizes and cellular locations, as shown in Figure 2.2 A), the 
endocytosis and subsequent transport along the microtubules [144-146]. Rosman et al. reported a 
study regarding the intracellular behaviors of nanoparticles by quantifying the number of AuNPs 
within cells and the degree of aggregation using both optical DF microscopy and high-resolution 
TEM. They were able to employ the combined techniques to analyze the uptake of AuNPs with 
different shapes and surface coatings into epithelial cells [142].  
AuNPs trafficking along microtubules. Nan et al. developed a novel strategy for the 
tracking of AuNPs in 2D with ~ 1.5 nm spatial precision and 25 µs time resolution by utilizing 
a quadrant photodiode to record the positions of the AuNPs [145]. This technique is able to clearly 
resolve the 8 nm individual steps of cargoes that are carried by kinesin, as well as the 12, 16, and 
20 nm steps by dynein with high localization precision and high time resolution (Figure 2.2 B) 
[145]. Schneider et al. visualized the AuNP-loaded motor proteins traveling along the microtubule 
using a parabolically-shaped quartz prism-based widefield total internal reflection (TIR) 
illumination design that allows the detection of single-molecule fluorescence and single-particle 
scattering with the same setup and high S/N ratios.  Their results demonstrated sub-nanometer 
localization accuracy for the scattering of 40 nm AuNPs, and they imaged the characteristic 8-
nm walking step distance of individual kinesin-1 motor proteins along the microtubules [146].  
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Imaging biological processes. Additionally, DF microscopy incorporating AuNPs can be 
used for understanding biological processes. El-Sayed and co-workers have reported Au 
nanospheres functioning as DF probes for cell division [147]. AuNPs localized in the nuclear 
region were tracked in real time during the mitosis of a HSC-3 cancer cell (Figure 2.2 C). In 
addition, real-time tracking of virus-cell interactions was assisted by AuNPs in order to 
understand the respiratory syncytial virus infection of HEp-2 cells (Figure 2.2 D). Streptavidin 
(SA)-biotin binding chemistry, a study where AuNPs and virus particles are respectively 
modified with SA and biotin, allows for the stable binding of AuNPs to viruses without affecting 
their virulence [148]. A possible concern regarding this type of study is the endocytosis of free 
AuNPs (unbound to virus) that will complicate the detection. 
 
FIGURE 2.2. (A) Dark field (DF) microscopy showing the evolution of AuNP color in HeLa 
cells at the different durations (0.5-24 h) of incubation. Printed with permission from 
Springer Nature [144]. (B) The walking steps of cargoes detected that are carried by dynein 
with ~ 1.5 nm spatial precision and 25 µs time resolution. Printed with permission from 
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John Wiley and Sons [145]. (C) Human oral squamous cell carcinoma (HSC-3) cell division 
process (prophase to cytokinesis) visualized by the AuNPs. Printed with permission from 
SPIE [147]. (D) Real-time tracking (0-100 s) of AuNPs labeled respiratory syncytial virus 
(indicated by blue and red arrows) infecting HEp-2 cells. Printed with permission from 
Springer Nature  [148]. 
Measuring biomolecular dynamics and mechanics.  
While the location of an individual, isolated nanoparticle can be determined by DF 
microscopy with nanometer spatial precision due to the strong scattering signal, the resolution 
for determining the distances between two identical particles is low (limited by the diffraction 
limit to ∼250 nm). Thanks to the SPR shift with the change of inter-particle distances, the 
detection of close distances between AuNPs is possible. Using this method, the nanometer-level 
distance between two proteins inside cells was able to be measured, as reported by Rong et al. 
[149]. As shown in Figure 2.3 A, in the top case, AuNP-labeled fibronectin-integrin protein 
complexes are largely separated (separation distance ∆’ is larger than AuNP diameter D), and the 
SPR of the AuNPs are same as individual particles (530 nm). However, in the bottom case, the 
proteins are close to each other (separation distance ∆’’ is smaller than AuNPs diameter D), and 
the plasmon coupling between individual AuNPs causes a red shift of the SPR to 580 nm. This 
method can improve the resolution of optical imaging by more than one order of magnitude, 
where the detection threshold of 15 nm can be obtained with the chosen 530 nm/580 nm filter 
[149]. However, a possible concern regarding this type of study in general is the aggregation of 
AuNPs inside cells, which will cause a similar red-shift, and it is difficult to differentiate if this 
shift is from the small distance of the separated proteins or the AuNPs aggregation. Aside from 
measuring protein distances inside the cells, Yeung and co-workers recently measured the cell 
mechanical force using AuNPs and DF microscopy according to the color change [150]. 
Mechanical force plays important roles in cell signaling for various physiological functions [151], 
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and AuNP-based optical fluorescence imaging was previously developed to measure small forces 
in cells [152]. As shown in Figure 2.3 B, by using a single plasmonic nanospring that attaches to 
the cell surface integrins and DF microscopy, the force applied on the spring can result in an SPR 
alteration, which can be used for real-time measure of forces in live biological systems. In 
addition, based on the distance-related color change, AuNRs and DF microscopy also enables 
quantitative imaging of mRNA splice variants in live cells. The probes that Lee et al. developed 
consist of 40 nm AuNPs functionalized with two oligonucleotides that can match to specific 
mRNA sequences (BRCA1 mRNA). As shown in Figure 2.3 C, the formation of a dimer could 
cause the SPR color to be red-shifted and intensity to be greatly enhanced. The location and 
number of dimers can thus be determined and quantified using the signal intensity and spectral 
peak shift by DF microscopy [153].  
AuNRs have also been used to detect the dynamic behavior of proteins. Lambertz et al. 
monitored the oscillations of the MinDE protein wave propagation on from Escherichia coli (E. 
coli) membranes [154]. As shown in Figure 2.3 D, the attachment of proteins MinD and MinE to 
the membrane can be detected by the shifting of the AuNRs SPR (Δλ), which exhibits four 
phases. Enzymatic reactions in live cells can also be indicated by the SPR shift. A single AuNP 
was used by Zhang et al. as a real-time probe for the detection of the NADH-dependent 
intracellular metabolic enzymatic pathways [155].  The NADH-mediated reduction of Cu2+ onto 
AuNPs that form Au@Cu core-shell nanoparticles causes a red-shift of the SPR spectra of 






FIGURE 2.3. (A) Schematic of using surface plasmon resonance (SPR) wavelength shift to 
determine the distance of proteins (labeled by AuNPs) in live cells. If the separation 
distance (∆’) is larger than AuNP diameter D, the SPR band is at about 530 nm. If 
separation distance (∆’’) is smaller than D, the SPR band is at 580 nm. Printed with 
permission from American Chemical Society [149]. (B)  Schematic of using SPR shift to 
determine the cellular mechanical forces. Printed with permission from American 
Chemical Society [150]. (C) AuNRs enables quantitative imaging of mRNA splice variants in 
live cells. The real-color images (top) and spectra of monomer and dimer from mRNA 
splice variants.  Printed with permission from Springer Nature [153]. (D) AuNR and dark 
field microscopy for monitoring protein dynamic behavior on membranes (reflected on the 
AuNR SPR shift, Δλ, in stage I, II, III and IV during a cycle). Printed with permission from 
American Chemical Society [154]. (E) AuNPs with Cu2+ detection of NADH-dependent 
intracellular metabolic enzymatic pathways. The deposition of Cu2+ on AuNPs causes red 
shift of SPR. Printed with permission from John Wiley and Sons [155]. 
In vivo dark field imaging.  
Although widely used in single cell imaging, the DF technique has several obstacles that 
inhibit its application on animal imaging. Light scattering from surrounding tissue is a widely 
noted drawback of DF microscopy, and it limits the use of this imaging method within deep 
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tissue. The current in vivo DF imaging still exclusively works on the tissue slides sections, such 
as for observing the AuNPs distribution in tumors, the tumor’s vasculature and organs [156, 157]. 
To characterize the biodistribution profiles of AuNPs, SoRelle et al. developed adaptive 
algorithms for the analysis of hyperspectral DF images that achieve improved sensitivity and 
specificity with the capability of identifying single nanoparticles in ex vivo mouse tissue sections 
[157]. The dependence on size for the optimal uptake of nanoparticles into brain tissue was 
highlighted by Betzel et al. who used DF images to display the enhanced internalization of 
glucose-coated 5 nm AuNPs into exosomes in comparison to 20 nm nanoparticles in brain slide 
sections. AuNPs were then used as tracking probes to map the movement of intranasally 
administered exosomes through mice focal brain ischemic-like damage, confirming their 
valuable use as contrast agents in DF microscopy applied to exosome labeling and exosome-
based treatment [158].  
Plasmon helps improve spatial resolution 
DF imaging is yet another method that suffers from the optical diffraction limit, and as 
such, improving the resolution has been a huge subject of research in recent years [14, 159]. Figure 
2.4 A shows a traditional working principle of DF microscopy. For selective illumination and 
decreasing background, Noji and his coworkers developed a simple DF microscope that 
employed perforated mirror and objective-based TIR. Due to the TIR illumination applied on a 
thin layer, a low background was achieved (Figure 2.4 B-D). The system was applied to 
visualize the rotation of F1-ATPase attached to 40 nm AuNPs at 1-2 nm spatial resolution and 
9.1 μs temporal resolution with 120º steps and short catalytic dwells on μs-to-ms timescales [160]. 
Another study established a super-resolution imaging of AuNPs with enhanced DF imaging 
based on wavelength modulation [161]. Individual bandpass filters were used to reduce the 
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interference and to differentiate the adjacent AuNP, AuNR and silver nanoparticle at specific 
SPR wavelengths. The 2D Gaussian fitting algorithm was used to localize the nanoparticles with 
nanoscale precision.  
While such techniques only reduced the interference of overlapping scattering in two 
dimensions, a very recent study has seen the development of DF imaging that accurately shows 
the 3D distribution of AuNPs within cells through the reduction of all background interference. 
This technology, known as orientation-dependent localization microscopy (ODLM), relies on the 
principle of cross-polarization microscopy to isolate the scattering of polarization-sensitive 
AuNRs, while intracellular structures incapable of depolarizing light are largely eliminated 
(Figure 2.4 E). Not only does this type of imaging allow for greater accuracy in pinpointing the 
localization of AuNPs within cells, but it also shows their specific orientation on an individual 
particle level without the interference of scattering from 3D subcellular structures [162].  
 
FIGURE 2.4. (A) The working principle of dark field (DF) microscopy. Printed with 
permission from Iowa State University [163]. (B) Schematic illustrations of objective-type 
total internal reflection dark-field microscopy (TIRDFM) with a perforated mirror (PM) 
and (C) vertical illumination dark-field microscopy (VIDFM) with a dot mirror (DM). (ND) 
neutral density filter, (BE) laser beam expander, (DP) diaphragm, (M) mirror, (L) lens.  (D) 
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Intensity profiles of 40-nm gold nanoparticles by TIRDFM (left) and VIDFM (right). Pixel 
size = 88.5 nm. The profile was fitted by 2D-Gaussian. FWHM of PSF were 672 ± 36 and 
623 ± 41 nm (n = 15), and 259 ± 48 and 212 ± 34 nm (n = 15) in the x- and y directions, for 
TIRDFM and VIDFM, respectively. Values are means ± SD. B-D are printed with 
permission from Elsevier [160]. (E) Setup for orientation-dependent localization microscopy 
(ODLM) for background free 3D imaging. Printed with permission from Springer Nature 
[162]. 
1.4.2.2 Differential Interference Contrast (DIC) Microscopy 
DIC microscopy utilizes two-beam interferometry in which objects cause a phase shift of 
the light beams, producing a pseudo-3D, shadowcast image (Figure 2.5 A). DIC microscopy 
allow for the direct observation of many subcellular organelles, such as microtubules, in 
unstained living cells with sufficiently high contrast. DIC microscopy has been extensively used 
in cell biology to study microtubule assembly/disassembly dynamics, motor protein-
microtubules binding, organelle trafficking in axon, cell division, and even intact organisms such 
as embryos [164, 165]. AuNPs used as contrast agents in DIC microscopy allows for the imaging of 
nanoparticles and cellular features simultaneously [166]. Thanks to the high absorption and 
scattering cross-sections arising from the SPR as well as the excellent photostability of the 
AuNPs, relatively low illumination light intensity (standard halogen lamp is commonly used) is 
sufficient for DIC imaging of AuNPs in the cellular environment. This enables the continuous 
observation of dynamic bio-nano interactions for long periods of time with minimal disruption. 
Three-dimensional selective imaging of gold nanoparticles 
The challenge of differentiating AuNPs probes from small subcellular features, especially 
small intracellular spherical vesicles, in DIC images can be relatively easily circumvented by 
wavelength-dependent DIC microscopy to selectively image AuNP probes in live cells [167].  This 
method can turn “on/off” the AuNP signals by simply applying two bandpass filters in the light 
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path. AuNP probes generate high contrast in the SPR wavelength channel, while the non-SPR 
wavelength channel that “turns off” the AuNP probes, is used as a control (Figure 2.5 B).  
The use of full NA objective and condenser affords the shallower depth of field and thus 
better achievable axial (z) resolution than the conventional bright field and DF microscopes for 
optical sectioning of the samples. It was proven to provide good resolution both laterally and 
vertically for 3D imaging, which can be conveniently realized with a vertical scan of the focal 
plane through the specimen to acquire a series of z-stacked images and 3D image reconstructions 
using software [164]. When combined with AuNP imaging, full NA objective and condenser can 
be used to characterize the 3D localization and distribution of AuNPs as well as the aggregations 
of the AuNPs within cells [85, 140, 168]. For example, when the efficiency of different nuclear 
localization peptides that aid in the nuclear uptake of AuNPs was tested, video-enhanced color 
DIC microscopy allowed for localization of nanoparticles within HeLa and HepG2 cells [140]. 
Chithrani et al. used the combination of DIC and confocal microscopes to measure the uptake of 
transferrin-coated AuNPs into cells, where DIC was used to determine the z-positions of the 
nanoparticles [168]. Similarly, we utilized the optical sectioning ability of DIC microscopy to 
determine the subcellular location of nuclear targeting AuNPs, which were shown to be trapped 
and congregated at the outer nuclear membrane (Figure 2.5 C-F) [85].  
Improving localization, precision, and resolution 
It is important to obtain positions of the targeted single nanoparticle probes with high 
localization accuracy and precision in order to resolve the dynamic motions and interactions. Yet, 
the intrinsic diffraction limit of light prevents DIC microscopy from resolving nanoparticles that 
are separated by less than roughly half of the wavelength. The asymmetric point spread functions 
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(PSF) further complicated the localization in DIC microscopy as they cannot fit into a simple 
mathematical equation like the common localization strategies used in other imaging techniques 
[169]. Despite such limitations, recent advancements in both instrumentation and methodology 
allow researchers to achieve improved resolution and localization of AuNPs in DIC microscopy 
[169-171]. Chen et al. reported the use of a structured illumination DIC (SI-DIC) microscope in the 
attempt of increasing the lateral resolution of DIC microscopy [170]. A lateral resolution of 
approximately 190 nm, a value that is double the wavelength found in conventional DIC 
microscopy, was achieved in the imaging of 53 nm polystyrene beads. This method can be 
adopted for sub-diffraction-limited imaging of AuNPs. Gu et al. reported a model-based 
correlation mapping method for precise 3D localization of spherical AuNPs and successfully 
applied the technique to localize 40 nm AuNPs inside fixed HeLa cells as well as to track the 
AuNPs in live A549 cells [171]. However, the model-based correlation mapping method does not 
work well for the localization of AuNRs as the DIC image pattern changes with respect to the 
orientation of the AuNRs. Three different methods have been developed to solve this dilemma 
[169, 172, 173]. A dual-channel imaging system was developed by Gu et al. to localize AuNRs in the 
bright-field channel using transverse SPR with high accuracy as well as to track the rotational 
motions of the AuNRs in the DIC channel at the longitudinal SPR wavelength [172]. Zhao et al. 
presented a new localization strategy by combining computer simulated DIC images with the 
experimentally measured lateral shear distance in order to improve the localization accuracy of 
AuNRs [169]. 
Additionally, DIC microscopy has been used to study the interactions between 
nanoparticles and biomolecules using plasmon resonance energy transfer (PRET) to reveal 
cellular process within live HeLa cells [174]. This technique relies on the energy transfer from 
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AuNPs to cytochrome c, a cellular protein involved in several signal transduction pathways, the 
most notable being the apoptosis signaling pathway. It is quantified by dips in the intensity of 
nanoparticle emissions that are measured by the change in the AuNPs’ DIC contrast upon the 
interaction with endogenic cytochrome c protein during ethanol-induced apoptosis.  
Coupling DIC with other imaging techniques will definitely be a trend in future 
development. Integrated DIC microscopy will be able to provide more comprehensive molecular 
and structural information of the biological system and will help to decipher more complex 
interactions of nanoparticles and biological surroundings in dynamic cellular processes. 
 
FIGURE 2.5. (A) Differential interference contrast (DIC) microscopy working principle. 
Printed with permission from American Chemical Society [166]. (B) AuNP probes “turn on” 
in the surface plasmon resonance (SPR) wavelength channel, while they “turns off” in the 
non-SPR wavelength channel in HeLa cells. Printed with permission from American 
Chemical Society [167]. (C) Scheme of optical section for nucleus targeted AuNPs’ 3 
 
 49 
dimensional cellular distributions, in ovarian cancer cell HEY A8. (D-F) the DIC images 
from layer 1-3 in C. Printed with permission from American Chemical Society [85].  
 
1.4.2.3 Other Techniques for Visualizing AuNPs. 
Interferometric scattering (iSCAT) microscopy  
iSCAT is another label-free imaging method for visualizing AuNPs with high spatial 
resolution and sensitivity. In iSCAT microscopy, the samples are illuminated, and the reflected 
and scattered lights are collected and interfere at the detector [175]. It is composed of three main 
parts: (1) reflected light, (2) scattered light, and (3) the interference of the reflected and scattered 
light [176]. iSCAT collects the scattered light, which is the main signal in a DF image. Different 
from the DF microscope, the iSCAT has dominated reflected light that is avoided, however, in 
DF microscopy. The instrumentation set up and the operating principle are shown in Figure 2.6 
A and B. An iSCAT image of a 30 nm AuNP moving along the microtubule is shown in Figure 
2.6 C [177]. 
Using AuNPs as probes, iSCAT is applicable in resolving protein conformational 
changes down to 2 nm with millisecond temporal resolution [177]. By attaching an AuNP as small 
as 20-30 nm on targeted motor proteins (such as myosin-5, kinesin-1, and dynein as examples), 
iSCAT was able to directly observe the structural transitions and protein dynamics [178].  High-
resolution tracking of kinesin showed that it uses a two-step powerstroke mechanism for 
maximum velocity [177]. Hancock group reported direct observation of the binding of individual 
tubulin dimers to growing microtubules [179]. iSCAT is also used for studying the behavior of 
lipids. Hsieh et al. achieved 1.9 nm spatial precision at 1 ms temporal resolution for tracking 
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single particles on supported lipid membranes [180]. To resolve the dynamic molecular interaction 
between lipid rafts at the nanoscale, iSCAT is employed to record the motion of individual lipids 





FIGURE 2.6. (A) Optical setup for interferometric scattering (iSCAT) microscopy. OBJ: 
microscope objective; PBS: polarizing beam splitter; QWP: quarter-wave plate. (B) 
Operating principle of iSCAT. A and B are printed with permission from Elsevier [178]. (C) 
Raw iSCAT image of a 30 nm AuNP walking along a microtubule. (Inset) The image after 
background subtraction. Printed with permission from National Academy of Sciences [177]. 
Photothermal imaging. 
For many of the existing imaging methods that based on AuNPs’ Rayleigh scattering, 
their signal needs to be differentiated from the background. In practice, the minimum size of 
AuNPs is well above 30-40 nm. Consequently, the detection of smaller AuNPs is challenging. 
However, for smaller AuNPs, their strong absorbance could be converted to heat that warms up 
the environment surrounding the AuNPs. The temperature change of the medium will result in a 
reflection index change that shifts the phase of a transmitted light beam. By using this 
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“photothermal” imaging, we can see the AuNPs scale down to ~1 nm in size [182]. As shown in 
Figure 2.7 A, a green heating laser is focused on the sample and is absorbed by AuNPs as it 
generates a heat wave. The other red laser is split by a Wollaston prism into two orthogonally 
polarized beams, one of which coincides with the heating spot of the green laser. The two beams 
are recombined and the relative phase difference can be identified by the detector. The 
photothermal imaging is capable of differentiating very small Au nanospheres, which are nearly 
invisible in DIC microscopy (Figure 2.7 B-D) [183].  Recently, Zharov et al. demonstrated a 
super-resolution photothermal microscopy utilizing the non-linear dependence of signal on laser 




FIGURE 2.7. (A) Optical setup of photothermal optical microscope. (B) Differential 
interference contrast (DIC) imaging and (C-D) photothermal images of a sample 
containing 300 nm latex spheres, 80 nm Au nanospheres, and 10 nm Au nanospheres. DIC 
image shows the 80 nm Au nanospheres and 300 nm latex spheres, while the 10 nm Au 
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nanospheres are invisible. (C) The photothermal image with lower laser heating intensity 
showing the 80 nm Au nanospheres. (D) The photothermal image with higher laser heating 
intensity enables clear visualization of 10 nm Au nanospheres with 80 nm AuNPs reaching 
saturated detection. Printed with permission from American Association for the 
Advancement of Science [183].  
1.4.3 Molecular Fingerprinting by Surface-enhanced Raman Scattering (SERS) 
Compared with other imaging and sensing techniques, SERS can provide highly sensitive 
and abundant structural information (Figure 2.8 A). SERS can detect biomolecules of interest 
that surround the nanoparticles by a factor of over 10 orders of magnitude compared to normal 
Raman signals [21]. Furthermore, SERS signals increase in sensitivity when the distance between 
the Raman reporters and the AuNPs decreases – the shorter the distance, the stronger the SERS 
signal [184], making it ideal for studying bio-nano interactions. The powerful targeting of 
nanoparticles through ligand conjugation creates high specificity on the locations of the 
biomolecules conjugated nanoparticles. The surface plasmon of AuNPs is stable and provides 
consistent signals for long-term imaging.  The range of accessible wavelengths for SERS 
detection extends from the whole visible spectrum to NIR [185], the latter accounting for the 
maximum penetration depth within biological samples.  
1.4.3.1 Single Molecule SERS 
Ultrasensitive detection at extremely low concentrations (femto- or attomole) is limited 
by diffusion; therefore, the time needed to find and detect a molecule could be unrealistically 
long. To solve this problem, de Angelis and co-workers developed a method that combines 
super-hydrophobic artificial surfaces and nanoplasmonic structures to detect a few molecules 
(10-18 mol L-1). By loading a drop of solution that contains the molecules onto a super-
hydrophobic surface (periodical silicon micropillar arrays with plasmonic nanostructures on the 
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top of the pillars), the droplet gradually evaporates to increase the concentration of the molecules 
inside and shorten the detection time with SERS or surface-enhanced fluorescence (Figure 2.8 B 
and C) [186]. A similar but more practical strategy has been reported by Yang et al. for the 
quantitative detection of rhodamine 6G (R6G) down to 10−15 mol·L−1 using a platform named 
slippery liquid infused porous surface-enhanced Raman scattering (SLIPSERS), in which a drop 
of the analytes and SERS substrates (e.g., AuNPs) were added onto a slippery surface, and the 
resulting evaporation of the liquid droplet allows for nearly 100% analyte collection efficiency 
(Figure 2.8 D and E) [187].  
DNA origami has been recently utilized for directed formation of Au nanostructure for 
single-molecule SERS due to its ability to exert precise control over the geometrical 
configuration such as fabricating the Au nanodimers with a hot spot. Sen et al. prepared Au 
nanostar dimers on dimerized rectangular origami structures, with 7 and 13 interparticle gaps and 
achieved 2 × 1010 and 8 × 109 enhancement, respectively [188]. Ding’s group constructed 80 nm 
plasmonic bowtie nanostructures via a DNA origami-based bottom-up assembly strategy that 
have an approximate 5 nm gap and obtain SERS enhancement about 109 [189]. The DNA origami 
technique is very promising for revolutionizing the SERS detection, providing accurate 
fabrication methods for SERS probes with a high degree of customization.  
1.4.3.2 SERS in Studying the Bio-nano Interaction 
Researchers have tracked the nanoparticle motion inside living cells and have provided 
the molecular maps of organelle transport and liposomal accumulation of the AuNPs, indicating 
the different types of transport pathways [190, 191]. The SERS spectra changes in space and time 
during AuNP endocytosis provide the change in the cellular environment (Figure 2.8 F). 
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Consequently, the SERS spectra provide molecular maps dynamics during organelle transport 
and lysosomal accumulation of AuNP [190]. In addition, SERS was used to monitor the real-time 
photothermal ablation of cancer cells, for “seeing-and-treating”. When exposed to light, AuNPs 
can convert light energy to heat, which can be used to kill cancer cells (otherwise known as the 
photothermal effect). Ali et al. used SERS to study the molecular mechanism of AuNR-assisted 
photothermal ablation and observed an increase in specific Raman bands during the process [192]. 
A similar method for SERS-guided photothermal therapy has been used by Sun et al. [193]. SERS 
has also been employed to image and explore the biosynthetic mechanism of AuNPs. As shown 
in the study by Lahr et al. the intracellular and extracellular AuNP biosynthesis process by green 
algae was revealed by SERS by identifying the surface-associated biomolecules. The SERS 
peaks indicate the participation of identified molecules in elucidating the mechanism of the 




FIGURE 2.8. (A) Principle of surface-enhanced Raman scattering (SERS). (B) Sing-
molecule detection by super-hydrophobic surface (periodical silicon micropillar arrays 
with plasmonic nanostructures on the top of the pillars). (C) The optical images of the 
analyte drop evaporating at four different times. The B and C are Printed with permission 
from Springer Nature [186]. (D) Single-molecule detection platform named slippery liquid 
infused porous surface-enhanced Raman scattering (SLIPSERS). (E) Ultra-sensitive 
detection of BSA protein using the platform of D. D and E are printed with permission 
from National Academy of Sciences [187]. (F) SERS spectra changes during AuNP 





1.4.3.3 In vivo SERS Imaging for Tumor Diagnosis and Therapy 
In 2008, one of the pioneer studies demonstrated the ability to collect the SERS 
spectra from tumor-bearing mice that were injected with AuNP probes [195]. Recently, 
several studies reported the use of SERS in vivo that mainly focus on tumor detection and 
imaging. SERS has been applied to ex vivo analysis of tissue slides. It could assist in 
cancer surgery to ensure complete removal of tumors, with fast speed and high sensitivity. 
Wang et al. developed probes that targeted and visualized a multiplexed panel of cancer 
biomarkers. The AuNP probes were then put onto freshly excised tissues to determine the 
presence of cancer cells. This technique could achieve in fast detection (less than 
15 minutes) for potential intraoperative use in guiding breast-conserving surgeries 
(Figure 2.9 A) [196]. A dual probe approach that consists of two types of SERS probes 
(one EGFR-specific and one non-specific) was applied to fresh tissue for measuring the 
EGFR concentration with the subtraction of the background signal [197]. Kircher et al. 
showed a triple-modality magnetic resonance imaging (MRI)–photoacoustic imaging–
Raman imaging (MPR) nanoparticle (Figure 2.9 B), where SERS was used to accurately 
delineate the margins of brain tumors in living mice due to its ultrahigh sensitivity and 
spatial resolution. Raman imaging allowed clear signal from particles down to 50 pM, 
which is very low for in vivo imaging [198]. Although working well in glioblastoma mouse 
models, this method has not been very successful in other extracranial tumor models, a 
result possibly due to the lower enhanced permeability and retention EPR effect, as 
mentioned by the one of the group’s recent paper [199].  
1.4.3.4 Recent Improvements of Gold Nanoparticle-based SERS. 
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Although the SERS probes have high sensitivity, the Raman intensity is greatly 
attenuated as it travels through tissue due to scattering. To increase the tissue penetration, 
a combination of the deep Raman spectroscopy with surface-enhanced, spatially offset 
Raman spectroscopy (SESORS) was developed and greatly improved the penetration 
depth from less than 5.5 mm to 25 mm thickness [200]. As mentioned earlier, the Raman 
reporter in the NIR range could reduce the tissue scattering greatly. Gold nanostructures 
such as AuNRs could assist in this purpose. Maltzahn et al. used nanorods coated with 
SERS active molecules that could be uniquely distinguished in vivo, over a spectral sharp 
bandwidth of 6 nm in the NIR (is much smaller than that of semiconductor quantum dots 
(QDs) (~30 nm FWHM), organic fluorochromes, and Raleigh scattering nanoparticles). 
This platform has been used for both SERS imaging and plasmonic photothermal therapy 
in mice [201]. Qian et al. used functionalized AuNRs (conjugated with Raman markers), 
for sentinel lymph node (SLN) mapping and tumor targeting of mice, as well as for the 
observation of  the distribution and excretion of intravenously injected AuNRs in deep 
tissues through purely optical imaging in vivo [202].  
The studies that use SERS as an imaging tool are greatly limited by resolution and 
speed. Kang et al. developed a method to achieve high-speed and high-resolution live cell 
SERS imaging, using NIR excitation (785 nm) and high-speed galvano mirror-equipped 
confocal Raman microscopy system. This system leads to accomplish the high resolution 
(50 × 50 pixels) single live cell imaging within 30 s (10 ms/pixel) and with subcellular 
resolution of cytoplasm, mitochondria, and nucleus [203]. The SERS-sensitive AuNPs 
have a highly narrow intra-nanogap (1.2 nm) and Raman markers embedded, allowing for 
high-sensitive imaging.  
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To improve the SERS probes for high-sensitive bioimaging, bi-layered Raman-
intense gold nanostructures with hidden tags (BRIGHTs) were developed in 2013. The 
Raman reporters are trapped between the core and shell of the gold nanostructure. This 
design exhibited great stability and demonstrated more than two orders of magnitude in 
the enhancement of the SERS signal compared with conventional AuNP SERS probes 
[204].  
SERS presents its own problems for spectroscopy, such as the complex and 
overlapping Raman bands that are sometimes difficult to understand. In many cases, the 
SERS bands are a mixture of all types of molecules in the environment of AuNPs. The 
method used in El-Sayed’s lab utilized mass spectrometry along with SERS to improve 
the understanding of the cellular process in plasmonic photothermal therapy (PPTT).  By 
using metabolomics and proteomics, the changes in SERS bands can be assigned to 
specific chemical compounds within the cells with an improved degree of confidence 








FIGURE 2.9. (A) Surface-enhanced Raman scattering (SERS) aids cancer surgery. 
Printed with permission from Springer Nature [196]. (B) Schematic of SERS probes 
for confirming the brain tumor margins. Printed with permission from Springer 
Nature [198]. (C) SERS and mass spectrometry-based proteomics and metabolomics 
for understanding the cell death mechanism after plasmonic photothermal therapy. 
Printed with permission from American Chemical Society [192]. 
1.4.4 Conclusions and future outlook 
Here we provide a survey of the recent advances regarding the use of AuNPs and 
optical imaging together for application in biological and clinical studies. After the 
massive development in the synthesis and surface modification of AuNPs for decades, we 
now have gained great knowledge of this type of nanoparticle. Various types of AuNPs 
have been experimentally and theoretically studied for their optical properties and 
biological applications. Nonetheless, there are still many challenges, issues and 
opportunities for further exploration in this field. On the technological development side, 
the following improvements are desirable. 
(1) While 2D single particle tracking (SPT) techniques are well established, 3D 
SPT remains challenging. However, in most occasions, 3D information is much needed 
in order to recover the bio-nano interaction accurately. In general, 3D SPT techniques 
rely on simultaneously recording multiple images or manipulating the point spread 
function. Significant amounts of effort have been dedicated towards the development of 
3D SPT for bio-nano interaction [173, 205]. Future development is still needed to provide 
the multi-particle 3D tracking ability with expanded tracking range (from a few 
micrometers in depth to the whole cell thickness) and sub-diffraction-limited resolution.  
(2) The spatial-temporal distribution of nanoparticles in cells can be monitored 
with several microscopic methods with high resolution. However, due to the plasmon 
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coupling effect, it is difficult to discern the small distances between adjacent AuNPs [206], 
resulting in large uncertainties in the localization of AuNPs. To measure the inter-particle 
distances, one strategy involves using “plasmon rulers” with high sensitivity. The 
plasmon ruler is based on the spectra-shift of the SPR when two plasmonic AuNPs 
approach each other with sensitive color changes under the microscope. Although the 
SPR shifting is regarded as a sensitive detection of molecules in live cells, concerns arise 
since the stability and the aggregation of AuNPs can also affect the SPR peak. For 
example, the red-shift of the SPR peak could also result from AuNPs aggregation, thus 
complicating the detection of biomolecules. 
(3) Traditional methods of AuNP fabrication are usually based on seed growth 
methods or lithography. Recently, new breakthroughs such as the usage of DNA self-
assembly for synthesizing plasmonic gold structures in literally any size and shape [207] 
provide new possibilities for fabricating ultra-sensitive hot-spots for single-molecule 
imaging by SERS and PEF. 
(4) Advanced scattering or fluorescence-based imaging techniques with increased 
signal-to-noise ratios and resolution can be coupled with other technological innovations 
to further improve imaging capabilities of AuNPs in vivo. However, the practical 
application of in vivo imaging is still difficult due to the low penetration depth of the 
scattered light in tissue samples. To lower the scattering background and improve the 
detection depth, AuNPs that scatter NIR light (such as AuNRs, core-shell AuNPs, etc.), 
especially in the NIR II window (1000–1700 nm), should be developed and used [208]. 
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On the application side, there are also major challenges: First, it is difficult to 
acquire the fundamental understanding of bio-nano interactions in complex biological 
environments. While most of the past and current studies focus on observing the 
nanoparticles’ behaviors in internalization, transport and bio-distribution, the detailed 
mechanism of how the nanoparticles interact with different biomacromolecules, such as 
proteins, and how they trigger the subsequent biological response is still unknown. The 
advancement of the super-resolution microscopic techniques is promising in shining a 
light on the basic understanding of this process in real time. Second, the clinical 
application is still lacking, which requires more information on the long-term toxicity of 
AuNPs in vivo. The safety of AuNPs in clinical use is still questionable. However, 
several recent reports estimated the toxicity of AuNPs in mice that seems to accumulate 











After summarizing current advance of using gold nanoparticles in optical imaging 
and biological sensing, we are introducing our recent developments for using the SERS 
and Rayleigh scattering properties for detecting biological processes and studying bio-
nano interation, in Section 2.2 and 2.3. 
1.5 Simultaneous Time Dependent Surface-Enhanced Raman Spectroscopy 
Reveals Cancer Death Mechanisms Associated With Gold Nanorod 
Photothermal Therapy[192] 
Note: Yue Wu and Moustafa Ali have equally contributed to designing, performing, 
analyzing, and writing the research in the 2.2 section.  
Summary. In cancer plasmonic photothermal therapy (PPTT), plasmonic 
nanoparticles are used to convert light into localized heat, leading to cancer cell death. 
Among plasmonic nanoparticles, gold nanorods (AuNRs) with specific dimensions enabling 
them to absorb near-infrared laser light have been widely used. The detailed mechanism of 
PPTT therapy, however, still remains poorly understood. Typically, surface-enhanced Raman 
spectroscopy (SERS) has been used to detect time-dependent changes in the intensity of the 
vibration frequencies of molecules that appear or disappear during diff erent cellular 
processes. A complete proven assignment of the molecular identity of these vibrations and 
their biological importance has not yet been accomplished. Mass spectrometry (MS) is a 
powerful technique that is able to accurately identify molecules in chemical mixtures by 
observing their m/z values and fragmentation patterns. Here, we complemented the study of 
changes in SERS spectra with MS-based metabolomics and proteomics to identify the 
chemical species responsible for the observed changes in SERS band intensities during PPTT. 
We observed an increase in intensity of the bands at around 1000, 1207, and 1580 cm−1, 
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which were assigned in the literature to phenylalanine, albeit with dispute. Our metabolomics 
results showed increased levels of phenylalanine, its derivatives, and phenylalanine-
containing peptides, providing evidence for more confidence in the SERS peak assignments. 
To better understand the mechanism of phenylalanine increase upon PPTT, we combined 
metabolomics and proteomics results through network analysis, which proved that 
phenylalanine metabolism was perturbed. Furthermore, several apoptosis pathways were 
activated via key proteins (e.g., HADHA and ACAT1), consistent with the proposed role of 
altered phenylalanine metabolism in inducing apoptosis. Our study shows that the integration 
of the SERS with MS-based metabolomics and proteomics can assist the assignment of 
signals in SERS spectra and further characterize the related molecular mechanisms of the 
cellular processes involved in PPTT. 
1.5.1 Introduction 
Plasmonic nanoparticles offer a powerful means to follow dynamic changes 
associated with intracellular molecular events in real time [209, 210],[211]. Their localized 
surface plasmon resonance (LSPR) confers these particles unique optical properties. For 
example, the electromagnetic fields on the surface of plasmonic nanoparticles are greatly 
increased and exhibit exponential decay patterns following non-radiative (heat) or 
radiative (e.g., light-scattering) processes [212, 213]. Raman scattering from the molecules 
localized near the plasmonic nanoparticles’ surface is therefore enhanced by orders of 
magnitude, resulting in the well-known surface-enhanced resonance spectroscopy (SERS) 
phenomenon [214], [215]. SERS has been successfully applied to single cell analysis, where 
plasmonic gold nanoparticles are placed inside the cell and the resulting SERS spectrum 
collected in order to record the intracellular microenvironment changes occurring over 
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time near the nanoparticles. Our group reported on the spectral changes observed by 
SERS during the full cell cycle of a single cancer cell [216]. The time required to kill 
cancer cells, associated with the time taken for the SERS spectrum to stop changing when 
the cells were given anti-cancer drugs [212],[216]  or were heated [217], was also determined. 
However, the molecular species associated with the observed SERS bands could not be. 
confidently assigned, preventing elucidation of the molecular mechanisms involved in 
these critical cellular processes.  Photothermal therapy has its foundation in the targeted 
destruction of cancerous cells via the heat released by gold nanorods (AuNRs) following 
near-infrared (NIR) radiation absorption. The so-called “water wavelength window” 
between 700 and 1200 nm is widely considered to be the optimal spectral region for 
conducting PPTT[23],  [218], as tissue and water absorption are minimized in this range. 
AuNRs, on the other hand, readily absorb NIR laser light, resulting in effective 
photothermal generators for both in vitro and in vivo applications. AuNRs-based PPTT 
has been successful at inducing cancer cell apoptosis [219], resulting in in vivo tumor 
removal[220], [221], [222]. 
Despite the operational success of PPTT, the molecular mechanisms associated 
with PPTT-induced apoptosis remain largely unknown or under dispute. We observed 
PPTT-induced apoptosis initiated through heat-shock proteins previously [223], while 
several reports indicate it is mediated by the mitochondrial apoptotic pathway via Bid 
activation and caspase 3 activity [56]. Although SERS reports on the real-time 
biomolecular dynamics in the microenvironment associated with the PPTT process, 
SERS spectra from cells are incredibly complex, reflecting overlapping signals from a 
variety of proteins and metabolites that are difficult to assign to individual species. It has 
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been reported, for example, that the 1000 and 1580 cm−1 peaks showed significant 
increases during cell apoptosis [216], with great debate about their assignment [224]. One 
report in the published literature assigned the 1000 cm−1 signal to phenylalanine[225], 
while a different report assigned it to tryptophan[225]. Furthermore, it has been argued8 
that these SERS signals actually reflect changes in protein structure, a topic that is still 
being intensively debated. One hypothesis states that the 1000 cm−1 signal is indicative of 
the exposure of protein hydrophobic rings following conformational changes [216], while 
others report that the protein conformation change induced by adding methanol or sodium 
dodecyl sulfate (SDS) [226] or increasing temperature [217] does not alter the intensity of 
the 1000 cm−1 peak, contradicting the hypothesis that this signal is associated with 
alterations in protein conformation.  
Herein, we monitored the SERS spectral signature in vitro during apoptosis as a 
function of PPTT exposure time. We also performed metabolomics and proteomic studies 
on cell lysates under identical PPTT conditions. Integrative multi-omics network analysis 
revealed specific alterations that explain the underlying changes in SERS spectral data, 
demonstrating the power of combining SERS with MS for studying cellular processes 
following PPTT. 
1.5.2 Methods 
Materials. Tetrachloroauric acid trihydrate (HAuCl4·3H2O), trisodium citrate, 
NaBH4, ascorbic acid, CTAB, AgNO3, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), NaCl, and sodium deoxycholate (SDC) were purchased from Sigma-
Aldrich (USA). Methoxypolyethylene glycol) thiol (mPEG-SH, MW 5000) was 
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purchased from Laysan Bio, Inc. Cell-penetrating peptide RGD 
(RGDRGDRGDRGDPGC) and nuclear localization signal NLS (CGGGPKKKRKVGG) 
peptides were obtained from GenScript, Inc. Dulbecco’s phosphate-buffered saline (PBS), 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), antibiotic 
solution, and 0.25% trypsin/2.2 mM EDTA solution were purchased from VWR. 
Mammalian cell protease inhibitors were purchased from Roche Applied Sciences, 
sequencing grade trypsin was purchased from Promega, and Lysyl endopeptidase (Lys-C) 
was from Wako. 
Instrumentation. Gold nanoparticles were imaged using a JEOL 100CX-2 
transmission electron microscope, and their average size was then measured by ImageJ 
software. UV−vis spectra were obtained using an Ocean Optics HR4000CG UV−NIR 
spectrometer. SERS spectra were collected using a Renishaw InVia Raman microscope 
equipped with a 785 nm diode Raman excitation laser and a Leica optical microscope. 
Comprehensive metabolomics analyses were performed with ultra-performance liquid 
chromatography−mass spectrometry (UPLC-MS), using a Waters ACQUITY UPLC H 
Class system fitted with a Waters ACQUITY UPLC BEH C18 column (2.1 mm × 50 mm, 
1.7 μm particle size, Waters Corp., Milford, MA, USA), coupled to a Xevo G2 QTOF 
mass spectrometer (Waters Corp., Manchester, UK) with an electrospray ionization 
source. The typical resolving power and mass accuracy of the Xevo G2 QTOF mass 
spectrometer were 25 000 (fwhm) and 1.8 ppm at m/z 554.2615, respectively. Proteomics 
analysis was done on a hybrid dual-cell quadrupole linear ion trap−orbitrap mass 
spectrometer (LTQ Orbitrap Elite, Thermo Fisher) with Xcalibur 3.0.63 software. Flow 
cytometry experiments were conducted on a BD LSR II flow cytometer (BD Biosciences).  
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 Synthesis, Conjugation, and Characterization of AuNSs and AuNRs. Gold 
nanospheres with an average diameter of 30−40 nm were synthesized using the citrate 
reduction method. Briefly, 200 mL of 0.254 mM HAuCl4·3H2O solution was heated 
until boiling and then reduced by adding 5 mL of 0.35% of trisodium citrate. The solution 
was then left heating until it turned wine red, followed by cooling under water flow. The 
citrate-stabilized AuNSs were first centrifuged at 5000g for 10 min and then redispersed 
in deionized (DI) water to remove extra citrate for the next step of conjugation. AuNRs 
with an average size of 25 nm × 6 nm (length × width) were synthesized using a seedless 
growth method. Briefly, 5 mL of 1.0 mM HAuCl4 was added to a mixture of 5 mL of 
0.20 M CTAB, 250 μL of 4.0 mM AgNO3, and 8 μL of 37% HCl. Next, 70 μL of 78.8 
mM ascorbic acid was added, and then 15 μL of 0.01 M of ice-cold NaBH4 was 
immediate injected. The solution was left undisturbed for 12 h, followed by 
centrifugation at 21000g for 50 min. It was redispersed in DI water, and a second 
centrifugation at 19000g for 40 min removed the extra CTAB. TEM was used to measure 
the sizes and homogeneity of the nanoparticles. AuNSs and AuNRs were then conjugated 
according to previous work.8 First, mPEG-SH (1 mM) was added to the nanoparticles 
overnight to achieve about 1000 ligands on each particle. The PEGylated nanoparticles (1 
nM) were then treated with RGD (1 mM) and NLS (1 mM) to achieve 104 and 105 molar 
excess, respectively. The number of the ligands bound to the AuNPs was about 25% of 
the added ligands, evaluated on the basis of Ellman’s protocol [227]. The solution was then 
shaken overnight at room temperature. Excess ligands were removed by centrifugation. A 
UV−vis spectrometer and zetasizer were used to test the conjugation. Surface 
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modification causes a red shift of the UV−vis spectra due to the change in the dielectric 
constant of the surrounding environment of AuNSs. 
Cell Culture, AuNPs Incubation, and Plasmonic Photothermal Therapy. 
Human oral squamous cell carcinoma (HSC-3) cells were grown in DMEM medium 
containing 10% (v/v) FBS and 1% (v/v) antibiotic solution. Cells were kept at 37 °C in a 
humidified incubator under 5% CO2. HSC-3 cells were incubated overnight with 2.5 nM 
AuNRs in complete media and then were exposed to a CW laser (808 nm 5.8 W/cm2) for 
different times. The concentration of nanoparticles was carefully chosen to avoid 
cytotoxicity or perturbation of the cell cycle. 
In Vitro SERS Measurement. Time-dependent SERS spectra were collected 
throughout the NIR laser exposure period to monitor molecular changes in the plasmonic 
nanoparticle microenvironment during photothermal heating of the AuNRs. The Raman 
laser was directed into a microscope and, after focusing on the sample by a 50×/0.75 N.A. 
objective, formed a 1−2 μm spot size. Spectra of molecules in the single cell were 
measured with a 1200 lines/mm grating and collected by a CCD detector in the range of 
400−1800 cm−1 using a Renishaw InVia Raman spectrometer. Spectrum baseline was 
removed using R Package Baseline (version 1.2-1). Dark-field images were taken by a 
Lumenera Infinity2 CCD camera. For SERS studies, the cells were seeded on glass 
coverslips in complete growth medium for 24 h to achieve a 40% final confluence before 
SERS study. The cells were then incubated with 0.05 nM PEG/RGD/NLS-functionalized 
AuNSs in supplemented DMEM cell culture medium for 24 h. Six hours before the SERS 
examination, the cell media (with AuNSs) were removed, and a 2.5 nM concentration of 
AuNRs suspended in supplemented medium was added to the cells to perform PPTT. 
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Apoptosis/Necrosis Assay. HSC-3 cells were cultured in 12-well plates for 24 h 
and then treated with a 2.5 nM concentration of AuNRs@NLS for 24 h. After AuNRs 
incubation, PPTT was applied for different time periods. Before the apoptosis/necrosis 
assay, the cell culture medium was removed, and cells were collected after trypsinization, 
followed by washing with cold PBS twice. The cells were the dispersed in 493 mL of 
Annexin V binding buffer, and 5 μL of Annexin V FITC (BioLegend) and 2 μL of PI 
(BioLegend, 100 μg/mL) were added to the cell suspension and incubated for 15 min at 
room temperature. The cells were then filtered and subjected to flow cytometry analysis 
using a BSR LSR II flow cytometer (BD Biosciences). A 488 nm laser was applied for 
excitation, and FITC was detected in FL-1 using a 525/30 BP filter, while PI was 
detected in FL-2 using a 575/30 BP filter. Standard compensation using unstained and 
single-stained cells was done before performing actual experiments. FlowJo software 
(Tree Star Inc.) was used for analysis of the viable, apoptotic, and necrotic cells from at 
least 10 000 events. 
Sample Preparation for Metabolomics Experiments. Cells were cultured in 60 
mm Petri dishes. The culture media was removed, and cells were washed three times with 
PBS, followed by a wash with DI water for 2 s and immediate removal of the wash 
solution. Immediately, 7 mL of metabolite extraction solvents (HPLC-grade 
methanol:acetonitrile (ACN):0.5 M formic acid (FA), 2:2:1 v/v/v, −20 °C) was added for 
quenching and lysing the cells.65 Cells were then scraped down, and the cell suspension 
was transferred to centrifuge tubes, followed by vortexing and sonication in an ice−water 
bath and incubation on ice for 15 min for metabolite extraction. The cell suspension was 
then centrifuged at 20400g at 4 °C for 15 min. Solvent in the sample was evaporated 
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using a CentriVap vacuum concentrator until dryness. The dried samples were kept at 
−80 °C until analysis. 
Sample Preparation for Proteomics Experiments. Cells were cultured in 60 
mm Petri dishes. Ice-cold lysis buffer (50 mM HEPES, pH 7.8, 150 mM NaCl, 0.1% SDS 
(optional), 0.5% SDC, 1% Triton X 100 or NP-40, phosphatase inhibitors) was added 
directly to the cells after they were washed twice with PBS. The cells were then scraped 
down and the obtained mixtures homogenized with sonication and vortexing. Cell debris 
was then removed by centrifugation at 18000g for 20 min at 4 °C. Four volumes of ice-
cold acetone:ethanol:acetic acid (50:50:0.1 v/v/v) was added to the supernatant to 
precipitate the proteins at −20 °C overnight. After centrifugation, the protein pellet was 
redissolved in denaturing buffer (pH 8.0) containing 8 M urea and 50 mM HEPES, and 
the protein concentration was tested using a Bradford assay. The disulfide bonds in the 
protein solution were reduced by 2 mM dithiothreitol at 37 °C for 2 h and subsequently 
alkylated by addition of 6 mM iodoacetamide. The solution was kept in darkness at room 
temperature for 40 min. 
Ultra-Performance Liquid Chromatography (UPLC)-MS Metabolomics 
Analysis. Before analysis, ultra-pure water was added to each dried sample to obtain a 
final biomass concentration of ∼50 000 cells/μL. Samples were further vortexed and then 
centrifuged at 15 000 rpm for 10 min at 4 °C. The supernatant of each biological sample 
was transferred to auto-sampler vials for UPLCMS analysis. Gradient elution was 
employed in the chromatographic separation method using 0.1% acetic acid in water 
(mobile phase A) and ACN (mobile phase B), with the following program: 0−1 min, 98% 
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A, 1−3 min 98%−70% A, 3−8 min 70%−50% A, 8−10 min 50%−5% A, 10−15 min 5% 
A. The flow rate was constant at 0.3 mL min−1. After each sample run, the column was 
re-equilibrated to the initial conditions in 6 min. The injection volume was 5 μL. The 
column and auto-sampler tray temperatures were set at 35 and 5 °C, respectively. The 
mass spectrometer was operated in negative ion mode with a probe capillary voltage of 
2.2 kV and a sampling cone voltage of 45.0 V. The source and desolvation gas 
temperatures were set to 120 and 350 °C, respectively. The nitrogen gas desolvation flow 
rate was 650 L h−1. The mass spectrometer was calibrated across the range of m/z 
50−1200 using a 0.5 mM sodium formate solution prepared in 2-propanol:water (90:10 
v/v). Data were drift-corrected during acquisition using a leucine enkephalin (m/z 
554.2615) reference spray (Lock Spray) infused at 3 μL min−1. Data were acquired in the 
range of m/z 50−1200, and the scan time was set to 1 s. Technical duplicates were 
acquired in all cases. Tandem MS experiments were carried out by fast data-dependent 
acquisition (fast DDA) or MS/MS in negative polarity and resolution mode. Targeted 
ions for MS/MS were entered in an include list. A 0.2 s continuum MS survey scan was 
collected from 50 to 650 Da until the intensity of an individual precursor ion rose above 
5000, and then we switched to MS/MS acquisition, in which a 0.1s continuum scan was 
collected from 30 to 650 Da. The MS/MS scan switched off once the accumulated total 
ion current reached 100 000 or after 0.25 s. A collision energy profile of 15, 25, and 35 V 
was applied to the trap cell for ion fragmentation. For the MS/MS method, the scan time 
was 1 s, and collision voltages between 8 and 30 V were applied to the trap cell. Data 
acquisition and processing were performed with Masslynx v4.1 software. 
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LC-MS/MS Analysis for Proteomic Experiments. Purified and dried peptide 
samples were dissolved in a 10 μL solution containing 5% ACN and 4% FA, and 3 μL 
was loaded onto a microcapillary column packed with C18 beads (Magic C18AQ, 3 μm, 
200 Å, 100 μm × 16 cm, Michrom Bioresources) by a Dionex WPS-3000T PLUS auto-
sampler (UltiMate 3000 thermostated Rapid Separation Pulled Loop Well Plate Sampler). 
Peptides were separated by reverse-phase chromatography using an UltraMate 3000 
binary pump with a 110 min gradient of 8−38% ACN (with 0.125% FA) for the 
triplicates. Peptides were detected with a data-dependent Top 20 method (the 20 most 
abundant ions were selected for MS2) in a hybrid dual-cell quadrupole linear ion 
trap−Orbitrap mass spectrometer (LTQ Orbitrap Elite, Thermo Fisher, with Xcalibur 
3.0.63 software). For each cycle, each full MS scan (resolution: 60 000) in the Orbitrap at 
106 AGC target was followed by up to 20 MS/MS for the most intense ions in the LTQ. 
The selected ions were excluded from further analysis for 90 s. Ions with singly or 
unassigned charge were not sequenced. For each full MS scan, the maximum ion 
accumulation time was 1000 ms, and that for MS/MS scans was 50 ms. Mass spectra 
Raw files were converted into mzXML format and then searched using the SEQUEST 
algorithm (version 28).68 Spectra were matched against a database containing sequences 
of all proteins in the UniProt Human (Homo sapiens) database (downloaded in February 
2014). The search was performed using following parameters: fully digested with trypsin; 
up to 3 missed cleavages; fixed modifcations: carbamidomethylation of cysteine 
(+57.0214); variable modifcations: oxidation of methionine (+15.9949). False discovery 
rates (FDRs) of peptide and protein identifications were controlled by the target-decoy 
method. Linear discriminant analysis was used to control the quality of peptide 
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identifications using parameters such as Xcorr, precursor mass error, and charge state. 
Peptides less than seven amino acid residues in length were deleted. Furthermore, peptide 
spectral matches were filtered to <1% FDR. 
Data Analysis. For metabolomics, spectral features (tR, m/z pairs) were extracted 
from UPLC-MS data using Progenesis QI version 2.0 (Nonlinear Dynamics, Waters 
Corp.). The data preprocessing procedures included retention time alignment, peak 
picking, integration, and deconvolution to group the adducts derived from the same 
compound. Raw data from metabolomics were normalized using supervised 
normalization of the microarray (SNM).73 In the SNM procedure, variances due to 
biological and technical replicates were adjusted by setting them as variables in the 
model. A variance explained by different experimental treatments (control, 
AuNRs@NLS, and AuNRs@NLS/PPTT) was fitted as a biological variable in the model. 
Clustering analysis on the similarity matrix of metabolomics data was carried out to 
verify the reproducibility of metabolomics experiments. Hierarchical clustering was done 
with JMP software (version 9, SAS Institute Inc., Cary, NC). Metabolomics data were 
log2 transformed before analysis of variance (ANOVA), which was used to detect 
differential levels of metabolites between control and treatment groups. We fitted models 
with treatment conditions as fixed effects. A Benjamini−Hochberg 5% FDR correction 
was used to select differential metabolites. For identified differential metabolites 
perturbed by PPTT, we used the Mummichog program for network-level metabolites 
annotation. The MS mode considered in Mummichog was negative ion in order to 
compute isotopic and adduct species. The metabolites identified as being affected by 
PPTT were subjected to pathway analysis using the MetaCore pathway analysis software 
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(from Thomson Reuters). For proteomics, raw data were also normalized using SNM. 
Clustering analysis on the similarity matrix of data was also carried out to show the 
reproducibility of the experiments. Hierarchical clustering was done with JMP software. 
The identified proteins were subjected to pathway analysis using the MetaCore software 
to study the effect of PPTT.  
1.5.3 Results 
1.5.3.1 Formulation of AuNRs and cell uptake 
To perform PPTT inside human oral squamous cell carcinoma (HSC-3) cells, 
AuNRs were used in order to efficiently convert NIR light into heat. The AuNRs were 
synthesized using a seedless method [228] with an average size of 25 nm × 6 nm, as shown 
in Figure 2.10 b (transmission electron microscopy (TEM) image), and an absorption 
maximum at about 800 nm (as shown in the UV−vis spectrum in Figure 2.10 c). This 
particle size is favorable in conducting PPTT, as it has better efficiency for conversion of 




FIGURE 2.10. Characterization of conjugated AuNRs and measurement of HSC-3 
(human squamous carcinoma) cell endocytosis with AuNRs. (a) Schematic showing 
the surface conjugation of the AuNRs with PEG, followed by RGD and NLS. (b) 
Transmission electron microscopy (TEM) image of conjugated AuNRs. Scale bar = 
100 nm. (c) UV−vis absorption spectra of the unconjugated AuNRs (black spectrum) 
and AuNRs conjugated with NLS (red spectrum). (d) Dark-field images of control 
HSC-3 cells (not exposed to AuNRs), cells exposed to AuNRs@PEG, and cells 
exposed to AuNRs@NLS for 24 h. Scale bar = 20 μm. (e) UV−vis absorption spectra 
of the AuNRs@NLS dispersed in culture media before (black spectrum) and after 
(red spectrum) incubation with cells.  
For formulation of AuNRs@NLS, we first used methoxypolyethylene glycol thiol 
(mPEG-SH) to modify the surface of AuNRs to gain better biocompatibility [230]. The 
PEGylated particles were then functionalized with Arg-Gly-Asp (RGD) peptides (known 
to bind to Rvβ6 integrin on the surface of cancer cells to enhance the receptor-mediated 
endocytosis of the nanoparticles [231]) and nuclear localization signal (NLS) peptides 
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(peptide sequences that are recognized by importin and translocate near the nucleus [232]), 
as shown in Figure 2.10 a. Successful surface modification of AuNRs@NLS is evident 
in the red-shift of the plasmon peak of AuNRs, from 800 nm for the as-synthesized 
AuNRs to 825 nm for AuNRs@NLS (Figure 2.10 c). The zeta potentials of the AuNRs 
at different stages were measured (Table 2.1) to confirm surface modifications. The as-
synthesized cetyltrimethylammonium bromide (CTAB)-coated AuNRs had highly 
positive surface charges, as imparted by the CTAB cationic surfactant. Following PEG 
modification, the AuNRs became negatively charged (−10.2 ± 6.73 mV). The zeta 
potential of the AuNRs became positive again after further modification of the RGD and 
the NLS peptides. 
Table 2.1. Zeta potential results for AuNRs with different surface modifications 
Nanoparticles Zeta potential value/ mV 
CTAB-coated AuNRs 22.9±15.1 
AuNRs@PEG -10.2±6.73 
AuNRs@PEG@RGD/NLS 35.7± 8.96 
The uptake of AuNRs was first monitored by dark-field (DF) microscopy. The 
HSC cells were incubated with a 2.5 nM concentration of AuNRs for 24 h. For 
AuNRs@NLS, as shown in the DF image (Figure 2.10 d), clear internalization was 
observed compared with cells not exposed to AuNRs and cells exposed to AuNRs 
without targeting agents. The DF image shows that AuNRs@NLS accumulated in 
nuclear regions. In addition, the UV−vis spectra of culture media with AuNRs before and 
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after incubation with cells were also collected (Figure 2.10 e), which showed a decrease 
of the peak intensity that reflects the portion of AuNRs being uptaken by the cells. 
Differential interference contrast (DIC) microscopy also confirmed the cellular 
internalization of AuNRs@NLS (Figure 2.11). In summary, AuNRs were successfully 
formulated and then introduced into cells with good cell uptake. The cell viability and 
apoptosis were tested under different concentrations of AuNRs. The results indicate that 
the concentration of the AuNRs utilized in this study is much lower than that affecting 
cell viability or inducing apoptosis (Figure 2.12). 
 
FIGURE 2.11. Differential interference contrast (DIC) microscopy image of the 




FIGURE 2.12. Cell viability (XTT assay) (a) and flow cytometry (apoptosis/necrosis 
assay) (b) results for HSC cells incubated with AuNRs. 
1.5.3.2 SERS of cancer cells undergoing AuNRs-based photothermal therapy 
The AuNRs with dimensions 25 nm × 6 nm and concentration 2.5 nM were 
selected for use for heat generation. After incubation with AuNRs for 24 h, a continuous-
wave (CW) 808 nm NIR laser with power of 5.8 W/cm2 [229, 233, 234] was used for 
irradiation of the cells for different time intervals. The laser wavelength overlapped with 
the longitudinal SPR peaks of the AuNRs. The temperature rose to 45 °C after 2 min of 
laser exposure. The effect of PPTT was confirmed using a cell viability assay and an 
apoptosis/necrosis assay. The cell viability results showed a significant decrease in the 
percentage of viability (∼40%) for the HSC cells incubated with AuNRs (2.5 nM) after 
exposure to the 808 nm NIR laser for 3 min (Figure 2.13). In the apoptosis/necrosis 
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assay, cells were labeled with Annexin V and propidium iodide (PI), and the fluorescent 
signals were examined by flow cytometry. As shown in Figure 2.13, the number of 
apoptotic cells significantly increased after PPTT was applied. The decrease of cell 





FIGURE 2.13. Apoptosis/necrosis assay (a to e) and cell viability assay (f) for the 
HSC-3 samples treated with PPTT at different time; Q1 (necrosis), Q2 (apoptosis), 
Q3 (early apoptosis) and Q4 (early apoptosis). 
For real-time SERS measurement, spectra were collected at a single spot of cells 
to avoid variations due to changing location. A 785 nm laser was focused on a single cell, 
and spectra were recorded. As our AuNRs have weak SERS signals (due to their small 
size), in order to enhance the signals, 40 nm gold nanospheres (AuNSs) with the same 
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surface modification as AuNRs were used to assist the detection [235]. Detailed 
information about AuNSs@NLS characterization and cellular uptake is given in Figure 
2.14. The introduction of AuNSs does not affect AuNRs uptake or SERS spectra shapes 
during the PPTT process due to their small amount and the fact that they do not absorb 
NIR light (Figure 2.15). SERS spectra of HSC cells without PPTT were comparable with 
our previous publications[216], [224],[236]; possible assignments for each peak are given in 
Table 2.2. Upon NIR laser exposure, the band around 1000 cm−1 increased in intensity, 
due mainly to the benzene ring breathing of phenylalanine as mentioned before [237]. 
Though in most publications this band is assigned to phenylalanine, some debate is still 
going on regarding its assignment [226], [238]. Further, we observed that the enhancement of 
the 1000 cm−1 peak was accompanied by the enhancement of the 1207 and 1580 cm−1 
bands (Figure 2.16 a), which are attributed to the in-plane CH stretching vibration and 
sidechain vibration coupled with the in-phase motion corresponding to phenylalanine [216, 
239]. The same experiment was repeated three times, and the same trend of peak intensity 
changes of 1000, 1207, and 1580 cm−1 was obtained (Figure 2.16 b and 2.17). SERS of 
cells 12 h after PPTT has also been performed to confirm that the signal remains altered 
(Figure 2.18). On the other hand, a control experiment was conducted on cells without 
laser exposure. No obvious SERS spectral change was observed during NIR laser 
irradiation of the control (Figure 2.19). This gave us more evidence of the phenylalanine 




FIGURE 2.14. Characterization of AuNSs@PEG@RGD@NLS. (a) Transmission 
electron microscope (TEM) image of conjugated gold nanospheres (AuNSs). Scale 
bar = 100 nm. (b) UV-Vis absorption spectra of the unconjugated AuNSs (black 
spectrum), PEG conjugated AuNSs (red spectrum) and AuNSs conjugated with 
NLS (green spectrum). (c) Zeta potential of AuNSs with different conjugations. (d) 
The dark field images of HSC-3 cells with or without AuNRs@NLS incubation for 




FIGURE 2.15. The uptake of AuNRs by HSC-3 cells before and after 24 h 
incubation. The pre-existence of AuNSs does not affect the further internalization of 
AuNRs. 
 
FIGURE 2.16. (a) SERS spectra collected from a single HSC-3 cell under NIR laser 
exposure (808 nm diode laser, 5.8 W/cm2) at 1 and 2 min delays. The 750, 1000, 1207, 
and 1580 cm−1 bands are shown in red and placed in red boxes. (b) Bar graphs of 
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the Raman bands associated with biomolecules located within the AuNP plasmonic 
field.  
Table 2.2. Tentative assignment of Raman bands in the SERS spectra collected from 
HSC cells [236, 240]. 
Wavenumber (cm-1) Tentative assignments of SERS bands 
495-510 -S-S- 
640−660 -C-S- 
820−850 Tyr and lipids O−C−C−N symmetric 
stretches  
990-1010 Phe ring breathing 
748-758 pyrrole breathing mode ν15 in cytochrome 
c 
1012−1030 In-plane bending mode of Phe and ring 
breathing of Trp 
1200−1210 C6H5−C stretch of Phe and Tyr 
1584−1592 Phe 
Generally, we can rule out the possibility of tryptophan contributing to the 1000 
cm−1 signal since side-chain vibrations in its SERS spectrum appear at 758, 869, 1011, 
1357, 1410, 1546, and 1602 cm−1, corresponding to the counterparts at 756, 874, 1009, 
1358, 1423,1558, and 1619 cm−1 in the solid Raman spectrum [241]. However, our SERS 
data did not show obvious increases of these peaks. Therefore, our SERS results support 
the conclusion that the phenylalanine increases in the microenvironment around the 




FIGURE 2.17. Additional SERS spectra collected from single HSC-3 cell (incubated 
with AuNRs 24 h prior to PPTT) under NIR laser exposure of (808 nm diode laser 
5.8 w/cm2) at different times (1 and 2 minutes).  
In addition to the phenylalanine bands, we also observed a 750 cm−1 band whose 
intensity increases during PPTT (Figure 2.16), which has been assigned to the pyrrole 
breathing mode ν15 in cytochrome c [242],[243].  This result suggested the increase of 
apoptotic cells during thermal heating through cytochrome cmediated apoptosis. This 





FIGURE 2.18. SERS spectra collected from single HSC-3 cell 12 hours after PPTT 
(incubated with AuNRs 24 h prior to PPTT, under NIR laser exposure of 808 nm 




FIGURE 2.19. SERS spectra of a) PPTT on cells with AuNSs alone (without AuNRs) 
and b) cell incubated with AuNRs but no laser exposure. 
1.5.3.3 Metabolomics and Proteomics Experiments Confirming Perturbation of 
Phenylalanine Metabolism during gold nanorod-based photothermal therapy  
 For metabolomics experiments, we analyzed the metabolites of cells using 
liquid chromatography−mass spectrometry (LC-MS). Two biological replicates and two 
technical replicates were conducted. A total of 1122 tentative features (retention time (tR), 
m/z pairs) were detected in metabolite extracts, corresponding to 152 metabolites with 
detectable ([M − H]−) primary ion. Hierarchical clustering analysis on the similarity 
matrix of metabolomics data was carried out to verify the reproducibility of the 
experiments (Figure 2.20 b). Among these, 238 metabolomics features were 
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differentially expressed in the AuNR@NLS-treated group when compared to the control 
group (FDR = 0.05, corresponding to p = 0.015) (Figure 2.20 e); 483 metabolomics 
features were differentially expressed in the AuNR@NLS/PPTT group when compared 
to the control group (FDR = 0.05, corresponding to p = 0.015) (Figure 2.20 f). 
Specifically, many of these features corresponded to an increase in the relative amount of 
phenylalanine (Figure 2.21 a) and related species after PPTT (Figure 2.21 b−d and 
2.22). Phenylalanine derivatives and phenylalanine-containing short peptides, such as 
glutamylphenylalanine (Figure 2.21 b), asparaginyl-phenylalanine (Figure 2.21 c), and 
histidinyl-phenylalanine (Figure 2.21 d), were among those altered, explaining the trends 
observed in the SERS data. Tandem MS experiments confirmed the identity of the 








FIGURE 2.20. Clustering analysis and differential analysis of proteomics and 
metabolomics data. (a) Clustering analysis of proteomics data. Two biological 
replicates (labeled as B1 and B2) and three MS technical replicates (labeled as T1, 
T2, and T3) were conducted. Clustering analysis indicated good reproducibility for 
the proteomics experiments. (b) Clustering analysis of metabolomics data. Two 
biological replicates (labeled as B1 and B2) and two MS technical replicates (labeled 
as T1 and T2) were conducted. Clustering analysis indicated good reproducibility 
for the metabolomics experiments. (c) Volcano plot showing that 434 proteins were 
differentially expressed in AuNR@NLS group compared to control group (p=0.1). 
In total, 1341 proteins are identified. (d) Volcano plot showing that 402 proteins 
were differentially expressed in AuNR@NLS/PPTT group in contrast to control 
group (p=0.1). (e) Volcano plot showing that 238 metabolomics features were 
differentially expressed in AuNR@NLS group compared to control group 
(FDR=0.05, corresponding to p=0.015). A total of 1122 metabolomics features were 
detected in metabolite extracts, corresponding to 152 metabolites with primary ion 
([M-H]-). (f) Volcano plot showing that 483 metabolomics features were 
differentially expressed in AuNR@NLS/PPTT group in contrast to control group 




FIGURE 2.21. Metabolite perturbations observed in HSC-3 cells treated with 
AuNRs-PPTT (NLS conjugated particles). (a−d) Bar graphs showing the 
normalized abundance of phenylalanine-related metabolites altered following PPTT: 
(a) L-phenylalanine (the result was confirmed by MS/MS, shown in panel e); (b) 
glutamyl-phenylalanine; (c) asparaginyl-phenylalanine; and (d) histidinyl-
phenylalanine. Normalized abundances of metabolites following AuNRs@NLS 
without PPTT are also given for comparison. (e) Product ion spectrum obtained 
under data-dependent acquisition conditions for the precursor ion at m/z 164.0710. 
Matching of this mass spectrum to the Metlin database MS/MS reference spectrum 
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of phenylalanine (10 V collision energy) is shown, with mass accuracies indicated for 
each ionic species detected. 
 
FIGURE 2.22. Heat map showing fold change (log2) of key metabolites related to 
phenylalanine metabolism in treatment experiments (AuNRs@NLS, 
AuNRs@NLS/PPTT) compared to control group. 
Furthermore, we also conducted a label-free quantitative proteomics experiment 
for studying alterations in protein abundances and seeking possible evidence for, and 
understanding of the mechanisms responsible for the phenylalanine concentration 
increase. A test experiment was done to measure the accuracy of our proteomics 
workflow using the reported method [244], where 99% of the proteins have shown accurate 
quantification (Figure 2.23). Mitochondrial acetyl-CoA acetyltransferase (ACAT1) has 
been shown to be involved in the development of doxorubicin resistance to decrease cell 
apoptosis [245]. Another mitochondrial protein, hydroxyl-coenzyme A dehydrogenase/3-
ketoacyl-coenzyme A thiolase/enoylcoenzyme (HADHA), has been shown to prevent 
chemically induced apoptosis in cancer treatment [246] [247]. In our experiments, both 
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proteins were observed to be down-regulated following PPTT treatment, suggesting that 
the anti-apoptotic protection was turned off resulting in enhanced vulnerability to 
apoptosis (Figure 2.24 b,c). 
 
FIGURE 2.23. Quantification accuracy examination of proteomics workflow: Log2 
ratio distributions of quantified peptides from 2 identical test samples (yeast whole 





FIGURE 2.24. (a) Schematic diagram explaining the molecular apoptosis 
mechanisms involved in altering phenylalanine metabolism as induced by PPTT. 
(b−g) Bar graphs showing the normalized abundance of key proteins contributing to 
apoptosis involved in altering phenylalanine metabolism following PPTT: (b) 
HADHA, (c) ACAT1, (d) Lamin B1 (LMNB1), (e) PAK1, (f) PPP1R12A, and (g) 
LAMP2. Normalized abundances of key proteins following AuNRs@NLS without 
PPTT are also given for comparison. 
In addition to the phenylalanine metabolism pathway, three possible mechanisms 
of phenylalanine-induced apoptosis were suggested by the results. First, increased 
phenylalanine was shown to induce apoptosis by involvement of the Fas receptor (FasR)-
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mediated cell death receptor pathway [248]. In this study, two proteins (Lamin B1 and 
PAK1) in the Fas/Fas ligand death receptor pathway were identified. These two proteins 
have been previously demonstrated to be associated with apoptosis. Lamin B1, as the 
major component of the nuclear lamina underlying the nuclear membrane, plays an 
important role in maintaining nuclear membrane integrity. Destruction of nuclear 
membrane integrity being a hallmark of apoptosis. During apoptosis, Lamin B1 mRNA 
level have been shown to decrease [249], which could result from induction of either p53 
or pRB tumor suppressor pathways [250] [251]. Literature results also show that the Fas/Fas 
ligand complex downstream effector PAK1 is required to prevent apoptosis by limiting 
the expression of pro-apoptotic proteins or modulating posttranslational modifications on 
effectors [252]. In this study, both of these proteins were down-regulated, suggesting a 
cellular shift toward apoptosis, and reduced anti-apoptotic protection (Figure 2.24 d,e).  
Phenylalanine has also been shown to activate mitochondriamediated apoptosis 
through the Rho/ROCK pathway 36,47. In this study, we identified down-regulation of the 
myosin phosphatase targeting subunit 1 (PPP1R12A) in PPTT-treated cells, this being a 
downstream effector of ROCK (Figure 2.24 f) that would contribute to the apoptotic 
phenotype following PPTT. In apoptotic cells, PPP1R12A is cleaved, with the cleaved 
PPP1R12A inhibiting myosin II binding, which results in membrane blebbing and 
apoptosis [253].  
A third mechanism of phenylalanine-induced cell death involves a component in 
Granzyme B signaling-mediated apoptosis, known as lysosome-associated membrane 
protein 2 (LAMP2). This protein was down-regulated following PPTT treatment (Figure 
2.24 g). LAMP2 is critical to maintain lysosome integrity and normal cellular function, 
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and lower levels of LAMP proteins have been positively associated with apoptosis [254]. It 
is not yet conclusively established, however, whether decreased LAMP2 levels are 
alsodirectly associated with phenylalanine-induced apoptosis. 
1.5.4 Discussion. 
Time-dependent SERS has recently enabled researchers to probe molecular 
changes in single (cancer) cells over time during the full cell cycle, or as the cell dies 
from exposure to drugs or from heat treatment. SERS accurately follows changes in 
cellular and subcellular environments during the onset and progression of processes such 
as apoptosis and mitosis [216, 236] in real time and at a single-cell level. Cells present 
several active molecular Raman bands associated with biomolecules located within the 
AuNP plasmonic field. 
Herein, we coupled SERS measurements with metabolomics and proteomics 
experiments performed on the same set of samples, aiming to study the change of the 
subcellular microenvironment around AuNRs during the PPTT process. Our SERS data 
showed that the 1000, 1207, and 1580 cm−1 bands increased during PPTT, which 
suggested an increase of phenylalanine and its derivatives. These findings were 
confirmed with whole cell metabolomics experiments using high-resolution mass 
spectrometry. We observed an increase of free phenylalanine, together with an increase 
of its derivatives and phenylalanine-containing peptides. Integrative analysis of 
proteomics and metabolomics data also showed that the proteins and metabolites in the 
phenylalanine metabolism pathway related to apoptosis were perturbed in apoptosis 
direction. Elevated levels of phenylalanine have been implicated in mitochondria-
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mediated apoptosis through Rho/ROCK pathway and Fas/Fas ligand mediated apoptosis 
[248, 255]. In this study, both pathways were changed in favor of apoptosis in PPTT, where 
the level of phenylalanine was increased. In addition, the results suggested that, during 
phenylalanine induced apoptosis, lysosome integrity may have been perturbed, which 
may further contribute to cell death. This hypothesis was further strengthened by the 
observation of an increasing pattern of pyrrole breathing mode ν15 in cytochrome c 
shown in the SERS spectra (750 cm−1), which suggests the increase of apoptotic cells 
during thermal heating through cytochrome c-mediated apoptosis, which is in agreement 
with flow cytometry data (Figure 2.13.). Meanwhile, some other apoptosis pathways 
were revealed by proteomics, shown in Figure 2.25. 
 
FIGURE 2.25. Other apoptosis pathways revealed by proteomics results. 
Further investigations into the mechanism of how PPTT treatment increases 
phenylalanine levels in cells focused on the fact that phenylalanine can be converted to L-
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tyrosine [256]. Metabolomics data indicated that, after PPTT treatment, the level of L-
tyrosine was actually decreased (Figure 2.26). Based on our results, the channel allowing 
for the conversion from phenylalanine to L-tyrosine could have contributed to the 
accumulation of phenylalanine, which further induced mitochondria-mediated apoptosis. 
 
FIGURE 2.26. Pathway map showing that the phenylalanine metabolism pathway 
was perturbed after PPTT and key proteins (HADHA, ACAT1) were down-
regulated, which triggers apoptosis. (Red) means upregulation after PPTT, (blue) 
means down-regulation after PPTT. In the thermometer sign, 1 refers to 
metabolomics results, 2 refers to proteomics results. The thermometers are filled to 
various degrees, corresponding to the amount by which the markers were up-
regulated or down-regulated. 
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Note: in the figure, “Acetyl-CoA acyltransferase” represents “hydroxyacyl-CoA 
dehydrogenase/3-ketoacylCoA thiolase/enoyl-CoA hydratase (trifunctional protein), 
alpha subunit”, which is a protein complex catalyzing the 3-hydroxyacyl-CoA 
dehydrogenase and enoyl-CoA hydratase activities. HADHA and HADHB are both 
subunits of this protein complex. HADHA is down-regulated, while the HADHB is 
upregulated. However, the down-regulation of HADHA is the rate limiting step forming 
the effective protein complex. Therefore, the activity of protein complex Acetyl-CoA 
acyltransferase is down-regulated, contributing to the mitochondria mediated apoptosis 
process. ACAT1 is acetyl-CoA acetyltransferase 1, which is a mitochondrially localized 
enzyme that catalyzes the reversible formation of acetoacetyl-CoA from two molecules 
of acetyl-CoA. ACAT2 is cytosolic localized acetyl-CoA acetyltransferase 2, which 
involved in lipid metabolism. The mitochondrial isoform ACAT1 is down-regulated hints 
its perturbation contributes to mitochondria mediated apoptosis processes, while the 
cytosolic isoform ACAT2 is not related to this process. 
We observed in our results (Figure 2.21, 2.22 and 2.24) that several 
metabolites/proteins change abundance in the presence of AuNRs even without light 
exposure, possibly due to the gold nanoparticles alone which could perturb apoptosis 
pathways of the biological system, as has been reported previously [257]. This effect, 
however, compared to the effect of PPTT treatment on apoptosis pathways, occurs to a 
much smaller extent and did not cause actual apoptosis (Figure 2.12).  
Besides the phenylalanine-dependent process, we further identified significantly 
perturbed pathways by integrative analysis of proteomics and metabolomics (Figure 
2.27). Other amino acid metabolism pathways are enriched, including methionine-
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cysteine-glutamate and lysine metabolism, both of which are very essential for the basic 
survival of the cells. Interestingly, we also found clues on the perturbation of pathways 
related to lipid metabolism and ketone body metabolism. 
 
FIGURE 2.27. Significant pathways identified from proteomics (red bars) and 
metabolomics (light pink bars) that perturbed by photothermal therapy.  
In conclusion, by integrative analysis of Raman spectroscopy profiles, 
metabolomics, and proteomics mass spectrometric data, we discovered that free 
phenylalanine and associated metabolites are significantly perturbed by PPTT, leading to 
cell apoptosis. We therefore propose that phenylalanine measurements by SERS can be 





1.6 Improving the Flow Cytometry-based Detection of Gold Nanoparticle Cellular 
Uptake 
Summary. Due to the considerable amount of applications of gold nanoparticles 
(AuNPs) in biological systems, there is a great need for an improved methodology to 
quantitatively measure the uptake of AuNPs in cells. Flow cytometry has the ability to 
measure intracellular AuNPs by collecting the light scattering from a large population of 
live cells through efficient single cell analysis. Traditionally, the side scattering setting of 
the flow cytometer which is associated with a 488 nm excitation laser (SSC channel) is 
used to detect nanoparticle uptake. This method is limited as AuNPs do not have the 
optimized response when excited with this laser (for Au nanospheres, AuNSs, the SPR 
peak is around 520-540 nm, for Au nanorods, AuNRs, the SPR peak will be in higher 
wavelength to infrared range). Here, we reported that the use of more red-shifted 
excitation lasers, will greatly enhance the optical signal needed for the flow-cytometry 
based detection of AuNSs (25 nm) and AuNRs (40 x 80 nm, width x length) uptake in 
triple negative breast cancer cells (MDA-MB-231). 
1.6.1 Introduction. 
Gold nanoparticles (AuNPs) emerges to be a key branch of materials that are  
widely used in diverse scientific fields such as chemistry, biology, medicine and 
engineering [13, 14]. AuNPs have great and unique optical properties due to their 
interaction with light. When AuNPs are excited by light at specific wavelengths, the 
interaction between the electromagnetic field of light and the conduction electrons of 
AuNPs causes the electrons to oscillate in resonance with the frequency of light [11], 
 
 103 
which  is termed the surface plasmon resonance (SPR). The SPR gives AuNPs unique 
optical properties which include their large scattering cross-sections, that are 5 orders of 
magnitude higher (from the 80 nm gold nanospheres) than the light emission from 
fluorescent molecules such as fluorescein [1].  The strong scattering of AuNPs allow them 
to be easily detected by scattering based detection methods. Additionally , AuNPs can be 
easily surface-modified with many types of functional groups, such as proteins, peptides, 
oligonucleotides, etc, while still maintaining their optical properties [12].  
The amount of intracellular AuNPs can be positively correlated to their possible 
effects at cellular levels. Currently, several methods can be used for measuring 
intracellular AuNPs. Element analysis techniques such as inductively coupled plasma 
(ICP)-based spectroscopic methods (including optical emission spectrometry (ICP-OES), 
and mass spectrometry (ICP-MS)) are commonly regarded as the most accurate AuNP 
quantification methods. However, an obvious drawback of this type of method is that it 
only provides the average amount of AuNP intracellular content, with little to no 
information regarding the  distribution within the cell population or spatial location [258]. 
In addition, spectroscopic methods that use UV-Vis and Beer-Lambert’s law which 
correlate the AuNP concentration with the absorbance at their SPR peak could also be 
regarded as a fast detection of average AuNP uptake [259], though the accuracy might not 
be comparable to other methods. On the other hand, many microscopic methods that 
provide the distribution and spatial location of AuNPs are used in quantifying AuNPs as 
well. These methods include transmission electron microscopy (TEM) and optical 
microscopies such as dark-field microscopy (DFM) that is based on light scattering [142, 
258]. Although TEM provides much higher resolution (Ångstrom to nanometer) when 
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compared to   DFM (>250 nm) for measuring intracellular spatial distribution, it requires 
complex and laborious sample section preparation. In addition, the number of measured 
cells are always limited. Flow cytometry (FCM) is a cell sorting method that can detect 
the fluorescence or scattering from cells. AuNPs uptake can be quantified from the side 
scattering signal (SSC) as the existence of AuNPs increases the SSC response from the 
flow cytometer. A recent article measured the SSC signal from intracellular AuNPs and 
compared this data  with similar data from the ICP-MS, which showed a perceptible 
agreement between the two methods [260]. The FCM method is beneficial as it is quick 
and without labor-intensive and complicated sample preparation. It is very effective for 
measuring not only the average amount of AuNP intracellular content, but it  also 
provides  information regarding AuNP distribution within the cell population. In addition, 
we can sort portion of cells using FCM based on specific AuNP content which is useful 
for further studies, such as proteomics and gene sequencing. 
Traditionally, the side scattering mode with 488 nm laser illumination (SSC 
channel) was used for measuring the intracellular AuNP amount[260], but AuNP scattering 
detection is not optimized under this illumination laser due to the SPR phenomenon. For 
most of the spherical AuNPs (AuNSs), the SPR peak is around 510-550 nm, while for Au 
nanorods (AuNRs), the SPR peak will be a higher wavelength ranging from the visible 
range of the electromagnetic spectrum to the infrared region. In addition,  the aggregation 
of AuNPs inside cells will cause a red shift of the SPR peak [144]. Therefore, we 
hypothesized that the use of an incident light with a higher wavelength is a promising 
approach to improving the flow cytometry-based detection of intracellular AuNPs by way 
of SSC signals. 
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Herein, we measured the FCM side scattering of intracellular AuNSs (25 nm) and 
AuNRs (40 x 80 nm, width x length) using incident lasers with different wavelength. Our 
results show that by red-shifting the illuminating laser wavelength, the signal will be 
greatly enhanced for detecting both AuNSs and AuNRs cellular uptake using FCM. 
1.6.2 Methods. 
Materials. Tetrachloroauric acid trihydrate (HAuCl4·3H2O), trisodium citrate, 
silver nitrate (AgNO3), sodium borohydride (NaBH4), ascorbic acid, 
cetyltrimethylammonium bromide (CTAB), paraformaldehyde, glutaraldehyde, 
ethylenediaminetetraacetic acid (EDTA), HEPES, bovine serum albumin (BSA), were 
purchased from Sigma (St. Louis, MO). Dulbecco’s modified Eagle’s medium (DMEM), 
fetal bovine serum (FBS), antibiotic/antimycotic solution, phosphate buffered saline 
(PBS), and 0.25% trypsin/2.2 mM EDTA solution were purchased from VWR. 
Methoxypolyethylene glycol thiol (mPEG-SH, MW 5000) was purchased from Laysan 
Bio, Inc. Cell-penetrating peptide RGD (RGDRGDRGDRGDPGC) and Nuclear 
localization sequence NLS (CGGGPKKKRKVGG) peptides were purchased from 
GenScript, Inc. All the water used in experiments was purified with a Milli-Q system 
from Millipore (Milford, MA). 
Instrumentation. Gold nanoparticles were imaged under a JEOL 100CX-2 
transmission electron microscope (TEM). The average sizes of AuNPs were measured by 
ImageJ software based on the TEM images. The spectra of AuNPs were obtained using 
an Ocean Optics HR4000CG ultraviolet-visible-near infrared (UV−Vis-NIR) 
spectrometer. The surface charge of AuNPs (zeta potential) was determined by use of a 
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ZetaSizer 3000 (Malvern Instruments). Flow cytometry experiments were performed on 
BD LSR Fortessa supplied with 405 nm, 488 nm, 561 nm, and 640 nm excitation lasers.  
The BioTek Synergy H4 Hybrid plate reader was used for reading the XTT cell viability 
assay results. Dark field microscopy is equipped with Lumenera Infinity2 CCD camera. 
Gold Nanoparticle Synthesis, Conjugation, Characterization. Gold 
nanospheres (AuNSs) with an average diameter of 40 nm were synthesized using the 
citrate reduction method. 500 mL of 0.254 mM HAuCl4. 3H2O solution was heated until 
boiling and reduced by adding 9 mL of 0.35% citrate solution quickly to the precursor 
solution. Solution was left under heat and an observable color change occurred from light 
yellow to burgandy upon reaction completion. Solution was then removed from the 
heating apparatus and cooled with a water bath. Newly synthesized AuNSs were purified 
via centrifugation with initial conditions being 1,500 g for 5 minutes and adding DI H2O 
to the pellets.  
Gold nanorods were synthesized using a seed growth method that developed by 
our lab [4]. Briefly, to prepare Au seed, CTAB solution (5 mL, 0.20 M) and HAuCl4 (5.0 
mL of 0.00050 M) was mixed with stirring. Then, 0.60 mL of ice-cold NaBH4 (0.010 M) 
was added. The mixture was vigorously stirred of generate Au seed for 2 min. A 
brownish yellow solution was formed. Next, to prepare the growth solution, 5.0 mL of 
HAuCl4 (1.0 mM), 270 μL of AgNO3 (4.0 mM), 5.0 mL of CTAB (0.2 M) and 70 μL of 
ascorbic acid (78.8 mM) was gently mixed. The prepared Au seed (12.0 μL) was then 
added to the growth solution and allowed to react with no disturbance for hours. The as-
synthesized AuNRs were washed by DI H2O via centrifugation twice with initial 
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conditions being 10,000 g for 30 minutes and 5,000 g for 10 min. TEM was used for 
imaging the sizes and the homogeneity of the AuNPs prepared.  
For surface modification, the purified nanoparticles were treated with 
polyethylene glycol (PEG, 1 mM) as an initial conjugation step and left on a shaker 
overnight with 1:1,000 (AuNP: PEG). RGD (1 mM) and NLS (1 mM) were added 
concurrently, with 1:10,000 (AuNP: RGD) and 1:100,000 (AuNP: NLS) after initial 
conjugation step and shaken overnight. Conjugated AuNPs were then centrifuged and re-
dispersed in DI water. To test the surface modification, UV−Vis-NIR spectrometer and 
zetasizer were used. The AuNPs’ spectra red shift due to the changes in the dielectric 
constant of the surrounding environment of AuNPs offers verifiable evidence of 
conjugation success.  
The molar concentrations (C) of the AuNPs (AuNSs and AuNRs) are calculated 
based on Beer’s law A=ε ×b× C, where A is the extinction of AuNPs (O.D.), ε is the 
molar extinction (L mol-1 cm-1), b is the path length of the sample (1 cm). Both of the 
AuNSs and AuNRs have ε~3 × 109 L mol-1 cm-1 according to literatures[7, 261], due to their 
specific sizes and/or aspect ratios. 
Cell culture and incubation with AuNPs. Human breast adenocarcinoma MDA-
MB-231 cells were cultured in Dulbecco’s Modified Eagle Media (DMEM) (without 
Phenol red) with 1% antibiotic and 10% Fetal Bovine Serum under standard incubation 
conditions (5% CO2, 37℃). Cells were treated with differing concentrations of AuNSs 
and AuNRs (C0, control no AuNPs; C1, 0.033 nM; C2, 0.083 nM; C3, 0.17 nM; C4, 0.33 
nM and C5, 0.5 nM) for 24 h. UV-Vis-NIR spectra was taken of media solutions with 
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varying concentrations of AuNSs and AuNRs before and after a 24 h incubation period. 
The difference of the absorbance peaks corresponds to a quantification of cellular uptake.  
The cellular uptake of AuNPs can also be measured by dark field imaging. The cellular 
uptake of AuNPs were also measured by dark field microscopy. For dark field imaging, 
the cells were fixed with paraformaldehyde and glutaraldehyde and subsequently imaged 
with a Lumenera Infinity2 CCD camera. 
Cell Viability Assay. To examine the toxicity effect of the AuNPs, XTT cell 
viability assays were performed according to the Biotium ™ experimental protocol, in 
which the XTT activation reagent was mixed with the XTT solution and added to cells. 
After a 24 h incubation time with AuNPs, absorbance signals from cells were obtained 
via a plate reader. Background absorbance was subtracted from signal absorbance to 
collect normalized absorbance values.  
Flow Cytometry Measurements. Following AuNP treatment, cells were 
trypsinized, centrifuged at 1500 x g for 5 mins, and re-suspended with FBS sorting buffer 
composed of phosphate buffer saline (PBS), 1mM EDTA, and 25 mM HEPES. The 
samples were then washed with PBS three times, and fixed with paraformaldehyde. 
Samples were analyzed using a flow cytometer supplied with 488 nm, 561 nm, and 687 
nm excitation lasers. Side scattering signals (SSC) from cell samples were collected from 
varying excitation laser sources and detected with corresponding detection channels.  
Data output was analyzed utilizing the FlowJo ™ software. Signals were transformed into 
histogram plots to visualize the comparisons among detection channels and excitation 
laser combinations.  
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Data Analysis.  A Two Tailed T-Test was performed to determine the statistical 
significance. The analyses were performed with the alpha type error set at 0.05. 
1.6.3 Results  
Two types of gold nanoparticles (spheres and rods) are synthesized and surfaced 
modified with PEG, RGD, and NLS according to our previous methods discussed in 
Section 2.2. No obvious toxicity effect was observed after incubation with MDA-MB-
























































FIGURE 2.28. MDA-MB-231 cell viability when incubated with different 
concentrations of gold nanoparticles (a) AuNSs, (b) AuNRs.  
1.6.3.1 Flow Cytometry Method Development for Measuring Cellular Uptake of Gold 
Nanoparticles 
In flow cytometry, there are two modes of scattering measurements, t side 
scattering and forward scattering. The forward scattering channel (FSC) intensities of the 
MDA-MB-231 cells incubated with AuNPs were similar to those of the controls (Figure 
2.29), which is in agreeance with previous reports [260, 262]. The side scattering channel 
(SSC) usually indicates the scattered light collected at the perpendicular direction (90o) of 
 
 110 
the incident laser (usually 488 nm), which is commonly used as an indication of the cell’s 
internal complexity or granularity. When nanoparticles are internalized into the cells, 
they increase the complexity of cells which could be attributed to the increased SSC 
intensity. Several studies have indicated  that when cells uptake gold, TiO2, ZnO 
nanoparticles, etc, the SSC intensity increases [260, 263, 264]. Due to the high scattering 
coefficients of AuNPs (∼5 orders of magnitude greater than conventional fluorescent 
dyes), SSC could be especially beneficial for detecting signals from AuNPs. The SSC 
supplied with a 488 nm laser illumination is a commonly used setting for flow cytometry 
based detection of intracellular AuNPs, but is not  optimized for detecting AuNPs. For 
most of spherical AuNPs, their SPR peaks are located between 510-550 nm; while for Au 
nanorods (AuNRs), the SPR peak will be tuned to higher wavelength from visible range 
to infrared. In addition,  the aggregation of AuNPs inside cells will cause red shift on the 
SPR peak [144]. Therefore, herein, we used an incident light with higher wavelength, 








FIGURE 2.29. FSC signals of MDA-MB-231 cells without (Ctrl, blue) or with 
AuNPs (0.5 nM, red).  
The conventional 488-SSC was examined first, and the result is shown in Figure 2.30. 
The cells incubated with 0.17 nM AuNPs showed only a very minor increase in the 488-
SSC channel as compared with the control. Therefore, to optimize the incident laser, 
three different incident lasers (488, 561, 687 nm) were used. The scattering intensities 
were collected for different samples (C0-C5). As shown in Figure 2.31 (for AuNSs) and 
Figure 2.32 (for AuNRs), the SSC intensities increase when the intracellular AuNPs 
increase. The 687 nm incident laser gives the most significant change when measuring 
cells with varying intracellular AuNPs concentration (Figure 2.31 m-r, 2.32 m-r), while 
488 nm, which is the default SSC channel laser, gives the worst performance (Figure 
2.31 a-f, 2.32 m-r). Therefore, optimizing the incident laser could greatly assist the 
detection of intracellular plasmonic nanoparticles using flow cytometry. This can also be 
seen from the histograms in Figure 2.33. 
The quantitative relationship between the scattering intensities and the amount of 
AuNPs from UV-Vis measurements were examined. The relation between flow 
cytometry and UV-Vis data was fitted with a linear function, as shown in Figure 2.34. 
The 687 nm incident laser gives the largest slope of fitting and a much improved R2 




FIGURE 2.30. SSC signals of MDA-MB-231 cells with 488 nm incident laser is not 
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FIGURE 2.31. Flow cytometry scatter plots of MDA-MB-231 cells incubated with different concentrations of AuNSs in 
DMEM media (sample C0, control no AuNPs; C1, 0.033 nM; C2, 0.083 nM; C3, 0.17 nM; C4, 0.33 nM and C5, 0.5 nM). The 
plots are side scattering (SSC-A) versus forward scattering (FSC-A) under different incident lights (a-f, 488 nm; g-i, 561 nm; 
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FIGURE 2.32. Flow cytometry scatter plots of MDA-MB-231 cells incubated with different concentrations of AuNRs in 
DMEM media (sample C0, control no AuNPs; C1, 0.033 nM; C2, 0.083 nM; C3, 0.17 nM; C4, 0.33 nM and C5, 0.5 nM). The 
plots are side scattering (SSC-A) versus forward scattering (FSC-A) under different incident lights (a-f, 488 nm; g-i, 561 nm; 



















FIGURE 2.33. Side scattering intensity (SSC-A) histograms of MDA-MB-231 cells 
with different incident light wavelengths (488 nm, A for AuNSs and D for AuNRs; 
561 nm, B for AuNSs and C for AuNRs; 687 nm, C for AuNSs and F for AuNRs). 
Cells with different intracellular concentrations were measured. Red, blue, orange, 
light green, dark green and tan lines represent samples C0-C5 (C0, Ctrl; C1, 0.033 




FIGURE 2.34. Cellular AuNPs versus scattering intensities, including linear 
regression lines: (a) gold nanospheres (AuNSs) and (b) gold nanorods (AuNRs). 
Blue: 488 nm incident laser; orange: 561 nm incident laser; black: 687 nm incident 
laser. 
1.6.4 Discussion  
Gold nanoparticles are widely studied as intracellular imaging probes or as 
therapeutic reagents. To study the AuNPs amount in cells, the ICP-MS, spectroscopic 
method or imaging are used. Some of these methods are labor-intensive due to 
complicated sample preparation procedures, destructive to the cells because of biological 
incompatibilities, and lacking in the information provided as they only provide the 
average intracellular particle amount. Flow cytometry can act as an easy and efficient 
method for not only measuring average cellular uptake, but also providing information 
regarding the AuNPs distribution within the cell population. Herein, by improving the 
sensitivity of the flow cytometry- based detection of intracellular AuNPs, through simply 
increasing the incident laser wavelength and collecting the scattering signals, we are able 
to distinctly differentiate cells with different AuNPs amount. 
The objects (cells or particles with size range of 1-40 µm[264]) in flow cytometry 
detection usually requires fluorescent labels. Several types of nanoparticles present high 
scattering cross sections, which enables sensitive scattering detection for their existence 
in cells. TiO2 nanoparticles, which are used as ingredients in sunscreen and paints, can 
absorb UV light. As the default, flow cytometry side scattering channel (488 nm) are 
close to the extinction range of TiO2, good resolution has been reported to differentiate 
cell samples with and without TiO2, using the default setting of SSC channel in flow 
cytometry [262, 263]. Zucker et al claimed that by using flow cytometry, they were able to 
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detect as low as 5-10 TiO2 nanoparticles per cell, which is very sensitive
[263]. Ag 
nanoparticles, which presents the SPR at around 400-500 nm, have strong scattering at 
this range, are also suitable for the default 488 nm SSC channel [265]. In addition, for the 
internalization of other types of nanoparticles, such as CuO[266], superparamagnetic iron 
oxide nanoparticles (SPIONs) [267], ZnO2 
[264],  this method might also apply according to 
previous reports.The same method using 488 nm laser was also been used in the case of 
AuNPs [260].  However, the response of AuNPs scattering under 488 nm is not optimized. 
In our results, we demonstrated that by using a higher-wavelength incident laser, we are 
able to achieve much better signals of intracellular AuNPs. 
It is widely recognized that when cells undergo apoptosis, the shrinkage of the 
cell body will cause a decrease of the FSC signal, and an increase of the cell granularity 
(due to the apoptotic body that is produced inside the cells) which will cause a 
subsequent increase of the SSC signal [264]. Therefore, it is always beneficial to know the 
cause of an increased SSC signal which could be due to the apoptosis process or 
nanoparticle uptake. A fast way to distinguish between these two causes is to reference 
the change or lack thereof in the FSC, as many studies reports no change of FSC when 
NPs internalized [260, 264], including this work. Another way is to add a cell apoptosis 
analysis to see if there is apoptosis process happening.  
1.6.5 Conclusion. 
By increasing the incident laser wavelength, the scattering signal of cells with 
different AuNPs (AuNSs and AuNRs) concentrations can be much better differentiated. 
This simple method will be very useful in detecting cellular gold nanoparticles combining 
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with sorting cells with specific gold nanoparticle amount. The greatest advantage of using 
flow cytometry is its ability for subsequent studies, such as proteomics, gene sequencing, 




GOLD NANOPARTICLES CHANGES THE MECHANICAL 
PROPERTIES OF CANCER CELLS IN INHIBITING THE CANCER 
CELL MIGRATION AND INVASION 
Previously, the optical properties of AuNPs has been explored for developing 
theranostics agents for cancer. In this section, we studied the impact of AuNPs on the 
mechanical properties of cancer cells for inhibiting cancer cell migration and invasion. 
Note: Yue Wu and Moustafa Ali have equally contributed to designing, performing, 
analyzing, and writing the research in this section.  
1.7 Nuclear Membrane-targeted Gold Nanoparticles Inhibit Cancer Cell 
Migration and Invation [85] 
Summary. Most cancer patients die from metastasis. Recent studies have shown 
that gold nanoparticles (AuNPs) can slow down the migration/invasion speed of cancer 
cells and suppress metastasis. Since nuclear stiffness of the cell largely decreases cell 
migration, our hypothesis is that targeting AuNPs to the cell nucleus region could 
enhance nuclear stiffness, and therefore inhibit cell migration and invasion. Our results 
showed that upon nuclear targeting of AuNPs, the ovarian cancer cell motilities decrease 
significantly, compared with non-targeted AuNPs. Furthermore, using atomic force 
microscopy, we observed an enhanced cell nuclear stiffness. In order to understand the 
mechanism of cancer cell migration/invasion inhibition, the exact locations of the 
targeted AuNPs were clearly imaged using a high-resolution three-dimensional imaging 
microscope, which showed that the AuNPs were trapped at the nuclear membrane. In 
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addition, we observed a greatly increased expression level of lamin A/C protein, which is 
located in the inner nuclear membrane and functions as a structural component of the 
nuclear lamina to enhance nuclear stiffness (Figure 3.1). We propose that the AuNPs that 
are trapped at the nuclear membrane both: 1) add to the mechanical stiffness of the 
nucleus and 2) stimulate the overexpression of lamin A/C located around the nuclear 




















FIGURE 3.1. Figure abstract that shows (top) before the gold nanoparticle (AuNPs) 
treatment, the ovarian cancer cell (HEYA8) migration ability was high. However, 
upon nuclear targeting AuNPs treatment, the AuNPs were trapped at the nuclear 
membrane (middle). The trapped AuNPs in the membrane enhanced the nuclear 
stiffness of the cell (Bottom).  Meanwhile, we observed that Lamin A/C protein 
expression increased, which is a protein located in the inner nuclear membrane that 




Metastasis, a process in which cancer cells migrate to other locations of the 
human body, is responsible for most cancer-related mortality. It usually begins with local 
invasion to the surrounding tissues, followed by intravasation into the lymph and blood 
microvasculature before the cancer cells finally colonize within the microenvironment of 
other locations in the patient’s body [65, 268]. Many treatments for inhibiting metastasis are 
based on drugs that target specific proteins that promote the cell migration or invasion 
process; however, past attempts to develop anti-metastasis drugs have not been 
efficacious in clinical trials [67].  In  many cases, the anti-cancer drugs that target specific 
proteins on the cancer cells might lose their efficacy after several months of treatment 
due to protein mutations thus conferring drug resistance to cancer cells [269]. Moreover, 
the anti-cancer drugs could  cause side effects to appear in healthy tissues [270]. 
Recent advances in nanomedicine provide us with a great opportunity to avoid the 
drawbacks of current drugs [69, 269, 271], [130], [272, 273]. Nanoparticles have been widely used 
in cancer diagnosis and cancer therapy thanks to their intrinsic chemical, physical and 
optical properties [272, 274]. Nanoparticles with proper surface modifications can target 
tumors selectively [233, 234, 271, 275],  and their effects on cancer cell migration or metastasis 
have drawn attention from many researchers [73], [132, 276], [76]. In 201, Murphy et al. 
reported that gold nanoparticles (AuNPs) with different surface charges and sizes can 
affect cancer cell migration [73]. In 2014, Chor Yong Tay et al.20 found that after 
incubation with nano-ceramics, such as titania, silica, and hydroxyapatite, cells showed 
significantly impaired wound healing capability because of the disruption of the 
intracellular microtubule assembly. In the same year, Zhou et al. [76] showed that gold 
nanorods (AuNRs) coated with bovine serum albumin (BSA) exhibited reduced cell 
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migration and invasion by impairing ATP synthesis, which subsequently inhibits the F-
actin cytoskeletal assembly and decreases metastatic ability of tumor [76]. Arvizo et al. 
used non-specific targeted gold nanospheres (AuNSs) to inhibit tumor growth and 
metastasis by abrogating MAPK signaling and reversing the epithelial-mesenchymal 
transition [84]. For most of the related works, non-specific targeted nanoparticles have 
been used. For instance, Zhou et al. [76] used BSA coated AuNRs that showed inhibitory 
effects on cancer cell migration, but the high concentration of AuNRs (50-200 µM) used 
might be an obstacle for clinical usage.  To maintain the nanoparticle effect on slowing 
the cancer cell migration and invasion with a minimized amount of nanoparticles, the 
intracellular locations of nanoparticles could be an important factor to consider. It is thus 
promising to design nanoparticles that can target specific intracellular regions to enhance 
the inhibition of cancer cell migration and invasion.  
Mechanical stiffness of cancer cells has been shown to grade metastatic potential 
in patient tumor cells [277], as well as in cultured cancer cell lines [278]. Lower stiffness is 
related to more invasive cells [279]. In eukaryotic cells, the nucleus contains most of the 
cell's genetic material and controls cell activities by transcriptional regulation. It is the 
largest and stiffest organelle in most cells and largely determines the cell migration 
ability[280]. Lamin A/C (LMNA) proteins are an important factor in nuclear stiffness. 
They form a dense protein network that connects the nuclear membrane and chromatin 
structures on the interior of the nuclear membrane. Recent studies have shown that 
nuclear lamin A protein scales with tissue stiffness [281] and generates a barrier to cells 
migrating through three-dimensional (3D) environments [282]. It is shown that lamin A/C 
deficiency hampers cell mechanics, polarization, migration and invasion [283] [284]. 
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Here, targeted AuNPs were used to locate the AuNPs to the cells, because of their 
specific physical and chemical properties and better biocompatibility than other 
nanomaterials such as nano-ceramics or silver nanoparticles [234, 285]. By targeting and 
locating the AuNPs to the cell in a manner to modulate the stiffness of its nucleus, we 
could improve the inhibition effect on cell migration and invasion. In our experiment, we 
used three ligands, methoxy-polyethylene glycol thiol (PEG) for increasing the 
biocompatibility of AuNPs, RGD (RGDRGDRGDRGDPGC) peptides for binding to the 
surface integrin of cancer cells and enhancing endocytosis, and nuclear localization signal 
(NLS, CGGGPKKKRKVGG) peptides for targeting the AuNPs to the nucleus. Cell 
migration or invasion abilities have been measured, and the results show a clear decrease 
in these functions after the nuclear targeting of the nanoparticles. For studying the cell 
mechanical response, atomic force microscope (AFM) showed that the two types of 
AuNPs (i.e. AuNRs and AuNSs) both significantly enhanced the nuclear stiffness. A 
high-resolution 3D optical imaging system showed the exact location of the nanoparticles, 
which were trapped at the nuclear membrane. The levels of lamin A/C were found to be 
elevated upon nanoparticle incubation, which could be an explanation for the observed 
enhanced nuclear stiffness causing inhibition of cell motility upon gold nanoparticle 
treatment. 
1.9 Methods 
Materials: Tetrachloroauric acid trihydrate (HAuCl4.3H2O), trisodium citrate, 
NaBH4, ascorbic acid, cetyltrimethylammonium bromide (CTAB), AgNO3, and bovine 
serum albumin (BSA) were purchased from Sigma-Aldrich (USA). 
Methoxypoly(ethylene glycol)-thiol (mPEG-SH, MW 5000) was purchased from Laysan 
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Bio, Inc. Cell penetrating peptide RGD (RGDRGDRGDRGDPGC) and nuclear 
localization signal (NLS, CGGGPKKKRKVGG) peptides were obtained from 
GenScript,Inc. Dulbecco’s phosphate buffered saline (PBS), RPMI-1640 cell culture 
media, fetal bovine serum (FBS), antibiotic solution, and 0.25% trypsin/2.2 mM EDTA 
solution were purchased from VWR. 8.0 µm polycarbonate membrane inserts were 
bought from Costar. Hoechst 33342 solution was purchased from Thermo Fisher 
Scientific (20 mM solution) 
Instrumentation: Gold nanoparticles were imaged using a JEOL 100CX-2 
transmission electron microscope (TEM) microscope and their average size was then 
measured by ImageJ software. UV−vis spectra were obtained using an Ocean Optics 
HR4000CG UV-NIR spectrometer.  Cell stiffness was obtained using a MFP-3D AFM 
(Asylum Research, Santa Barbara, CA) with a combined Nikon Ti inverted optical 
microscope (Nikon, Melville, NY) for optically aligning the probe (MCST-AUHW, 
Bruker, Camarillo, CA) with a nominal spring constant of 0.03 N/m) to the cells. 
Confocal images were taken with a Zeiss LSM 700-405 confocal microscope. 
Gold nanoparticle synthesis, conjugation and characterization: Gold 
nanospheres (AuNSs) with an average diameter of 35 nm were synthesized using the 
citrate reduction method [15]. Briefly, 100 mL of 0.254 mM HAuCl4.3H2O solution was 
heated till boiling, and then reduced by adding 2.5 mL of 0.35% of trisodium citrate. The 
solution was then left heating until it turned wine red, followed by cooling under water 
flow. The citrate stabilized AuNSs were centrifuged under 5000 g for 10 min and 
redispersed in deionized (DI) water to remove extra citrate and be ready for conjugation.  
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Gold nanorods (AuNRs) with an average size of 25 x 6 nm (length x width) were 
synthesized using a seedless growth method [228]. Briefly, 5 ml of 1.0 mM HAuCl4 was 
added to a mixture of 5 mL of 0.20M CTAB, 250 ul of 4.0 mM AgNO3 and 8 μL of 37% 
HCl. For reduction, 70 μL of 78.8 mM ascorbic acid was added, followed by immediate 
injection of 15 μL of 0.01M of ice-cold NaBH4. The solution was left undisturbed for 12 
hrs, then centrifuged at 21000 rpm for 50 min and redispersed in DI water followed by a 
second centrifugation at 19000 rpm for 40 min to remove the extra CTAB. TEM was 
used to measure the sizes and homogeneity of the nanoparticles. 
AuNSs and AuNRs were then conjugated according to previous work [286] , [233], to 
achieve nuclear and cytoplasmic targeting. For nuclear targeting, first, mPEG-SH (1 mM) 
was added to the nanoparticles for overnight to achieve about 1000 ligands on each 
particle. Then, the PEGylated nanoparticles (1 nM) were treated with RGD (1 mM) and 
NLS (1 mM) to achieve 104 and 105 molar excess, respectively. The solution was then 
allowed to shake overnight at room temperature. Excess ligands were removed by 
centrifugation. For preparing BSA conjugated nanoparticles, BSA (4.5 mM) was added to 
the nanoparticles and left for 3 h to incubate. UV-vis spectrometer and zetasizer was used 
to test the conjugation. Surface modification causes red shift of UV-vis spectra due to the 
change in the dielectric constant of the surrounding environment of Au nanoparticles. 
Cell culture and AuNPs incubation: The ovarian cancer HEY A8 cell lines were 
provided by Dr. G. Mills (MD Anderson Cancer Center, Houston, TX) and were grown 
in RPMI-1640 media supplemented with 10% FBS and 1% antibiotic-antimycotic 
solution (R10 medium). Cells were kept in a humidified incubator at 37 oC and under 5% 
CO2. After achieving 50% confluence, the cells were incubated with functionalized 
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AuNSs or AuNRs in supplemented DMEM cell culture medium for 24 h. The 
concentration of nanoparticles was carefully chosen to avoid cytotoxicity or perturbation 
to the cell cycle [287]. 
Apoptosis/necrosis assay: The HEY A8 cells were collected by trypsinization 
and washed with cold PBS twice. Then, cells were the dispersed in 493 mL of Annexin V 
binding buffer before labeling by 5 μL of Annexin V FITC (BioLegend) and 2 μL of PI 
(BioLegend, 100 μg/ mL). The mixture was then incubated for 15 min at room 
temperature. The cells were subjected to flow cytometry analysis using a BSR LSR II 
flow cytometer (BD Biosciences). For excitation, a 488 nm laser was applied. FITC and 
PI were detected in FL-1 and FL-2 using 525/30 and 575/30 BP filters, separately. 
Standard compensation using unstained and single-stained cells was conducted before 
performing actual experiments. FlowJo software (Tree Star Inc.) was used for data 
analysis. At least 10 000 events were collected for each experiment 57. 
Cell motility assay: HEY A8 cells were seeded on uncoated 24-well plate at a 
sub-confluent density for 24 hours. Then the cells were treated with nanoparticles of 
varying shapes and conjugated motifs before returning them to incubator for 12 hours to 
facilitate particle uptake. After the incubation period, cells were stained with nuclear dye 
Hoechst 33342 (dilution 1: 10,000) for 30-60 minutes. Cells were maintained at 37°C and 
5% carbon dioxide throughout the experiment using an environmental cell chamber 
(InVivo Scientific). For observation, a Nikon Eclipse Ti inverted epifluorescent 
microscope was used and both bright field (BF) and DAPI images were taken at multiple 
xy positions at 12-minute time interval for 6-8 hours at 10x magnification. The locations 
of cell nuclei, segmented from fluorescent images, were tracked in MATLAB to define 
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cell traces. The cell migration coefficients and directional velocities were determined by 
fitting the traces to the persistent random walk model. Briefly, mean square 
displacements were calculated from the two-dimensional tracking data and was used for 
fitting the following equation, 
(1) 
Where P= persistence time and μ=migration coefficient. 
Trans-well invasion assay: The Cultured 24 Well BME Cell Invasion Assay kit 
(Trevigen) was used according to the manufacturer’s instructions. For these studies, HEY 
A8 cells were seeded and grown in a 6 well plate to 60-80% confluency before treating 
with nanoparticles in serum free media for 24 hours. Cells were then detached, spun 
down and re-suspended in serum free media.  We also counted the cell number at this 
time to adjust the density to 500,000 cells/mL. Then 50,000 cells (100 μL) were added 
for each condition to the top surface of transwell inserts with 8 μm membrane pores 
coated with basement membrane matrix (BME). Cells were allowed to migrate toward 
the 10% FBS containing media in bottom chamber acting as the chemo attractant for a 
period of 32 hours. After the desired incubation time, non-migratory cells were gently 
removed from the top of each transwell using q-tips and the migrated cells at the bottom 
surface were detached using detaching buffer and incubated with Calcein AM. A plate 
reader was used to measure the fluorescence intensity, which is positively related to the 
number of trans-well cells. 
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Atomic Force Microscopy: AFM mechanical measurements [288], [289] of HEY A8 
cells were obtained using an MFP 3-D AFM (Asylum Research, Santa Barbara, CA) on a 
vibration isolation table (Herzan, Laguna Hills, CA). A silicon nitride cantilever (Bruker, 
Camarillo, CA) was used for the experiments. The pyramidal tip had a half angle of 35° 
and the radius of curvature of the point of the tip was 20 nm. Measurements were 
performed on cells plated to the glass bottom of the Fluorodish and in culture media at 
room temperature. For eliminating the effect of the overlapping neighboring cells on the 
stiffness, single cells were measured. Thermal calibration[290] yielded the cantilever 
spring constant, k=28.01pN/nm. A measurement rate of 0.39 Hz was used. The 5 nN 
force trigger resulted in indentations of approximately 4 μm for typical cells. Cells were 
optically located using a Nikon Eclipse Ti microscope (Nikon, Melville, NY). Force-
displacement curves were recorded to obtain the Young’s modulus of each cell. Two 
distinct sets of measurements were performed with the AFM. The first investigated 
changes in mean cell stiffness between populations treated with AuNPs@NLS and an 
untreated control population. The second set of measurements investigated subcellular 
elasticity of nucleus. For the first set of measurements, the cantilever probe was 
positioned over the individual cells for indentation and measurement. For the second set, 
the probe was positioned over the perinuclear region.  
Cell Imaging Using DIC Microscopy: An inverted Nikon Eclipse Ti-E 
microscope equipped with Perfect Focus System (PFS, 25 nm z-axial resolution) was 
used for imaging and z-stacks acquisitions under differential interference contrast (DIC) 
microscopy. The DIC mode utilized a pair of DIC polarizer and analyzer, a high 
resolution 100×I-R DIC slider, a high numerical aperture (N.A., 1.40) oil immersion 
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condenser lens, a Nikon CFI Apo TIRF 100× (N.A., 1.49) oil immersion objective, and a 
12 V/100 W halogen lamp as light source. Appropriate bandpass filters were placed in 
the light path. The z-stack movies were taken by a Hamamatsu ORCA-Flash 4.0 V2 
CMOS camera (C11440-22CU, pixel size: 6.5 µm × 6.5 µm) with Camera Link interface 
using Micro-Manager and analyzed using NIH ImageJ and reconstructed in Amira. Fixed 
HEYA8 cells on 22 mm × 22 mm glass coverslips were rinsed with DPBS at pH 7.4 and 
fabricated into a sandwiched chamber with two pieces of double-sided tape and a cleaned 
glass slide. PBS solution was added into the chamber to fill the space and the chamber 
was then sealed by clear nail polish. The so-formed sample slide was then place under the 
microscope for observation. Z-stacks were acquired using the Multi-Dimensional 
Acquisition function in Micro-Manger. More specifically, the DIC optical sectioning 
through the whole cell thickness was achieved by moving the objective on the motorized 
nosepiece using PFS at 65 nm/step at 33 ms (30 fps) exposure time. 
Scratch assay: The scratch assay has been performed according to former 
report[291].  Cells were cultured in a 6 well plate to a confluent monolayer. A p200 pipet 
tip was used to scrape the cell monolayer in a straight line to create an empty gap. The 
debris was then remove by washing the cells once with culture medium and then replace 
with 2 ml of fresh medium. Then the cells were imaged shortly after and 12 hours after 
scratch. 
Western blot: Briefly, cells were lysed in RIPA buffer (20 mM Tris pH 7.4, 150 
mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.1% Sodium Deoxycholate, 1% Triton X-100, 
0.1% SDS) containing protease inhibitors (Sigma-Aldrich). BCA assay (Pierce) was 
performed to measure the protein concentration and equal amounts of protein were 
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loaded on a SDS-PAGE gel. After SDS-PAGE, the resulting gels were transferred to 
PVDF membranes (Millipore) overnight. Afterwards, the gel was blocked with 5% milk 
in TBS (20 mM Tris, 150 mM NaCl). A rabbit polyclonal antibody to Lamin A/C was 
used as the primary antibody (Bethyl Laboratories, Inc.) overnight in 4 °C with shaking. 
A goat anti rabbit HRP labeled antibody was used as the secondary antibody (Jackson 
Immuno Research Laboratories). Blots were washed 3 times for 20 m in TBS after 
primary and secondary antibodies. Konica Minolta developer and Hyglo enhanced 
chemiluminescence (Denville) were used to develop the immunoblots. 
Immunofluorescence labeling and confocal microscopy: Cells were cultured on 
confocal chamber slides (MATECH Co. USA). After gold nanoparticle treatment[234], 
cells were fixed in 4% Paraformaldehyde/0.1% Glutaraldehyde for 10 min at room 
temperature the wash with PBS. Cells were then permeabilized with 0.1% Triton X-100 
for 5 min at room temperature. Cells were then blocked with 5% BSA and incubated with 
the primary antibody as stated in the Western-blot method for overnight. Cells were then 
incubated for 1 h with an Alexa Fluor 488 secondary antibody (Invitrogen) for 1 h before 
mounting with Prolong Gold (Invitrogen). Lastly images were taken with a Zeiss LSM 
700-405 confocal microscope and the fluorescence intensity was quantified in Image J. 
Data analysis: To determine the Young’s modulus, IGOR Pro software 
(Wavemetrics, Portland, OR) was used to apply the Hertzian contact model [292],[293] from 
10-90% of the maximum indentation of the extension force-displacement curve. Due to 
the unequal sample size and heteroscedasticity of the AFM data, overall statistical 
significance of differences in mean cell stiffness and nuclear stiffness between cells 
treated with AuNPs@NLS was tested using Welch’s analysis of variance (ANOVA). 
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Post-hoc analysis was performed using the Games-Howell test. For the rest of the studies, 
we used t-test. The analyses were performed with the alpha type error set at 0.05.  
1.10 Results and Discussion 
1.10.1 Gold Nanoparticle Synthesis, Conjugation, Cellular Uptake and Cytotoxicity 
Measurements  
The AuNRs with an average size of 25 (± 2) x 5 (± 0.5) nm were synthesized 
using a seedless method, with a surface plasmon resonance (SPR) peak centered ~ 800 
nm. The AuNSs with an average size of 35 ± 2 nm that absorb at 535 nm wavelength of 
light were synthesized using citrate reduction method. Both of the two types of the 
nanoparticles are widely used in the biological studies [294] [295] [285]. 
AuNPs were functioned with three ligands, methoxy-polyethylene glycol thiol 
(PEG), RGD (RGDRGDRGDRGDPGC) peptides and nuclear localization signal (NLS, 
CGGGPKKKRKVGG) peptides, as shown in schematic Figure 3.2 a. First, we 
conjugated the PEG to the surface of the AuNPs surface in order to enhance the 
biocompatibility [296]. The second ligand, RGD bound to surface integrins which are 
highly expressed on the surface of the cancer cells when compared to healthy cells to 
enhance the receptor-mediated endocytosis of the nanoparticles selectively to the cancer 
cells [231]. The third ligand, NLS, was recognized by importin and translocate into the 
nucleus [232]. Successful surface modification of AuNRs@PEG@RGD/NLS 
(AuNRs@NLS) is evident in the red-shift of the plasmon peak of AuNRs to longer 
wavelengths (we have previously desctibe this process in Figure 2.10). Similarly, the 
surface plasma peak of AuNSs@PEG@RGD/NLS (AuNSs@NLS) was also red-shifted 
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(Figure 3.2 b), which is in agreement with our former publication [286]. A TEM showing 





FIGURE 3.2. Characterization of Au nanoparticles. (a) Schematic figure of Au 
nanoparticle conjugation with PEG, RGD and NLS peptides. (b) UV-Vis extinction 
spectra of the unconjugated AuNSs (black spectrum), AuNSs@PEG (red spectrum), 
and AuNSs@PEG@RGD/NLS (green spectrum). (c) Transmission Electron 
Microscopic (TEM) image of gold nanospheres (AuNSs), Scale bar = 100 nm.  
The zeta potential of the AuNRs at the different conjugating stages of the three 
ligands were measured (Table 3.1) to confirm the surface modifications.  The as-
synthesized CTAB coated AuNRs has a highly positive surface charge (50.9 ± 7.97 mV); 
this makes sense as CTAB is a highly cationic surfactant. After PEG modification, the 
AuNRs become negatively charged (-13.6 ± 11.8 mV). The zeta potential of the AuNRs 
becomes positive again (14.9 ± 3.13 mV) after further modification with RGD and NLS 
peptides (Table 3.1). Also, the zeta potential of the AuNSs@NLS proved their successful 





Table 3.1. Zeta potential of AuNPs with different surface ligands 
 
To examine the cytotoxicity of the AuNPs, the XTT cell proliferation assay was 
conducted and no significant change of the cell viability was observed for nanoparticles 
at frequently used concentrations 0.5, 2.5 and 5 nM (for AuNRs) [234],[297] (Figure 3.3 a 
and b), and 0.05, 0.1 and 0.2 nM concentrations (for AuNSs) [236, 286]. Apoptosis/necrosis 
assay was also conducted for 5 nM of the AuNRs or 0.2 nM of the AuNSs (Figure 3.3 c, 
d and e) using flow cytometry. The results indicate that the concentrations of the AuNRs 
used in this study are lower than those affecting cell viability or inducing apoptosis.  
Au nanoparticles with different surface ligands Zeta potential (mV) 
AuNRs@CTAB 50.9 ± 7.97 
AuNRs@PEG -13.6 ± 11.8 
AuNRs@PEG@RGD@NLS 14.9 ± 3.13 
AuNSs@Citrate -29.7 ± 4.72 
AuNSs@PEG -12.1 ± 5.79 
AuNSs@PEG@ RGD@NLS 18.3 ± 7.55 
AuNRs@BSA -19.6 ± 9.89 









FIGURE 3.3. Au nanoparticles cytotoxicity measurements and cellular uptake. (a) 
Cell viability measurement (XTT assay, n=3) of HEY A8 cells after 24 h incubation 
with AuNSs@NLS at concentrations 0.05 nM (light blue), 0.1 nM (medium blue) 
and 0.2 nM (dark blue). (b) Cell viability (XTT, n=3) assay for cells after 1.5 nM 
(light blue), 2.5 nM (medium blue) and 5 nM (dark blue) of AuNRs@NLS 
incubation with HEY-A8 cells for 24h. (c, d, and e) Flow cytometry experiment for 
apoptosis/necrosis assay (c, Ctrl; d, cells incubated with 0.2 nM of AuNSs@NLS; e, 
cells incubated with 5 nM of AuNRs@NLS).  
The mass concentration (gram /L) of the two types of particles are very similar (SI, 
Equation 1). The uptake of AuNPs@NLS was monitored using dark-field (DF) 
microscopy and UV-Vis absorption. The HEY A8 cells, which were previously identified 
to be highly invasive cell line [298], were incubated with 2.5 nM of AuNRs@NLS or 0.05 
nM of AuNSs@NLS for 24 hrs. As shown in the DF image (Figure 3.4 a and b), clear 
internalization of both AuNPs (AuNRs@NLS and AuNSs@NLS) was observed. To 
evaluate the AuNPs uptake to the HEY A8 cells, UV-Vis spectra were collected for the 
AuNPs in culture media before incubation with cells and compared with the ones after 24 
h cell incubation (Figure 3.4 c and d).  According to the Beer’s law, the concentration of 
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gold nanoparticles is linearly correlated with the absorbance at their localized surface 
plasmon resonance (LSPR) wavelength. Therefore, the decrease of the absorbance 
indicates the portion of AuNRs internalized in cells [299], [300]. 
 
FIGURE 3.4. HEY A8 cell uptake of AuNRs@NLS and AuNSs@NLS. (a) Dark field 
images of cells without AuNPs incubation (Ctrl), with 2.5 nM of AuNRs@NLS and 
0.1 nM of AuNSs@NLS incubation. (c) UV-Vis spectra of 2.5 nM of AuNRs@NLS 
or 0.1 nM of AuNSs@NLS (d) in culture media before incubation with cells (black 









      
(2) 
where CAuNSs(g/L) or CAuNRs(g/L) is the mass concentration (in gram of gold/L), Mw(Au) 
is the molar mass of gold, ρ(Au)is the density, VAnNSs or VAuNRs is the volumn of the gold 
nanoparticles (AuNSs or AuNRs), CAuNSs or CAuNRs is the molar concentration of the gold 
nanoparticles (AuNSs or AuNRs), R is the average radius of the AuNSs, w and l are the 
width and length in the AuNRs. 
Non-targeted AuNPs with bovine serum albumin (BSA) coating were also 
fabricated. Successful surface modification of AuNPs@BSA (both AuNRs@BSA and 
AuNSs@BSA) was evident in the red-shift of the surface plasmon peak of AuNPs to 
longer wavelengths (Figure 3.5 a and b).  Zeta potential of AuNRs after BSA 
modification became negatively charged (-19.6 ± 9.89 mV, Table 3.1) due to the negative 
charge of BSA, while the as-synthesized CTAB coated AuNRs has highly positive 
surface charge (50.9 ± 7.97 mV, Table 3.1). The AuNSs@BSA also has a negative zeta 
potential of -15.2 ± 12.5 mV (Table 3.1). No toxicity effect of AuNPs@BSA was 
observed, as shown in Figure 3.5 c and d.  
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FIGURE 3.5. Characterization for AuNPs@BSA and HEY A8 cell uptake. (a) UV-
Vis extinction spectra of the unconjugated AuNSs@Citrate (black spectrum) and 
AuNRs@BSA (red spectrum). (b) UV-Vis extinction spectra of the unconjugated 
AuNRs@CTAB (black spectrum) and AuNSs@BSA (red spectrum). (c) XTT assay 
of HEY-A8 cells after 24 h incubation with AuNSs@BSA at concentrations 0.05 nM 
(light blue), 0.1 nM (medium blue) and 0.2 nM (dark blue), n=3. (d) XTT assay for 
cells after 1.5 nM (light blue), 2.5 nM (medium blue) and 5 nM (dark blue) of 
AuNRs@BSA incubation with HEY-A8 cells for 24h (n=3). 
1.10.2 Nuclear Targeting Gold Nanoparticles Inhibit Cancer Cell Migration and 
Invasion  
To test the cell motility, HEYA8 cells were incubated with AuNPs for 12 hours 
before staining with fluorescent nuclear dye. Cells were then placed on an inverted epi-
fluorescent microscope equipped with a cell culture chamber for continuous bright field 
and fluorescence imaging. The cell migration coefficients were then determined from the 
images. As shown in Figure 3.6 a, both nuclear-targeted AuNRs and AuNSs inhibit the 
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motility of HEY A8 cells. The average migration coefficient of the cells decreases from 3 
x 10-10 by a factor of 3-10 (Figure 3.6 a). We conducted a control experiment of non-
targeted AuNPs coated with BSA, (AuNPs@BSA, Figure 3.5).  The motility assay 
shows that there is no apparent inhibition of AuNRs@BSA or AuNSs@BSA on cell 
migration (Figure 3.6 b).  
The scratch assay was conducted to evaluate the migration ability. Results 
(Figure 3.6 c) indicate that the control cells had a completely healed “wound” after 24 h 
following AuNPs incubation, while the ones treated with AuNRs@NLS and 
AuNSs@NLS were not completely healed after 24 h. No obvious change in cell 
proliferation rate were observed after 24 hours (Figure 3.3 a and b), thus the scratch 
assay result merely reflects the migration ability of the cells. 
 
FIGURE 3.6. Effect of AuNPs (2.5 nM AuNRs@NLS and 0.1 nM AuNSs@NLS if 
not mentioned) on motility and invasion of HEY A8 cells. Cell migration study was 
performed to determine the effects of both AuNRs@NLS and AuNSs@NLS (a), and 
AuNRs@BSA (5 nM) and AuNSs@BSA (0.1 nM) (b) on the HEY A8 cells motility 
(error bar ±SEM, n=2). (c) Scratch assay of cells incubated with AuNRs@NLS and 
AuNSs@NLS displayed arrested healing/closing of the scratch. (representative 
pictures from 3 repeated experiments) (d) Invasion assay of cells without AuNPs or 
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with AuNRs@NLS and AuNSs@NLS treatment (error bar ± SD, n=3). *P < 0.05, 
**P < 0.01, ***P<0.001. 
In order to examine the invasion ability of HEY A8 cells after their treatment with 
the nuclear membrane-targeted AuNPs, the trans-well invasion assay was performed. The 
cells that invaded the basement membrane extract (BME) after 32 h were dissociated and 
stained with Calcein AM, a fluorescent dye that labels living cells. A control experiment 
has been performed to eliminate the possibility that gold nanoparticles could quench the 
fluorescence from Calcein AM (Figure 3.7). A significant decrease in fluorescence 
intensity was observed in the AuNPs treated groups, indicating the inhibition of the 





















FIGURE 3.7. The introduction of Au nanoparticles in cells does not affect the 
Fluorescent intensity of Calcein AM (n=3).  
In general, the cell migration and invasion abilities of HEY A8 cells were 
inhibited effectively by both AuNRs@NLS and AuNSs@NLS. 
1.10.3 Nuclear Targeting Gold Nanoparticles Enhance Nuclear Stiffness  
Next, we tested our hypothesis that the nuclear-targeted AuNPs can enhance 
nuclear stiffness. Cell stiffness as quantified by the Young’s modulus has been used as a 
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biomarker of the metastatic potential of cancer cells [298]. For AFM measurements 
(Figure 3.8 a), a beaded cantilever was lowered on top of the individual cells, producing 
an indentation in those cells and corresponding deflection of the AFM cantilever, which 
allowed for the measurement of cell stiffness. An overhead image of AFM cantilever tip 
next to HEY A8 cells with nanoparticles was shown in Figure 3.8 b. The distribution of 
Young’s moduli of individual cells, as well as that of the cell nucleus, from different 
nanoparticle treatments and the control is depicted in Figure 3.8 c and d. In our study, 
both AuNSs@NLS and AuNRs@NLS exhibit significant increase in the cell stiffness 
(Figure 3.8 c), which is similar to previous observations that nanoparticles could increase 
cell stiffness [301]. For the nuclear stiffness, as shown in Figure 3.8 d, the mean nuclear 
Young’s modulus of the cells treated with AuNPs (AuNRs and AuNSs) were also 
significantly higher than the mean nuclear Young’s modulus of the untreated cells, in 
agreement with the results of the overall cell stiffness.  In addition, we observed the 





FIGURE 3.8. Stiffness distribution of cells. (a) Schematic of measurements on cells 
with AFM; δ is indentation, Δx is cantilever deflection. To measure bulk cellular 
stiffness, a beaded cantilever was used to increase cell-probe surface area. (b) 
Overhead image of AFM cantilever tip next to HEY A8 cells with nanoparticles (c) 
Box-and-whisker plots of stiffness of single cells for different nanoparticles 
treatment, the percentiles are 10%, 25%, 50%, 75%, and 90%. Overall difference 
between means is significant (p-value calculated from ANOVA); (d) Box-and-
whisker plots of nuclear stiffness. *P < 0.05, **P < 0.01, ***P<0.001, n=3, cell 




FIGURE 3.9. Nuclear stiffness increase with the increased quantity of AuNRs. AFM 
result (left) and dark field images (right) show the stiffness and the nanoparticle 
uptake of AuNRs under different nanoparticle concentrations, respectively. n=3, cell 
counts>20 for each sample. 
1.10.4 AuNPs Accumulate at Nuclear Membrane Resolved by Three Dimensional 
Microscopy  
Resolving the exact localizations of AuNPs with regard to the nuclear membranes 
[302], [303] is a crucial, yet highly challenging, step in our attempt to understand the effects 
of AuNPs on the inhibition of cell migration/invasion.  Most commonly used optical 
microscopy methods, such as confocal fluorescence microscopy and dark field (DF) 
microscopy, do not offer the accurate locations of the nuclear membranes and AuNPs 
simultaneously, and they usually suffer from high background. On the other hand, TEM, 
despite its high resolving power, is limited by the high costs and tedious sample 
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preparation to gain the full 3D distribution of AuNPs inside the cells. To circumvent 
these challenges, we employed a recently-developed differential interference contrast 
(DIC) microscopy-based 3D imaging method to visualize and locate plasmonic AuNPs 
inside the cells [304]. As shown in Figure 3.10 a, the cells were placed in a sandwiched 
chamber. DIC optical sectioning was performed on the whole cell thickness. The arrow 
indicates the scanning optical sectioning of the cell, directed from layer 1 (close to the 
surface of the cover glass) to layer 2 (middle of the cell) and to layer 3 (top of the cell) 
(Figure 3.10 and 3.11). The DIC microscope, which was equipped with a set of high 
numerical aperture (NA = 1.4), oil-immersion condenser and objective, features a shallow 
depth of field in optical sectioning of a 3D specimen to generate sharply focused images. 
More importantly, the nuclear membranes are clearly visible under the DIC microscope 
to allow the determination of the relative positions of the nuclear membranes and AuNPs.  
 
FIGURE 3.10. Locations of AuNPs inside the HEYA8 cell (up) and lamin A/C 
protein location/expression (down) inside the HEY A8 cell. (a) Scheme of the cell 
sample in sandwiched chamber for 3 dimensional DIC microscope imaging. Z-axis 
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scanning step is 65 nm from the bottom (close to the attached glass surface) to the 
top of the cell.  Three layers from the bottom, middle, and the top of the cell, for 
cells incubated with 0.1 nM of AuNSs@NLS (b-d) and 2.5 nM of AuNRs@NLS (e-g) 
were imaged, corresponding to frame 75, 235, and 395 (AuNSs@NLS) and frame 49, 
179, and 285 (AuNRs@NLS) of the movies in the Supporting Information. (h) 
Western-blot results of lamin A/C, with beta-actin as reference protein. (i, j and k) 
Lamin A/C localization by confocal microscope of (i) cells without or (j) with 
AuNSs@NLS or (k) AuNSs@NLS incubation. The red arrows in (c) and (f) indicate 






















FIGURE 3.11. 3 dimensional (3D) view of HEY A8 cells incubated with AuNPs. (a 
and b) 3D figures of cells with 2.5 nM of AuNRs@NLS and 0.1 nM of AuNRs@NLS, 
showing xy, xz and yz planes (c and d) showing the z-stacking of 3 layers from the 
bottom of the cell (close to the attached glass surface as shown in the scheme), the 







FIGURE 3.12. The nuclear membrane targeting for AuNRs@NLS indicated by 
differential interference contrast (DIC) images. 
Figure 3.10 b to d shows the AuNSs@NLS locations inside the HEY A8 cells. 
The black spots in the figures are the nanoparticle aggregates, which are shown clearly 
surrounding the nucleus from difference optical sections. Similarly, Figure 3.10 e to g 
shows a similar distribution of AuNRs@NLS inside HEY A8 cells. Both AuNRs@NLS 
and AuNSs@NLS aggregates were located predominantly on the nuclear membranes 
(indicated by the red arrows in Figure 3.10 c and f, more evidences in Figure 3.12), 
while the internalization of nanoparticles inside the nucleus was rarely found, which was 
likely due to the large sizes of the nanoparticles and their aggregates compared to the 
nuclear pores (around 9~12 nm [305]).  
1.10.5 Nuclear Targeting Gold Nanoparticles Cause Lamin A/C Protein Increase.  
Lamins, especially lamin A/C, are intermediate filament proteins found at nearly 
all cell nuclei and contribute to nuclear stiffness and stability [306], [307]. Nuclear lamins 
interact with the membrane-associated proteins to form the nuclear lamina (30-100 nm 
thick), which is located in the interior of the nuclear membrane. It has been reported that 
lamin A/C-deficient cells exhibit severely reduced nuclear stiffness [281], [307]. To further 
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understand the biological mechanism for why nuclear membrane-targeting AuNPs 
increase nuclear stiffness and inhibit cancer cell migration/invasion, we measured the 
expression level of lamin A/C in Western-blots (Figure 3.10 h) and confocal microscopy 
imaging after immuno-staining (Figure 3.10). The results indicate a clear overexpression 
of lamin A/C after incubation with AuNSs@NLS or AuNRs@NLS. As shown in Figure 
3.10 i, j and k, the fluorescence signal from lamin A/C was increased as a circle-
surrounding the nucleus, which is in agreement with the location of nuclear lamina.  
AuNPs conjugated with a nuclear localization signal were thought to be able to 
internalize into the nucleus[302],[308]. In our study we clearly observed most of the NLS 
conjugated gold nanoparticles aggregated around the nuclear membrane. Without NLS, 
the nanoparticles (AuNPs@RGD) spread in the cytoplasm, instead of accumulating 
around the cell nuclear region, which has been discussed in our previous reports) [302]. 
Western blot experiment showed that the endocytosis and nuclear transportation has been 
activated upon nanoparticle incubation (Figure 3.13), due to the increased expression 
level of dynamin protein (a GTPase responsible for endocytosis in the eukaryotic cell) 
and GTP-binding nuclear protein Ran (involved in the transport into and out of the cell 
nucleus). Since the cellular and nuclear transportation are all activated, the trapping of 
AuNPs at the nuclear membrane was most likely due to the large size of the gold 
nanoparticles aggregates compared to the nuclear pores.  
It has been widely reported that following the entry of nanoparticles, they traffic 
through early endosomes to late endosomes and lysosomes (endolysosomal trafficking) 
[309]. To achieve nuclear membrane targeting, nanoparticles need to escape from the 
endosome and/or lysosomes. There are several well-established mechanisms explaining 
the cytosolic release of the NPs from endosomes or lysosomes. One of the most popular 
mechanism is through the charge interactions. The cationic nanoparticles could interact 
with the negatively charged phosphor lipid membrane, followed by “proton sponge” 
 
 147 
effect, causing endosomal membrane rupturing [310] and nanoparticle escaping. In our 
study, the positively charged AuNRs@NLS [311] could have the similar mechanism to 
escape from the endosome. In our results, most of the nanoparticles finally locates 
surrounding the cell nucleolus after incubation with cells overnight (Figure 3.10 b to g), 
indicating a good efficacy that gold nanoparticles escape from the endosome/lysosomes 
and target the nuclear membrane. Meanwhile, the above results show that the effect of 
endosome degradation [312] of the surface conjugated peptides might be very minor.  
Coincident with the increased nuclear stiffness by the AuNPs is the aggregation of 
the AuNPs at the nuclear membrane and the increase of the Lamin A/C expression, which 
is located at the inner side of nuclear membrane. Lamin A/C is known to maintain the 
mechanical strength of the nucleus [313], and is thus consistent with an inhibited cell 
migration or invasion. In our results, a clearly increased expression level of Lamin A/C 
was observed. Thus, we propose that the increase of nuclear stiffness not only due to the 
mechanical contribution of the presence of gold nanoparticles, but could also due to the 
increase of Lamin A/C. How AuNPs increase Lamin A/C is not yet well explored in 
literature. Figure 3.10 shows AuNPs closely contact with the nuclear membrane, which 
could potentially disturb the membrane integrity. Therefore, we propose it could be a 
cellular defense mechanism as lamin is known to remain the mechanical strength of 
nucleus. Interestingly, nuclear lamin-associated proteins, such as emerin, which stabilizes 
nuclear architecture for maintaining the structural integrity [312, 314], are also increased as 
the AuNPs are added at the nuclear membrane as shown in Figure 3.13. To investigate 
this mechanism, further studies such as proteomics and high-resolution imaging could be 








FIGURE 3.13.  Western blot of expression levels of Dynamin, Ran, emerin proteins 
and beta-actin from HEY-A8 cells (without AuNPs), HEY A8 cells with 0.1 nM of 
AuNSs@NLS and 2.5 nM of AuNRs@NLS treatment for 24 h.   
The clearance of nanoparticles from body after treatment has great importance to 
the evaluation of long-term effect of nanoparticles. While small nanoparticles 
(hydrodynamic diameter less than 5.5 nm) can be discard rapidly and efficiently through 
renal/urinary excretion [315]. big nanoparticles (over 18 nm) tend to accumulate in liver 
and spleen [316]. Such body deposition of metallic NPs over a long time period raises 
significant concerns regarding their long-term safety. A decrease of the liver content of 
gold has been reported after 1 month from 0.54% to the 0.07% [317]. The ultimate fate and 
the body elimination pattern of gold nanoparticles are not well studied. Future work will 
be focused on studying the effect of gold nanoparticles for preventing and treating the 
metastasis in animals. 
1.11 Conclusions 
This study shows that nuclear membrane-targeting AuNPs can increase nuclear 
stiffness and thereby inhibit cell migration and invasion. Compared with the previous 
studies with non-targeted AuNPs at relatively high amount (50-200 µM of 
AuNRs@BSA[76] and 5-20 µg AuNSs@Citrate[276]), the nuclear membrane-targeted 
AuNPs showed higher inhibition effects at significantly lower concentrations (0.1 nM for 
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35 nm AuNSs and 2.5 nM for 25  5 nm AuNRs). The AuNPs were found to be trapped 
on the nuclear membranes from mapping the 3D distributions of the AuNPs under a DIC 
microscope. The trapping of AuNPs at the nuclear membranes could possibly: 1) add to 
the mechanical stiffness of the nucleus, and, 2) stimulate the overexpression of lamin A/C, 
which is known to lead to nuclear stiffness and thus slows down cancer cell migration 
and invasion. This insight takes us one step closer to fully understand the effects on 




MOLECULAR UNDERSTANDING OF GOLD NANOPARTICLES 
AND PLASMONIC PHOTOTHERMAL EFFECT IN INHIBITING 
CANCER CELL MIGRATION  
 After studying the AuNPs impact on the mechanical properties of cancer cells in 
Chapter 3, we focused in Chapter 4 to systematically study their molecular mechanism in 
inhibiting cancer cell migration and invasion using gold nanorods and their photothermal 
effect. The ability of targeting gold nanorods (AuNRs) to cancer cell surface integrins 
and the introduction of NIR light to generate mild plamonic photothermal effect are 
shown to cause a broad regulation on cytoskeletal proteins which thus hamper the cancer 
cell migration and invasion, and disturb the cell junctions for inhibiting collective cancer 
cell migration.  
1.12 Targeting Cancer Cell Integrins Using Gold Nanorods in Photothermal 
Therapy Inhibits Migration Through Affecting Cytoskeletal Proteins[10]  
Note: Yue Wu and Moustafa Ali have equally contributed to designing, 
performing, analyzing, and writing the research in Section 4.1 of this chapter. 
Summary. Metastasis is responsible for most cancer-related deaths, but the 
current clinical treatments are not effective. Recently, gold nanoparticles (AuNPs) were 
discovered to inhibit cancer cell migration and prevent metastasis. Rationally designed 
AuNPs could greatly benefit their antimigration property, but the molecular mechanisms 
need to be explored. Cytoskeletons are cell structural proteins that closely relate to 
migration, and surface receptor integrins play critical roles in controlling the organization 
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of cytoskeletons. Herein, we developed a strategy to inhibit cancer cell migration by 
targeting integrins, using Arg–Gly–Asp (RGD) peptide-functionalized gold nanorods. To 
enhance the effect, AuNRs were further activated with 808-nm near-infrared (NIR) light 
to generate heat for photothermal therapy (PPTT), where the temperature was adjusted 
not to affect the cell viability/proliferation. Our results demonstrate changes in cell 
morphology, observed as cytoskeleton protrusions—i.e., lamellipodia and filopodia—
were reduced after treatment. The Western blot analysis indicates the downstream 
effectors of integrin were attracted toward the antimigration direction. Proteomics results 
indicated broad perturbations in four signaling pathways, Rho GTPases, actin, 
microtubule, and kinases-related pathways, which are the downstream regulators of 
integrins. Due to the dominant role of integrins in controlling cytoskeleton, focal 
adhesion, actomyosin contraction, and actin and microtubule assembly have been 
disrupted by targeting integrins. PPTT further enhanced the remodeling of cytoskeletal 
proteins and decreased migration. In summary, the ability of targeting AuNRs to cancer 
cell integrins and the introduction of PPTT stimulated broad regulation on the 
cytoskeleton, which provides the evidence for a potential medical application for 
controlling cancer metastasis. 
1.12.1 Introduction.  
Metastasis is a process that enables cancer cells to spread to other sites of the 
body, and is responsible for most cancer-related deaths [60-62]. The migration of cancer 
cells from one site to another requires dramatic remodeling of the cellular cytoskeleton [61, 
62, 64, 65]. Studies on the changes of cytoskeletal components could provide novel 
therapeutic approaches to prevent cancer cell migration and metastasis [64]. The targeting 
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of cytoskeletal components, such as actin or tubulin [318, 319], or regulatory proteins, such 
as Rho-ROCK or LIM kinases, has been shown to inhibit the invasive and metastatic 
behavior of cancer cells [320]. However, the pharmacological inhibitors of cytoskeleton 
have not been very effective in clinical trials due to their non-specific targeting of 
cytoskeleton in normal cells, which might cause side effects, such as cardiotoxicity [64, 319, 
321]. Moreover, in many cases, the anti-cancer drugs that target specific proteins might 
lose their efficacy after several months of treatment due to mutations of the proteins that 
result in the rise of drug resistance in cancer cells [68]. 
Recent advancements in nanomedicine provide us with great opportunities to 
avoid the drawbacks of commonly used drugs [69, 70]. Due to their small size and surface 
modifications, nanoparticles, in general, are able to target tumors selectively [71] and have 
been widely used in cancer diagnosis and therapy [72]. The recent discovery of 
nanoparticles’ effect on inhibiting cancer cell migration or metastasis starts to draw the 
attention of researchers [73-76, 322]. However, high concentrations of non-targeted 
nanoparticles (in µM) were used in these previous studies, which might be an obstacle 
when considering the translation to clinical usage. Additionally, several types of 
nanoparticles, including TiO2, SiO2, iron oxide, etc. have been found to exhibit toxicity 
when used in relatively high concentrations [323]. In our previous work, we designed 
nuclear membrane targeted gold nanoparticles (AuNPs) for inhibiting cancer cell 
migration by increasing their nuclear stiffness, which greatly reduced AuNPs dosage and 
could be favorable for clinical applications [324]. Therefore, to maintain the nanoparticles’ 
effect on impeding cancer cell migration, an intelligent design with a reduced quantity of 
nanoparticles promises to be crucial in the development of novel and effective anti-
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metastasis therapy. In addition, the preliminary observations of several groups have 
shown that this inhibition effect of nanoparticles are related to some individual 
cytoskeleton proteins [86, 132, 133], such as microtubule and actin. However, various 
mechanisms have been proposed. Tay et al. found that TiO2, SiO2, and hydroxyapatite 
nanoparticles could slow cancer cell migration by disrupting the intracellular microtubule 
assembly [74]. Soenen et al. reported that iron oxide nanoparticles at high concentrations 
within cells affect the cellular cytoskeleton and focal adhesion kinase [75]. Zhou et al. 
showed gold nanorods (AuNRs) can inhibit ATP production, thus inhibit F-actin 
cytoskeletal assembly and decrease cancer cell migration [76]. Therefore, a complete 
scope of the mechanism of nanoparticles’ effect on the cytoskeletal proteins needs to be 
explored by systematic biological strategy.  
In general, it has been reported that heat stress affects the cytoskeleton and 
induces their rearrangements [325]. Thus, we hypothesized that the use of gold nanorods 
(AuNRs), allows us to apply near-infrared (NIR) laser to generate heat efficiently through 
non-radiative processes [69, 219, 326]. AuNRs, due to their unique chemical, physical and 
optical properties, have been used in drug delivery [273], bio-imaging, and PPTT of cancer 
[223, 327].  NIR light is a low energetic (safe) light that can deeply penetrate the tissues, 
which could potentially enhance the AuNRs’ effects on cytoskeletal proteins and inhibit 
migration.  
Integrins are major adhesion and signaling receptor proteins that play an 
important role in regulating cytoskeleton [328], by providing a physical linkage between 
the cytoskeleton and the extracellular matrix (ECM), and receiving signals from the ECM 
[329]. They could perturb the down-stream cell adhesion and migration pathways and 
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modulate the cytoskeleton, thus regulating cell motility and migration [330]. Numerous 
studies have reported differentially expressed integrins in many cancers. Integrins αvβ3, 
α5β1, and αvβ6, are found in very low abundance, even undetectable levels, in most adult 
epithelial cells, whereas they can be highly overexpressed in many tumors [331]. Integrins 
are also regulators of metastasis. For instance, inducing the expression of the αvβ3 
integrin subunit in cancer cell lines increases their metastatic potential [332]. The Arg-Gly-
Asp (RGD) peptides are known for specific binding to a wide number of surface integrins, 
including αvβ3, α3β1 and α5β1 integrins 
[333, 334]. The good selectivity of RGD to cancer 
cells has been reported by numerous studies for delivering nanoparticles to cancer cells or 
tumors  [335]. 
To overcome the drawbacks of using nanoparticles, four aspects of the 
nanoparticle design have been considered to achieve more effective inhibition of cancer 
cell migration:  1) lowering the concentration of nanoparticles to nM dosage, as a means 
for lowering toxicity; 2) enhancing the selectivity to the cancerous cells;  3) applying NIR 
light to enhance the AuNRs’ effects on cytoskeletal proteins to inhibit migration; 4) most 
importantly, enhancing the migration inhibition effect by targeting AuNRs to integrin 
proteins to remodel the cytoskeleton with systematic understanding of the mechanism 
behind.  In our work, RGD peptides were conjugated on the surface of AuNRs to achieve 
the selective targeting of integrin. NIR light was applied to the AuNRs to generate mild 
heat. The concentration of the AuNRs and heat were kept well below the threshold to 
avoid negative effects on cell viability or proliferation. We compared both non-targeted 
and integrin-targeted AuNRs (AuNRs@RGD). Results indicated that, while both types of 
AuNRs decreased the cell migration speed, the targeted ones did so with a greater effect. 
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After applying NIR light, cell motility was further decreased. We have performed a 
proteomics study to understand the molecular mechanism, explaining how and why 
AuNRs have a wide range of effects in perturbing cytoskeletal proteins and cell migration 
pathways. Compared to the drugs composed of small molecules that target only a single 
protein, AuNRs exhibit great promise as a novel anti-metastasis strategy for clinical 
usage.  
1.12.2 Methods.  
Materials. Tetrachloroauric acid trihydrate (HAuCl4.3H2O), NaBH4, ascorbic 
acid, cetyltrimethylammonium bromide (CTAB), AgNO3, 4-(2- hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), NaCl, sodium deoxycholate, sodium dodecyl 
sulfate (SDS) and Triton X 100 were purchased from Sigma-Aldrich. 
Methoxypolyethylene glycol-thiol (mPEG-SH, MW 5000) was purchased from Laysan 
Bio, Inc. Cell penetrating peptide RGD (RGDRGDRGDRGDPGC) was obtained from 
GenScript, Inc. Dulbecco’s phosphate buffered saline (PBS), Dulbecco’s modified 
Eagle’s medium (DMEM), fetal bovine serum (FBS), antibiotic solution, and 0.25% 
trypsin/2.2 mM EDTA solution were purchased from VWR. Mammalian cell protease 
inhibitors and phosphatase inhibitors were purchased from Roche Applied Sciences, and 
sequencing grade trypsin was purchased from Promega. Lysyl endopeptidase (Lys-C) 
was purchased from Wako.  
Instrumentation. Gold nanoparticles were imaged using a JEOL 100CX-2 
transmission electron microscope (TEM) microscope, and their average size was then 
measured by ImageJ software. UV−vis spectra were obtained using an Ocean Optics 
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HR4000CG UV-NIR spectrometer.  An inverted Nikon Eclipse Ti-E microscope 
equipped with Perfect Focus System (PFS, 25 nm z-axial resolution) was used for 
imaging under a Nikon differential interference contrast (DIC) microscope. Proteomics 
analysis was performed on a hybrid dual-cell quadrupole linear ion trap − Orbitrap mass 
spectrometer LTQ Orbitrap Elite (Thermo Fisher) with XCalibur 3.0.63 software. Flow 
cytometry experiments were conducted on a BD LSR II Flow Cytometer (BD 
Biosciences).  
Synthesis, Conjugation and Characterization of AuNRs. AuNRs with an 
average size of 25  6 nm (length  width) were synthesized using a seedless growth 
method.[228]  5 ml of 1.0 mM HAuCl4 was added to a solution of 5 mL of 0.2 M CTAB, 
250 μL of 4.0 mM AgNO3, and 8 μL of 37% HCl. Then, 70 μL of 78.8 mM ascorbic acid 
was added, followed by immediate injection of 15 μL of 0.01M of ice-cold NaBH4. The 
solution was left undisturbed for 12 hours.  The particles were centrifuged at 21000 g for 
50 min and dispersed in DI water, followed by a second centrifugation at 19000 g for 40 
min to remove the extra CTAB. TEM was used to measure the sizes and homogeneity of 
the nanoparticles. 
After rinsing them with water, AuNRs were then conjugated with different 
surface ligands (PEG and RGD). For AuNRs@PEG, mPEG-SH (1 mM) was added to the 
nanoparticles overnight to achieve about 5000 ligands on each particle. For preparing 
AuNRs@RGD, first, mPEG-SH (1 mM) was added to the nanoparticles overnight to 
achieve about 1000 ligands on each particle. Then, the PEGylated nanoparticles (1 nM) 
were treated with RGD (1 mM) to achieve 10000 molar excess. The solution was then 
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allowed to shake overnight at room temperature. Excess of ligands were removed by 
centrifugation. UV-vis spectrometer and zetasizer were used to test the conjugation.  
Cell Culture, AuNR Treatments and PPTT. Cells were grown in Dulbecco’s 
modified Eagles’ medium (DMEM, Mediatech) containing 10% (v/v) fetal bovine serum 
(FBS, Mediatech) and 1% antimycotic solution (Mediatech) at 37 oC in a humidified 
incubator under 5% CO2. Cells were cultured in 60 mm dishes for 24 hours followed by 
incubation with AuNRs for 24 hours. Then, a CW 808 nm laser (5.8 W/cm2, spot size 5.6 
mm) was applied to the cells for 1 minute. To cover the entire area of the culture dish, the 
laser was applied spot by spot using scanning with each spot undergoing two minutes of 
laser exposure time. The cells were then harvested for MS analysis, with a final 
confluence about 80-90%.  
Sample Preparation for Proteomics Experiment. After treatment for 24 hours, 
cells were washed twice using PBS. Cell lysates were prepared by directly adding the 
lysis buffer (150 mM NaCl, 50 mM HEPES, pH =7.4, 0.1% SDC, 10 units/ mL 
benzonase, protease inhibitor cocktail) to the cells followed by scraping and collecting on 
ice. Lysates were vortexed for 90 s (30 s  3 times, 2 min pause), sonicated on ice, and 
centrifuged at 18000 g for 15 min at 4 oC. The supernatant solutions were saved and 
proteins were precipitated by adding 4 x excess volumes of ice-cold precipitation solvents 
(acetone: ethanol: acetic acid=50:50:0.1). After centrifugation, the protein pellet was re-
dissolved in an solution with 8 M urea and 50 mM HEPES (pH=8) [336]. 
Protein disulfide bonds were reduced using 1 mM dithiothreitol (DTT) followed 
by alkylation with 5.5 mM iodoacetamide. After the lysates were diluted twice (final urea 
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concentration of 4 M), endoproteinase Lys-C (1:100 w/w) was added to digest proteins 
for 4 hours. Then, modified sequencing grade trypsin (1:100 w/w) was used for further 
digestion in a more diluted solution with the final urea concentration of 1 M for overnight 
[337]. Protein concentration was measured by Bradford assay. 
RPLC-MS/MS Analysis for Label-free Quantitative Proteomics. The 
proteomics analysis was conducted using the previous reported method [338]. Briefly, 
purified and dried peptide samples from the previous step were dissolved in 10 μL 
solvent with 5% acetonitrile and 4% FA, and 4 μL of the resulting solutions were loaded 
onto a microcapillary column packed with C18 beads (Magic C18AQ, 3 μm, 200 Å, 100 
μm  16 cm, Michrom Bioresources) by a Dionex WPS-3000TPLRS autosampler 
(UltiMate 3000 thermostatted Rapid Separation Pulled Loop Well Plate Sampler). A 
reversed-phase liquid chromatography (RPLC) was employed for peptides separation 
with a 110 min gradient of 8-38% ACN (with 0.125% FA). Peptides were detected with a 
data-dependent Top20 method, i.e. for each cycle, one full MS scan (resolution: 60,000) 
in the Orbitrap was followed by up to 20 MS/MS in the ion trap for the most intense ions. 
The selected ions were excluded from further analysis for 90 seconds. Ions with singly or 
unassigned charge were not sequenced. Maximum ion accumulation times were 1000 ms 
for each full MS scan and 50 ms for MS/MS scans. The sample at each condition was 
repeated 6 times (2 biological and 3 technique replicates) for label-free quantification.   
Apoptosis/Necrosis Assay. After removing the cell culture media, and cells were 
washed with phosphate-buffered saline (PBS) and collected after trypsinization followed 
by washing with cold PBS twice again. Then, the cells were dispersed in a mixture of 493 
mL of Annexin V binding buffer, 5 μL of Annexin V FITC (BioLegend), and 2 μL of 
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propidium iodide PI (BioLegend, 100 µg / mL) and incubated for 15 min at room 
temperature. The cells were then filtered and subjected to flow cytometry analysis using a 
BSR LSR II flow cytometer (BD Biosciences). A 488 nm laser was applied for excitation, 
and FITC was detected in FL-1 using a 525/30 BP filter while PI was detected in FL-2 
using a 575/30 BP filter. Standard compensation using unstained and single-stained cells 
was done before running actual experiments. FlowJo software (Tree Star Inc.) was used 
for analysis of the viable, apoptotic and necrotic cells from at least 10000 events.  
Cell Imaging Using DIC Microscopy. The Nikon DIC mode utilized a pair of 
polarizer and analyzer, a high resolution 100×I-R Nomarski DIC slider, a high numerical 
aperture (N.A., 1.40) oil immersion condenser lens, a Nikon CFI Apo TIRF 100 × (N.A., 
1.49) oil immersion objective, and a 12 V/100 W halogen lamp as light source. 
Appropriate bandpass filters were placed in the light path. Fixed HEYA8 cells on 22 mm 
× 22 mm glass coverslips were rinsed with PBS at pH 7.4 and fabricated into a 
sandwiched chamber with two pieces of double-sided tape and a cleaned glass slide. PBS 
solution was then added into the chamber to fill the space, and the chamber was then 
sealed by clear nail polish. The so-formed sample slide was then place under the 
microscope for observation. Two scientific CMOS cameras were used to capture the DIC 
images: a Hamamatsu C11440-22CU, ORCA-Flash 4.0 V2 with a 2048 × 2048 pixel 
array and a pixel size of 6.5 μm × 6.5 μm and a Tucsen Dhyana 95 with a 2048 × 2048 
pixel array and a pixel size of 11 μm × 11 μm. These cameras performed similarly in our 
experiments. 
Scratch Assay. The scratch assay has been performed according to a former 
report [291]. Cells were cultured in a 6-well plate to a confluent monolayer. A p200 pipet 
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tip was used to scrape the cell monolayer in a straight line to create an empty gap. The 
debris was then removed by washing the cells once with a culture medium and then 
replaced with 2 mL of fresh medium. Then, the cells were imaged immediately after 
scratch and 12 hours after scratch.  
Proteomics Data Analysis. Two biological replications and three MS technical 
replications for each condition (control, AuNRs@PEG, AuNRs@PEG/NIR, 
AuNRs@RGD, AuNRs@RGD/NIR) were conducted. Raw data from proteomics was 
normalized using supervised normalization of the microarray (SNM) [339]. In the SNM 
procedure, variance due to biological and technical replicates were adjusted by setting 
them as variables in the model. Variance explained by different experimental treatments 
(control, AuNRs@PEG, and AuNRs@PEG+NIR for PEG-conjugated AuNRs group; 
control, AuNRs@RGD, and AuNRs@RGD+NIR for RGD-conjugated AuNRs group) 
was fitted as a biological variable in the model. Hierarchical clustering was done with 
statistical software R [340]. Proteomics data was log2 transformed before analysis of 
variance (ANOVA) which was used to detect differential expression of proteins between 
control and treatment groups, with treatment conditions set as fixed effects. P-value 
threshold at 0.1 was set to select differential proteins. The proteins identified as being 
affected were subjected to pathway analysis using the MetaCore pathway analysis 
software (“MetaCore from Thomson Reuters”).  
Western-blot Analysis. Briefly, cells were lysed in RIPA buffer (20 mM Tris pH 
7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.1% sodium deoxycholate, 1% Triton 
X-100, 0.1% SDS) containing protease inhibitors (Sigma-Aldrich). BCA assay (Pierce) 
was performed to measure the protein concentration, and equal amounts of protein were 
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loaded on a SDS-PAGE gel. After the protein separation, the resulting gels were 
transferred to PVDF membranes (Millipore) overnight. Afterwards, the gel was blocked 
with 5% milk in TBS (20 mM Tris, 150 mM NaCl). The primary antibodies (Bethyl 
Laboratories, Inc.) was incubated with the membrane overnight in 4 °C with shaking, 
followed by adding the secondary antibodies (Jackson Immuno Research Laboratories). 
Blots were washed three times for 20 m in TBS after primary and secondary antibodies. 
1.12.3 Results.  
1.12.3.1 AuNR Fabrication, Characterization, Cell Uptake and Cytotoxicity Studies.  
AuNRs with size of 25 (± 3)  6 (± 1) nm (length  width) and aspect ratio of 4.2 
were synthesized according the seedless method [228], as shown in the transmission 
electron microscope (TEM) in Figure 4.1 A. This size of AuNRs has shown better 
efficacy in heat generation in PPTT by our previous study [341]. The as-synthesized 
AuNRs were washed twice with water to remove cetyltrimethylammonium bromide 
(CTAB) to decrease the cytotoxicity and for the next step of surface modification. The 
AuNPs were functionalized with polyethylene glycol thiol (PEG) and RGD peptides to 
increase the biocompatibility [230] and achieve integrin targeting [333], respectively. 
Surface modification causes a red shift of the longitudinal surface plasmon resonance 
(SPR) band of AuNRs due to the change in the dielectric constant of the surrounding 
environment of AuNRs (as shown in the UV-Vis spectra in Figure 4.1 B). After 
PEGylation, the SPR band red-shifts to 785 nm for AuNRs@PEG (initially 771 nm). 
Further red-shift to 796 nm for AuNRs@RGD was observed, indicating the surface 
binding of RGD. In addition, the zeta potentials of the AuNRs at different stages were 
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measured to confirm the surface modifications. As shown in Figure 4.1 C, the as-
synthesized CTAB coated AuNRs had a positive surface charge of 22.9 ± 15.1 mV as the 
CTAB is a highly cationic surfactant. After PEG modification, the AuNRs became 
negatively charged (-10.2 ± 6.73 mV), then became positive again after further 
modification of the RGD peptides. The characterization results are consistent with those 
of our and other groups [286, 338], which indicates the successful conjugation of the RGD 





FIGURE 4.1. AuNR synthesis, characterization, HSC-3 cellular uptake, and 
cytotoxicity study. (A) TEM image of AuNRs. (B) UV-Vis spectrum of AuNRs with 
different surface ligands. Black, the as-synthesized AuNRs with CTAB on the 
surface; blue, PEGylated AuNRs; red, AuNRs conjugated with PEG and RGD. (C) 
Zeta potential shows the surface charge before/after conjugations. (D–F) DF image 
of cells without AuNRs, incubated with AuNRs@PEG or AuNRs@RGD, 
respectively (representative of replicated experiments, another two sets of results in 
FIGURE. 4.2). (G–K) Cell viability/apoptosis/necrosis assay of cells under different 
treatments, using flow cytometry. Q1, necrotic cells; Q2, late apoptotic cells; Q3, 
early apoptotic cells; Q4, viable cells (representative of replicated experiments, 
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statistical results in FIGURE. 4.2). (L) Western blotting for the BAX protein after 
four groups of treatments. 
Successful internalization of AuNRs within the cells was observed as monitored 
under a dark-field (DF) microscope (Figure 4.1 D-F and 4.2), where the brightness of 
the scattering light from AuNRs indicates the internalized AuNRs amount. The human 
oral squamous cell carcinoma (HSC-3) cells were incubated with 2.5 nM of AuNRs for 
24 hours. For AuNRs@RGD, clear scattering light of AuNRs was observed while 
AuNRs@PEG did not show high uptake when compared to the AuNRs@RGD. The 
difference in uptake of these two types of AuNRs is due to the binding of RGD to the 
surface integrin that enhances the endocytosis of AuNRs [342]. For further confirmation, 
the internalization of AuNRs was also measured by UV-Vis spectra (Figure 4.3 A) and 
the differential interference contrast (DIC) microscopy (Figure 4.3 B-D). In addition, the 
retaining of the Gaussian-shape peaks in the UV-Vis spectra of AuNRs after incubation 
with cells indicates the colloidal stability. Flow cytometry was used to measure the cell 
viability and apoptosis status, and the results indicated the 2.5 nM of AuNRs@PEG and 
AuNRs@RGD did not affect the cell viability or cause apoptosis (Figure 4.1 G and 4.4). 
This result confirms that the functionalization of AuNRs has been well performed by 
ligand-ligand exchange to replace the CTAB with PEG and RGD. A 808 nm CW NIR 
laser was applied for 1 minute to raise the temperature of the culture media to about 42  
1 oC. As the temperature increased, there was no obvious change in the cell viability and 
no sign of apoptosis/necrosis (Figure 4.1 G-K and 4.4).  In addition, no cell apoptosis 
occurred after AuNRs incubation and slight NIR exposure, as confirmed by our Western-
blot results (Figure 4.1 L). BAX, an important protein that participates in the initiation of 




FIGURE 4.2. DF image of cells without AuNRs (A and D), incubated with 
AuNRs@PEG (B and E), or AuNRs@PEG@RGD (C and F), respectively 
(replicated experiments of Fig. 1 D–F). (Scale bar, 50 μm.) 
 
FIGURE 4.3. HSC cell uptake of AuNRs. (A) UV-Vis spectra of AuNRs before and 
after incubation with cells. (B–D) DIC microscopy images of cells without 
nanoparticle incubation (B), incubated with AuNRs@PEG (C), and incubated with 




FIGURE 4.4. Apoptosis populations of HSC cells under different treatments, using 
flow cytometry. 
1.12.3.2 AuNR Inhibit Cancer Cell Migration and Invasion Ability  
To evaluate the AuNRs’ effect on cancer cell migration, we conducted a scratch 
assay [291] on the monolayers of cells that were incubated with or without AuNRs for 24 
hours. After introducing a “scratch” or “wound” into a cell culture, images were captured 
immediately and 12 hours after the scratch. Figure 4.5 A and 4.6 A indicates that cells in 
the control group had the “wound” completely healed, while cells treated with AuNRs 
were not completely healed. The integrin-targeting AuNRs (AuNRs@RGD) have a 
greater inhibition effect than the non-targeted AuNRs (AuNRs@PEG). In addition, NIR 




FIGURE 4.5. Changes of cell migration rate and shapes upon AuNRs treatments. (A) 
Images of HSC cell movement using scratch assay (representative of replicated 
experiments, another set of results in Figure. 4.6 A). (B) Changes in the cell shape 
using DIC images before and after AuNR or NIR treatments (representative of 
replicated experiments, another set of results in Figure. 4.6 B). (C) Western-blot 
analysis of integrin- and migration-related proteins in AuNRs@PEG and 
AuNRs@RGD (with or without NIR light). 
As mentioned above, the cell motility decreased upon the AuNR treatment. It is 
well known that changes in cell morphology are closely related to cell motility, which is 
initiated through two types of membrane protrusions: flat, sheet-like lamellipodia and 
needle-like actin-based filopodia (Figure 4.5 B). Both structures contain a large density 
of integrins [344] and play major roles in leading cancer cell migration and invasion [345]. 
To study the cell morphological changes (lamellipodia and filopodia), a differential 
interference contrast (DIC) microscope was used. The control sample exhibited a normal 
and extended lamellipodia and filopodia. After treating with AuNRs@RGD alone, the 
cells tended to have around shape with fewer lamellipodia and filopodia when compared 
to the control. When we applied AuNRs@RGD and NIR light together, the area of 
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lamellipodia was further decreased, and many needle-like filopodia appear outside the 
cell (more information in Figure 4.6 B). The morphological changes of integrin-rich 
lamellipodia and filopodia indicate that the integrin targeted AuNRs with or without NIR 
light are effective in changing the cytoskeleton structures, a probable cause for the 
decrease in cell motility.  
 
FIGURE 4.6. (A) Images of HSC cell movement under different conditions using 
scratch assay (replicated experiment). (B) Changes in the cell shape using DIC 
images before and after gold AuNRs or NIR treatments (replicated experiments). 
To study the molecular mechanism, we checked the expression levels of several 
proteins that are closely associated with integrin and cell migration. Two important 
down-stream regulators of integrin, Src and ERK1/2 were found to be down-regulated 
with the AuNRs treatment when compared with the control (Figure 4.5 C). Src is a 
critical protein which bridges between integrin and Rho (a main regulator of cytoskeleton) 
signaling [346], and ERK1/2 is a mitogen-activated protein kinase [347]. The decrease of Src 
and ERK1/2 indicates that targeting the surface integrin using AuNRs@RGD could block 
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the down-stream regulators of integrin signaling [348], which contributes to the inhibition 
of cell migration by AuNRs. Moreover, in a further investigation of integrin-related 
proteins, Figure 4.5 C showed that epithelial cadherin (E-cadherin) and phosphatase and 
tensin homolog (PTEN), were up-regulated upon AuNRs treatments. Recent discoveries 
have shown that E-cadherin have cross-talk with integrin signaling [349] that alter 
cytoskeletal organization [350]. Loss of E-cadherin is often associated with tumor invasive 
progressing [351]. In addition, the tumor suppressor protein PTEN has been reported to 
inhibit integrin-mediated cell migration, spreading, and adhesion and affecting mitogen-
activated protein kinase [352]. Our results indicated that the up-regulation of E-cadherins 
and PTEN contributes to the inhibition of cancer migrations. 
1.12.3.3 Proteomics Analysis Reveals the Inhibition of Migration Pathways  
To gain a global view of proteome change, label-free quantitative proteomics was 
conducted to identify and quantify protein expression changes in HSC-3 cells after 
incubation with AuNRs. Proteomics results indicated a wide range of perturbations of 
proteins in migration-related pathways after AuNRs treatment. In this experiment, cells 
were lysed and proteins were then extracted and digested. The purified peptides were 
analyzed by an on-line liquid chromatography-mass spectrometry (LC-MS) system. Two 
biological replications and three technical replications for each condition were conducted. 
In total, over 4000 proteins were identified and about 1800 common proteins were 
quantified in four treatment groups (AuNRs@PEG, AuNRs@PEG+NIR, AuNRs@RGD, 
and AuNRs@RGD+NIR) (Figure 4.7 A). The clustering analysis (Figure 4.8 A and B) 
shows that the control group and experimental groups were separately clustered, also 
indicating a good reproducibility of the proteomics experiments. Differential analysis 
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identified proteins with significant changes in AuNRs treated groups compared to the 
control group (Figure 4.8 C-F). The numbers of up- and down-regulated proteins in each 
group are shown in Figure 4.8 G. Comparison of differentially expressed proteins 
identified in the four treatments is shown in the Venn diagram (Figure 4.8 H). 
Expression levels of key proteins in migration-related pathways are shown in the heatmap 
(Figure 4.7 B), where a wide range of cytoskeletal proteins were observed to be affected 
in the four AuNRs treated groups. Pathway analysis using MetaCore (Thomson Reuters) 
reveals the perturbation of signaling pathways related to cell migration in all groups 
(Figure 4.7 C), including the cytoskeleton remodeling, Rho GTPase signaling, integrin-
mediated cell migration and invasion, etc. Per the pathway analysis results, 
AuNRs@RGD+NIR caused the greatest changes to the migration-related pathway and 
was considered the most effective for inhibiting cancer cell migration, followed by 




FIGURE 4.7. Experimental results of proteomics in the four treatment groups 
(AuNRs@PEG, AuNRs@PEG+NIR, AuNRs@RGD, and AuNRs@RGD+NIR). (A) 
Heatmap showing the expression levels of all of the quantified proteins. (B) 
Heatmap showing identified proteins contributing to migration inhibition. (C) Bar 
graph showing identified significant pathways related to migration. (D) Western-








FIGURE 4.8. Experimental results of proteomics and data analysis. (A) Clustering 
analysis of samples: AuNRs@PEG, AuNRs@PEG+NIR, and control. (B) Clustering 
analysis of samples: AuNRs@RGD, AuNRs@RGD+NIR, and control. (C–F) 
Volcano plots of proteins under perturbation by (C) AuNRs@PEG, (D) 
AuNRs@PEG+NIR, (E) AuNRs@RGD, and (F) AuNRs@RGD+NIR. (G) Numbers 
of regulated/unregulated proteins identified in each experiment. (H) Venn diagram 
showing the comparison of differentially expressed proteins identified in each 
experiment. 
 
A scheme (Figure 4.9) was concluded from the pathway maps to illustrate the 
changes of the key protein players in the migration-related pathways. AuNRs regulate the 
cell migration by affecting the cytoskeleton in four main ways: 1) Rho GTPases, 2) actin, 





FIGURE 4.9. Scheme representing the mechanisms involved in inhibiting cell 
migration upon AuNR treatments. When the AuNRs@RGD (in red) target the 
alpha/beta integrins, four different cytoskeletal proteins pathways are regulated, 
Rho (blue), Actin (yellow), Microtubule (green), and Kinase (pink), all of which 
affect the cell contractility and thus inhibit cell migration (shown in red at the 
bottom of the figure). 
1) Rho GTPases regulate the actin cytoskeleton [353], which plays an important role 
in cellular contractility (actomyosin contraction) by directly controlling the 
balance between myosin II and actin, and initiates the force needed for cell 
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migration [354]. Many key proteins in Rho GTPase signaling pathways were 
perturbed, including serine/threonine kinase ROCK, myosin heavy chain (MyHC), 
myosin essential light chain (MELC), myosin light-chain phosphorylation 
(MLCP), RhoA, -actinin, talin, etc., as shown in Figure 4.7 B and 4.9. All four 
treatments exhibit the regulation of Rho GTPase signaling to different extents. 
The AuNRs@RGD+NIR group has the highest statistical significance with the 
lowest p-value (1.510-10), reflecting this group’s highest efficacy in inhibiting 
the cancer cell migration-related pathways. Our results indicate the disruption of 
actomyosin contraction, which might prevent the generation of traction force 
during the migration process. 
2) In addition to disrupting actomyosin contraction, the effect of AuNRs on focal 
adhesions (or cell-matrix adhesion) was also observed. Focal adhesions are 
structures that contain integrin and other associated proteins, which form links 
between intracellular actin cytoskeleton and ECM [355]. The activated integrins 
couple to the actin cytoskeleton by recruiting actin-binding proteins [356]. Our 
results show that actin-binding proteins, including alpha-actinin, talin, vinculin, 
were down-regulated after AuNRs incubation (Figure 4.7 B and 4.9), suggesting 
the connectivity between integrin and actin cytoskeleton was likely weakened due 
to the blocking effect of AuNRs on the migration pathways.  
3) While the actin cytoskeleton provides contractile forces, microtubules form 
polarized network throughout the cell. The microtubule-associated proteins 
(MAPs) were significantly down-regulated (MAP2 and MAP4), indicating the 
rearrangement of microtubules. MAPs binds directly to the tubulin dimers of 
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microtubules which often leads to the stabilization and polymerization of 
microtubules [357]. The disruption of the intracellular microtubule assembly could 
also limit the cell motility [358]. 
4) Furthermore, our results show several kinases related to the integrin signaling 
pathways were perturbed, including integrin linked kinase (ILK), nuclear factor-
κB (NF-κB), the epidermal growth factor receptor (EGFR), caveolin, etc. These 
proteins are closely associated with integrin regulation and cell migration [359]. It 
has been reported that the overexpression of ILK could promote the migration and 
invasion of colorectal cancer cells via NF-κB signaling [360]. In the current results, 
the down-regulation of ILK and NF-κB is associated with reduced cancer cell 
migration ability. In addition, the expression level of EGFR, a surface receptor for 
epidermal growth factor decreased. The down-regulation of EGFR was also 
confirmed in the Western-blot results. EGFR is regarded as an important target 
for anticancer therapeutics [361]. Furthermore, STAT3, which is normally activated 
by tyrosine phosphorylation in response to the addition of EGFR [362] and can 
promote cell migration, was also down-regulated in all the AuNRs treated 
samples (Figure 4.7 D). 
1.12.4 Discussion.  
Current advances of nanoscience and nanomedicine enable us to fabricate 
“intelligent” nanomaterials that can specifically target cellular and subcellular locations 
in living animals for treating diseases [209, 295]. While larger nanoparticles (> 18 nm in 
diameter) can accumulate in organs such as the liver and spleen and be eliminated slowly 
[317], the long-term effect of AuNRs in mice shows no toxic effect after 15 months [363]. 
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The biocompatibility and special physicochemical properties of AuNRs provide us an 
effective and safe potential treatment of cancer. 
Our previous study has shown success in treating xenograft mice and natural 
mammary gland tumors in dogs and cats using AuNR-assisted PPTT, where no cancer 
relapse or metastasis occurred in any of the test subjects [272, 363], implying the potential 
effect of AuNRs in inhibiting cancer metastasis. We also designed nuclear membrane-
targeted AuNPs for inhibiting cancer cell migration and invasion, by mechanically 
increasing their nuclear stiffness, with greatly reduced AuNPs dosage [324, 363]. Herein, we 
reported that targeting AuNRs to cancer cell surface integrins could greatly rearrange the 
cytoskeleton proteins, thus enhance the inhibition effect on cancer cell migration. When 
compared to non-targeted AuNRs, the integrin-targeted AuNRs are more effective on cell 
migration inhibition with a nanoparticle concentration at the nM scale (1000 lower than 
the literature values [74-76], which could be safer for future clinical usage.  
Our result shows that cancer cells incubated with integrin-targeted AuNRs (with 
or without NIR light exposure) exhibited impaired migration abilities. Morphological 
changes were observed in cytoskeleton protrusions by targeting surface integrins using 
AuNRs, namely lamellipodia and filopodia, which form the leading edge for cell 
movement. These cytoskeleton protrusions were reduced after treating the cells with 
AuNRs@RGD. Furthermore, greater morphological changes were observed after 
applying NIR light. Integrins are often found in the tips or alone in the shaft of filopodia 
and lamellipodia, which creates the “sticky fingers” and facilitate the migration and 
invasion [364]. The reason for this morphological change has been explored in our Western 
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blot and proteomics analysis, which indicated that the integrin related proteins were 
obviously affected.  
In addition to the morphological change through lamellipodia and filopodia, 
systematic molecular mechanisms have been studied and many protein pathways exhibit 
changes after exposing to integrin-targeted AuNRs. This broad change of cytoskeletal 
proteins is possibly due to the ability of integrin in controlling cytoskeleton through many 
different ways as an up-stream surface receptor. Results show that by targeting surface 
integrins, the focal adhesion connecting the cytoskeleton to the extracellular matrix 
through integrin has been weakened. Moreover, the actomyosin contraction, which 
creates intracellular tension for migration, has been modulated through the Rho GTPase 
signaling. Though targeting integrins, both the change of actin and microtubule were 
observed, as well as several protein kinases that related to cytoskeleton and cancer 
progression and metastasis. All the above aspects could finally result to the inhibition of 
cancer cell migration.  
In summary, the ability of targeting AuNRs to cancer cell surface integrins and 
the introduction of PPTT caused wide-range regulation on cytoskeletal proteins, observed 
as lamellipodia/filopodia morphological changes and four major groups of migration-
related protein changes. Applying NIR light to generate mild heat further enhanced this 
effect. This strategy provides a potential application for controlling cancer metastasis. 
Future work will be focused on testing the effect of gold nanoparticles on preventing and 
treating cancer metastasis in animals. The injection method (either active or passive 
tumor targeting) should be decided and more investigation will be conducted.  
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1.13 Gold Nanorod-photothermal Theralpy Alters Cell Junctions and Actin 
Network in Inhibiting Cancer Cell Collective Migration[94] 
Summary. Most cancer-related deaths come from metastasis. It was recently 
discovered that nanoparticles could inhibit cancer cell migration. While most researchers 
focus on single-cell migration, the effects of nanoparticle treatment on collective cell 
migration has not been explored. Collective migration occurs commonly in many types of 
cancer metastasis, where a group of cancer cells move together, which requires the 
contractility of the cytoskeleton filaments and the connection of neighboring cells by the 
cell junction proteins. Here, we demonstrate gold nanorods (AuNRs) and the introduction 
of near-infrared light could inhibit the cancer cell collective migration by altering the 
actin filaments and cell junctions with significantly triggered phosphorylation changes of 
essential proteins, using mass spectrometry-based phosphoproteomics. Further 
observation using super-resolution stochastic optical reconstruction microscopy (STORM) 
showed the actin cytoskeleton filament bundles were disturbed, which is difficult to 
differentiate under a normal fluorescence microscope. The decreased expression level of 
N-Cadherin junctions and morphological changes of tight junction protein ZO-2 were 
also observed. All these results indicate possible functions of the AuNRs treatments in 
regulating and remodeling the actin filaments and cell junction proteins, which contribute 




FIGURE 4.10. Schematic of AuNRs and PPTT disturb the actin network and cell 
junctions. 
1.13.1 Introduction.  
Metastasis is responsible for over 90% of cancer-related deaths[62]. In order to 
initiate the metastasis, cancer cells must be equipped with the ability to migrate and 
invade the surrounding tissues, then intravasate to the microvasculature of the lymph and 
blood stream, and finally translocate to distant tissues and adapt in the microenvironment 
[62]. However, past attempts to develop anti-metastasis drugs have not been efficacious in 
clinical trials [128]. Recent advancements in nanomedicine provide new opportunities to 
avoid some drawbacks of commonly used cancer drugs, as nanoparticles can cross 
biological barriers, enter target cells with high selectivity, and function inside cell in a 
controlled manner [14, 129, 130]. Nanoparticles have shown promise as anti-metastasis drug 
delivery vehicles targeting invasive or metastasized cancer cells[79, 88, 131], and they could 
even function as anti-metastasis drugs without drug loading[85, 86, 132, 133]. The optical and 
mechanical properties, such as plasmonic photothermal effect and high mechanical 
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strength, as well as excellent biocompatibility of gold nanoparticles (AuNPs) make them 
very useful in attenuating cancer metastasis[134].  
Previously, we have developed cancer treatment using gold nanorods (AuNRs) 
for plasmonic photothermal therapy (PPTT). In PPTT, AuNRs that absorb the incident 
near infra-red (NIR) light to induce heat, and thereby could trigger tumor apoptosis [40]. 
AuNRs-PPTT has been applied successfully on treating tumor bearing mice, cats and 
dogs. In these studies, we observed that animals with induced or spontaneous tumors 
were effectively cured with no tumor reoccurrence or metastasis [9, 48, 365]. Our recent in 
vitro studies also revealed AuNPs and PPTT inhibits cancer cell migration and invasion 
[10, 85]. However, the mechanism of how AuNPs treatments inhibit cancer cell migration 
remains largely unresolved. 
While the mechanism of nanoparticles on inhibiting the migration of single cells 
have been explored in the previous works, the mechanism regarding collective cell 
migration has rarely been studied.  In collective cancer cell migration, a group of cancer 
cells migrate together, which might be a more efficient route for metastasis possibly due 
to a diverse cell population seeding other organs or the multicellular signal integration 
engaged [366]. Collective cell migration has been widely observed in human cancers, 
especially in human epithelial cancers such as breast cancer and colon cancer [366, 367]. It 
requires both the contractility of the cytoskeleton filaments and the active interactions of 
neighboring cells through the cell-cell junctions that connect the cytoskeleton of the 
neighboring cells [368]. This process is highly dynamic and regulated by signal 
transduction through protein phosphorylation [369, 370]. Given their important roles, it is 
imperative to understand the signals evolved in the cytoskeleton filaments and cell-cell 
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junctions shortly after AuNRs and PPTT stimulation for the rational design of effective 
strategies to inhibit cancer metastasis.  
In the current study, we hypothesized that the integrin-targeting AuNRs and PPTT 
treatment could affect the cytoskeleton and cell junctions, due to their interactions and 
connections as a network, to result in the inhibition of collective cancer cell migration (as 
shown in Scheme 1 in the Experimental section). To test this hypothesis, quantitative 
mass spectrometry (MS)-based phosphoproteomics was employed to examine the 
signaling pathways upon the stimulation of AuNRs and PPTT. A primary signaling 
pathway map has been constructed to display a large number of identified alterations. 
Furthermore, super-resolution microscopy imaging techniques were used to visualize the 
changes of key cytoskeletal and cell junction proteins. Both phosphoproteomics and 
super-resolution imaging results indicated possible functions of the AuNRs and PPTT in 
regulating and changing the architecture of the cytoskeletal filaments and cell junctions, 
contributing to the inhibition of collective cancer cell migration.   
1.13.2 Results and Discussion.  
1.13.2.1  Gold Nanorods and NIR Light Attenuate the Migration and Invasion of Cancer 
Cells 
The preparation of integrin targeted AuNRs was stated in our previous work [10]. 
Briefly, AuNRs with a size of 25 (± 3)  6 (± 2) nm (length  width) and an aspect ratio 
of 4.2, transmission electron microscopy (TEM) image) were synthesized using the 
seedless growth method [228]. Optimal heat-generating efficacy in PPTT with these 
AuNRs has been demonstrated previously [341]. To remove the cytotoxic 
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cetyltrimethylammonium bromide (CTAB), the as-synthesized AuNRs were washed 
twice with D.I. water. Then, the AuNRs were functionalized with polyethylene glycol 
thiol (PEG) and Arg–Gly–Asp (RGD) peptides to increase the biocompatibility [230] and 
obtain integrin targeting [333], respectively. The surface conjugations were confirmed by 
the red-shift of the longitudinal surface plasmon resonance (SPR) band and surface 
charge changes of the AuNRs, consistent with the previous reports [10]. For the details of 
the AuNRs synthesis, conjugation and characterization, please refer to 4.1 section. 
The binding of RGD peptide to the cell surface integrin could enhance the 
endocytosis of AuNRs [342]. The internalization of AuNRs within the cervical cancer cell 
line HeLa, was observed under a differential interference contrast (DIC) microscope 
(Figures 4.11 A and B). DIC images indicates the AuNRs@RGD distribute spread the 
cytoplasm and the cell junction areas (Figure 4.11 C). The z-scanning indicates the 
successful internalization of AuNPs inside cells after 24 h (Figure 4.13 A-C). The cell 
viability (XTT) assay revealed that the cells remained viable and had similar proliferation 
rates after incubation with AuNRs and after PPTT for 24 h (Figure 4.11 D). 
(AuNRs@PEG was used as a “bare”, nonspecifically targeted AuNRs for control, as 
shown in Figure 4.12 (no cytotoxicity), Figure 4.13 B (cellular uptake not obvious), 
indicating the importance of RGD peptides to increase cellular uptake). In addition, no 
observable change of the apoptosis regulator Bcl-2-associated X (BAX) protein indicates 
no apoptosis after treatment (Figure 4.11 E). We performed the same assays with the 




FIGURE 4.11. Cellular uptake, cytotoxicity and motility upon AuNRs treatments 
(the results of MCF-7 cells are in Figure S2-4). (A-B) Differential interference 
contrast (DIC) microscopic images of HeLa cells without (A) and with 
AuNRs@RGD after 24 h incubation (B). (C) DIC image of AuNRs@RGD distribute 
in the cell junction areas after 24 h incubation. The red arrows identify the locations 
of AuNRs. (D) Cell viability of HeLa cells after AuNRs and AuNRs+NIR treatments 
(n=3). (E) Western blotting for the BAX protein upon different treatments. (F and G) 
Scratch assay of HeLa cells (control, AuNRs treatment, and AuNRs+PPTT 
treatment) at 0 and 12 h (n=6). Student’s t test was used for statistical analysis. All 
values are expressed as means ± standard errors of the mean (SEM). ***p < 0.001, 
**p< 0.01, *p<0.05. If not specified otherwise, “AuNRs” in all other figures means 


































































FIGURE 4.12. Cytotoxicity of non-specifically targeted AuNRs (AuNRs@PEG) on 
HeLa and MCF-7 cells (n=3).  
 
 
FIGURE 4.13. Cellular uptake and cytotoxicity of AuNRs treatments of MCF-7 cells. 
(A-D) Differential interference contrast (DIC) microscopic images of MCF-7 cells 
without AuNRs (A) and with AuNRs@PEG (B), or with AuNRs@RGD for 24 h (C) 
and 30 min (D) with Z-scanning. The red arrow indicates the locations of AuNRs. 
Three layers (layer 1 locates close to the bottom (surface), layer 2 locates in the 
middle of cells, layer 3 locates in the top of cells) indicate clearly the internalization 
of AuNRs. (E) Cell viability of MCF-7 cells after 24 h AuNRs and AuNRs+NIR 
treatments (n=3). (F) Western blotting for the BAX protein upon different 
treatments (after 24 h).  
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To evaluate the effects of AuNRs on cancer cell collective migration, we 
conducted a 2D scratch assay [291, 371] on the monolayers of MCF-7 and HeLa cells that 
were incubated with or without the treatments. After introducing a “scratch” or “wound” 
into a cell culture, the cancer cells migrate collectively to the empty space, and images 
were captured immediately and 12 hours after the scratch of HeLa cells in Figure 4.11 F 
(or 24 hours of MCF-7 cells in Figure 4.14). The statistics (Figure 4.11 G) indicates that 
cells have exhibited significantly different wound-healing ability in the control groups 
compared with those treated with AuNRs, while the introduction of NIR light to generate 
PPTT further decreases the wound-healing ability of cancer cells. If only treated with 
same dose of NIR light (no AuNRs added), no change in the cell viability and motility 
was observed (Figure 4.15). Our result shows both specific targeted AuNRs 
(AuNRs@RGD) and nonspecific targeted AuNRs (AuNRs@PEG, Figure 4.16) could 
inhibit collective cell migration to different extents, among which the AuNRs@RGD 


































FIGURE 4.14. Scratch assay images of MCF-7 cells (control, AuNRs treatment, and 
AuNRs/PPTT treatment) at 0 and 24 h (n=6). Student’s t test was used for statistical 
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analysis. All values are expressed as means ± standard errors of the mean (SEM). 
***p < 0.001, **p< 0.01, *p<0.05. 
 
FIGURE 4.15. (A) HeLa cell viability comparing Ctrl (no treatment) and Laser 
treatment (no AuNRs added, n=3).  (B) Scratch assay images of HeLa cells (Ctrl and 




FIGURE 4.16.  Scratch assay images of HeLa cells (Ctrl, AuNRs@PEG, 
AuNRs@PEG+NIR treatments) at 0 and 12 h. 
1.13.2.2 Mass Spectrometry-based Phosphoproteomics Analysis Reveals Perturbations of 
the Signal Transduction of the Actin Network and Junction Proteins 
To elucidate the effects of AuNRs and PPTT treatments on cytoskeleton filaments 
and cell junctions, we examined the phosphoproteomics of cancer cells using quantitative 
mass spectrometry (MS). A simplified experimental procedure is shown in Figure 4.17 A 
(detailed and complete experimental procedure in the Method section, and Figure 4.18, 
including conditions of non-specific targeting AuNRs@PEG). Protein phosphorylation 
was identified and quantified in both HeLa and MCF-7 cells after incubation with AuNRs 
for 30 min or after AuNRs+PPTT treatment for 30 min. Three-plex dimethyl labeling was 
used for phosphoproteomic quantification, and titanium (IV) based immobilized metal 
ion affinity chromatography (Ti-IMAC) was used to enrich the phosphorylated peptides 
from the protein digest of cell lysate. The enriched phosphorylated peptides were 
analyzed by an on-line liquid chromatography-mass spectrometry (LC-MS) system. 
Three replications of each condition were conducted and about 1200 common 
phosphorylation sites (where the phosphorus group binds to the protein) were quantified. 
The clustering analysis (Figure 4.19) shows that the control and experimental groups 
were separately clustered with good reproducibility. Differential analysis identified 
proteins with significant changes in AuNRs-treated groups compared to the control group 
(Figure 4.20). The numbers of dysregulated phosphorylation sites of different treatments 
and their overlap in the Venn diagrams are shown in Figure 4.21. For instance, compared 
with the control group, the phosphorylation levels of 371 and 244 sites are significantly 
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up- and down-regulated, respectively, for HeLa cells upon AuNRs treatment. Further 





FIGURE 4.17.  Phosphoproteomics results. (A) Experimental workflow. Two comparisons were performed in data analysis.  
Comparison #1 (AuNRs vs. control): (B) Heatmap and (C) pathway analysis after AuNRs treatment. (D) Western blotting 
showing the altered phosphorylation sited in p120 Catenin (HeLa cells). (E)  Altered phosphorylation sited in p120 Catenin 
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(pS268) indicated by phosphoproteomics (HeLa cells). Comparison #2 (AuNRs + NIR vs. AuNRs): (F) Heatmap and (G) 
pathway analysis after AuNRs + NIR treatment.  (H) Western blotting showing the altered phosphorylation sited in GSK3 
(HeLa cells). (I) Altered phosphorylation sites GSK3 (pY216) indicated by phosphoproteomics (HeLa cells). Mean values in 





FIGURE 4.18. Experimental design of quantitative phosphoproteomics. Two sets of 
experiments were performed to examine the AuNRs and the photothermal effects 
separately. (A) Studying the protein phosphorylation upon treatments of 
AuNRs@PEG (30 min stimulation) and AuNRs@RGD (30 min stimulation). (B) 
Studying the protein phosphorylation upon photothermal effects (30 min 
stimulation) after overnight incubating the cells with AuNRs@RGD. The 







FIGURE 4.19. Clustering analysis of the samples. (A) AuNRs@PEG, AuNRs@RGD 
and control for MCF-7. (B) AuNRs@PEG, AuNRs@RGD and control for HeLa. (C) 
AuNRs@RGD, AuNRs@RGD+NIR, and control for MCF-7. (D) AuNRs@RGD, 
AuNRs@RGD+NIR, and control for HeLa. B1, B2, and B3 in the figures indicate 






FIGURE 4.20. Volcano plots of proteins under perturbation by (A) AuNRs@PEG 
for MCF-7, (B) AuNRs@PEG for HeLa, (C) AuNRs@RGD for MCF-7, (D) 
AuNRs@RGD for HeLa, (E) AuNRs@RGD+NIR for MCF-7 and (F) 








FIGURE 4.21. (A) Numbers of regulated/unregulated phosphorylated sites 
identified in each experiment. (B-C) Venn diagram showing the comparison of 
differentially phosphorylated sites identified in each experiment. 
Proteins with their significantly altered phosphorylation sites are listed in 
heatmaps (Figure 4.17 B and F) and Table 4.1. In order to understand the biological 
meanings of these phosphorylation changes, we performed pathway analysis (Figure 
4.17 C for AuNRs and G for AuNRs+PPTT), which revealed the significant 
perturbations to the signaling pathways related to the cytoskeleton and cell junctions. To 
further confirm the mass spectrometric results, the varied phosphorylated sites of p120 
catenin (pS268), and glycogen synthase kinase (GSK3, pY216), which are highly related 
to cell adhesive junctions, and are regulators to actin cytoskeleton and microtubules [372], 
respectively, have been validated by Western blot results (Figure 4.17 D, E, H, and J). 
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Table 4.1. Selected significantly dysregulated phosphorylation sites of the cytoskeletal and junction proteins, specifying the 
phosphorylation sites and biological functions. 
 
Category Protein Protein Function 
Phosphorylation sites 
altered 
Phosphorylation sites function 
Cytoskeleton 
Paxillin Form focal adhesions pS303, pS302, pS106, pS85 
Increase of pS85 has an important 
function in cell adhesion [373] 
MYH9 
Form stress fibers and create a contraction 
force in cell migration 444 
pS1943 pS1943 could alter cell motility[374] 
MLCP pS299, pS445, pS871 
pS445 is closely related to cell adhesion 
[375] 
MAP4 Promotes microtubule assembly 
pS1073, pS787, pS280, 
pS789 
pS1073 is related to cancer cell metastasis 
potential [376] and pS787 could promote 
tubulin polymerization [377] thereby 





Form cell-cell adhesion complexes, 
anchoring actin cytoskeleton and interacting 
with cadherins [378] 
pT654, pS641, pT634, 
pS652, pS655 
S641 affects cell motility[379] 
ZO-2 
Connect cytoskeletons of adjacent cells and 
act as barriers for the passage of molecules 
and ions[380] 
pS966, pS986, pS978, 
pS266, pS986, pS1159, 
pS130 
No information found 
Vimentin 
A hallmark protein of epithelial to 
mesenchymal transition (EMT), which is 
related to the increase of migration and 
invasive properties[381] 
pS459, pS56, pT458 
pS56 was reported with the function of 
cytoskeleton reorganization [382] 
Keratin 
18 
Keratin 18 and its filament partner keratin 8 
are regarded as the most commonly found 
members of the intermediate filament family. 
pS34, pT65, pS420, pS42 




We observed that our treatments can change the phosphorylation of the actin 
network, including i) proteins forming the focal adhesions (FAs), such as paxillin, zyxin, 
vinculin; ii) the myosin related proteins, such as myosin-9 and myosin-light-chain 
phosphatase (MLCP); iii) the actin-binding proteins, such as filamin, cortactin and 
drebrin. Moreover, changes of cell junctions, such as tight junction proteins ZO-1 and 
ZO-2 were also observed upon AuNRs stimulation. More changes were observed to ZO-2 
after PPTT, indicating an enhanced perturbation in the tight junctions. In addition, cell 
junction protein catenins, including alpha, beta, and p120 catenins, have altered 
phosphorylated sites upon treatment. Phosphorylation change of desmosomes junction 
related proteins, including desmoplakin, epiplakin, plectin, Keratin 18 and vimentin were 
observed. In addition, the phosphorylation of several microtubule (MT)-related proteins 
were changed, including microtubule associated proteins MAP4, microtubule associated 
protein 1B (MAP1B) and glycogen synthase kinase-3 alpha (GSK3A). Besides, 
Phosphorylation changes of many protein kinases that could regulate the cytoskeleton 
filaments and cell motility were observed, such as RAF proto-oncogene serine/threonine-
protein kinase (Raf1), mitogen-activated protein kinase kinase 2 (MAP2K2), cyclin-
dependent kinase (CDK1), RAC-alpha serine/threonine-protein kinase (AKT1), etc.    
Integrins are adhesive molecules located in the cell membrane and responsible of 
transporting signals and cell-cell communications [384]. The ability of integrin-targeted 
AuNRs to alter the junction proteins is linked to the coordination and interdependence 
manner of integrin and cell junction to form adhesive networks, by connecting through 
the actin cytoskeleton and sharing common signaling molecules [385]. For instance, 
integrin-induced signaling molecules focal adhesion kinase (FAK)  and paxillin regulate 
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the N-cadherin junctions in Hela cells [386]; -catenin links cadherin to the actin 
cytoskeleton[387]; and p120 catenin cooperates with cortactin to regulate lamellipodial 
dynamics and cell adhesion[388]. Here, we observed possible signal cross-talk between the 
cytoskeleton and cell junctions, such as the altered phosphorylation of paxillin, -, -, 
and p120- catenin, as well as cortactin. Based on the phosphoproteomics results, a 
schematic diagram is constructed to show the signal transduction upon AuNRs and PPTT 
stimulation (Figure 4.22). By targeting integrins, our treatments induced the protein 
phosphorylation change of the downstream actin cytoskeletal and junction proteins.  
 
FIGURE 4.22. Schematic diagram of the signaling pathways that are engaged with 
the cytoskeleton and cell junctions upon the AuNRs and PPTT treatment. The blue 
and red “P”s indicate the altered phosphorylation level upon AuNRs treatment and 
PPTT treatment (AuNRs+NIR), respectively. 
1.13.2.3 Super-resolution Imaging for Confirming Disturbed Cytoskeletal and Cell 
Junction Proteins 
Collective cell migration requires the cells are effectively coupled by cell 
junctions, coordinating their actin dynamics and intracellular signaling thereby forming a 
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functioning unit [367]. The actin cytoskeletons of neighboring cells are coupled by the cell 
junctions. The drag force between the cells is provided by actomyosin contractility [389], 
which is important in maintaining effective cell junction and collective migration [390]. 
Although the phosphorylation signal transduction takes place within a few minutes, the 
protein expression level may take hours to change. Therefore, to clearly observe the 
protein expression level changes, we monitored the actin filament structures after 24 
hours of AuNRs incubation with or without PPTT (Figure 4.23). Under a normal 
fluorescence microscope, it is difficult to differentiate changes of actin structure before 
and after treatments due to the insufficient resolution, as shown in Figure 4.23 A-C. 
Stochastic optical reconstruction microscopy (STORM) provides superior spatial 
resolution than conventional fluorescence microscopy to reveal the detailed actin 
cytoskeletal structures (Figure 4.24). By using STORM, we observed the morphological 
changes of the circumferential actin filaments at the cell-cell junctions.  Before AuNRs 
treatment, the well-aligned stress fibers (contractile actin bundles) are clearly visualized, 
with polymerized and stable structure (Figure 4.23 D). However, after AuNRs treatment, 
the actin bundles became thinner, showing a clear sign of disturbance (Figure 4.23 E). 
Furthermore, after NIR exposure, the circumferential actin filaments at cell junctions 
exhibited obvious changes (Figure 4.23 F): the stress fibers were greatly decreased, 
while coil, depolymerized and reorganized structures appeared, which possibly indicated 
the heating effect on harming the actin filaments polymerization at the junction sites. In 
addition, the actin structure at the cell leading edges (filopodia and lamellipodia) was also 
imaged (Figure 4.25), and the observed decrease in stress fibers in the cell leading edges 




FIGURE 4.23. STORM and epifluorescence images of actin filaments in the cell-cell 
junction upon different treatments: (A, D) Control; (B, E) AuNRs; (C, F) AuNRs + 
NIR. After NIR exposure, the actin filaments at cell junctions exhibited clearly 




FIGURE 4.24. Comparison of the resolution of STORM (A) and conventional 
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FIGURE 4.25. STORM images of actin filaments in individual HeLa cells. 
We further examined the AuNRs and PPTT effects on cell junctions in faster-
migrating HeLa cells and slower-migrating MCF-7 cells. Different cell lines could have 
highly diverse populations of cell junction proteins. The expression level of neural (N)-
cadherin in HeLa was found to be much higher than that in the MCF-7 cells[391] (not 
detectable in MCF-7 cells in our study). On the other hand, MCF-7 cells show 
significantly higher expression levels of tight junction proteins than HeLa cells (Figure 
4.26).  Therefore, we used HeLa cells as a model for studying the N-cadherin junction 








Figure 4.26. Low expression of tight junctions in HeLa cells compared with MCF-7 
cells. 
The N-cadherin junction is well known to be highly expressed in many aggressive 
tumors and promote metastasis[392]. It is reported that N-cadherin holds the cohesive cell 
clusters together, which tend to migrate persistently[393], a key role in collective migration 
[393, 394]. The expression level of N-cadherin junction is largely known as a marker for 
cancer motility and invasiveness. We observed a decreased expression level of N-
cadherin (Figure 4.27 A-E and 4.28) upon the AuNRs treatments by fluorescence 




FIGURE 4.27. (A-C) Immunofluorescence images of N-cadherin in HeLa cells 
before (A) and after AuNRs (B) and AuNRs+PPTT (C) treatments (more images in 
Figure S14). The fluorescence intensities in these images are normalized together. (D) 
The fluorescence quantification of the N-cadherin (n=20 cells, SEM).  (E) Western 
blot results also indicate a decreased expression level of N-cadherin after treatments. 
(F) Immunofluorescence images of tight junction protein ZO-2 in MCF-7 cells, 
before and after AuNRs or AuNRs+PPTT treatments. The morphology of ZO-2 
change from a normal and continuous line-like structure in the control group to a 
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discontinuous dot-like structure after treatments. The figures showed 3D scanning 
of ZO-2, where Layer 1 is close to the bottom of the cells, and Layer 3 is close to the 
top of the cells. Scale bar = 20 m. 
Tight junctions create strong intercellular links [395] at the invasion zone of tumors 
[367]. During tumor development, tight junctions are remodeled, enabling cancer cells to 
adopt a migratory behavior [396].  It has been reported that tight junction protein Zonula 
occludens ZO-1 can directly bind to integrin and regulate the mechanical properties of 
integrin-fibronectin links[397]. In addition, the tight junction proteins ZO-1, ZO-2 and ZO-
3 can bind to the cytoskeleton[398]. Here, we studied the tight junction changes by labeling 
ZO-2. We observed the morphology of ZO-2 change from a normal and continuous line-
like structure in the control group to a discontinuous dot-like structure after treatment, 
indicating possible impaired tight junctions (Figure 4.27 F). If only treated with same 
dose of NIR light (no AuNRs added), no changes in the actin filaments, N-cadherins, and 










FIGURE 4.28. Immunofluorescence images of N-cadherin in HeLa cells before and 





FIGURE 4.29. STORM images of actin filaments in the cell-cell junction for control 
(A) and laser control (no AuNRs) (B). Scale bar = 5 m. Immunofluorescence 
images of N-cadherin in HeLa cells for control (C) and laser control (no AuNRs) (D). 
Scale bar = 20 m. Immunofluorescence images of tight junction protein ZO-2 in 
MCF-7 cells, for control (E) and laser control (no AuNRs) (F). Scale bar = 20 m. 
This study differs from the previous works mainly in the following points: 1) 
Early signaling (30 min) was studied upon AuNRs and mild PPTT treatments using 
phosphoproteomics, while most of other work studied longer time scale, such as 
overnight or after several days [399]. 2) The alterations of cell junction were reported here, 
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while our previous work was focused on the cytoskeleton proteins after 24 h AuNRs 
and/or PPTT treatments [10]. 3) In addition, super-resolution imaging technique (STORM) 
revealed more detailed structural information on the effects of our treatment.  
We have previously studied the PPTT for triggering apoptosis[9, 40]. However, due 
to several reasons (such as the inhomogeneous distribution of AuNRs or the laser 
penetration ability), some locations within tumor might not generate apoptosis. In 
addition, it is possible for some cancer cells to develop thermal tolerance[223]. For those 
cells that not able to receive enough dose or resistant to the treatment to cause apoptosis, 
their ability towards metastasis could decrease upon treatment.  
Collective migration is widely observed in metastasis in vivo [400]. The 
relationship of cell mechanical properties (cell junction and adhesion, actomyosin 
contractility, geometry confinement, etc.) and cell collective migration in vivo has been 
reported previously [369, 401]. For instance, it has been reported that lipoma preferred 
partner (LPP), an actin-binding protein that could degrade N-cadherin in lung cancer, 
could inhibit collective cell migration during lung metastasis in mice model [402]. 
Regarding our treatment, future studies on metastatic mice models will be performed. 
As metastasis is a highly complex process, multiple factors, such as cytoskeleton, 
adhesion, extracellular matrix (ECM), tumor microenvironment, blood or lymphatic 
vessels, etc., will need to be considered for a comprehensive understanding of AuNRs-
PPTT in inhibiting metastasis. Zhang et al. have shown that photodynamic therapy (using 
liposome with porphyrin-18) can greatly disturb the ECM, therefore decrease the 
attachment of the cells with the ECM and affect the actomyosin contractility[403]. It will 
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be interesting to look into how AuNRs and PPTT affect ECM, tumor microenvironment, 
blood or lymphatic vessels in future studies.  
1.13.3 Methods.  
Experimental design. The experiment is based our hypothesized that integrin-
targeting AuNRs and PPTT treatment could affect the cytoskeleton and cell junctions, 
thus result in the inhibition of cancer cell collective migration. To test this hypothesis, 
phosphoproteomics was performed to understand the signal transduction among the 
integrin, cytoskeleton and cell junctions. Super-resolution imaging tools, as well as 





















FIGURE 4.30. Experimental design (A) and proposed mechanism (B) of AuNRs and 
PPTT in inhibiting cancer collective migration. Targeting integrin could affect the 
actin cytoskeleton and cell junctions to result in the inhibition of cancer cell 
collective migration. Phosphoproteomics and super-resolution fluorescence imaging, 
as well as Western blot, were the main experimental tools used in the current study. 
Materials. Dulbecco’s modified Eagle’s medium (DMEM), phosphate buffered 
saline (PBS), fetal bovine serum (FBS), antibiotic/antimycotic solution, and 0.25% 
trypsin/2.2 mM EDTA solution were purchased from VWR. Methoxypolyethylene 
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glycol-thiol (mPEG-SH, MW 5000) was purchased from Laysan Bio, Inc. Cell 
penetrating peptide RGD (RGDRGDRGDRGDPGC) was purchased from GenScript, Inc. 
Mammalian cell protease inhibitors and phosphatase inhibitors were purchased from 
Roche Applied Sciences, and sequencing grade trypsin was purchased from Promega. 
Tetrachloroauric acid trihydrate (HAuCl4.3H2O), ascorbic acid, cetyltrimethylammonium 
bromide (CTAB), AgNO3, NaBH4, 4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), NaCl, sodium deoxycholate, sodium dodecyl sulfate (SDS), paraformaldehyde, 
glutaraldehyde, formaldehyde-D2 (DCDO), sodium cyanoborohydride (NaBH3CN), 
formic acid (FA), trypsin (TPCK treated), iodoacetamide (IAA), dithiothreitol (DTT), 
trifluoroacetic acid (TFA) and triethylammonium bicarbonate buffer (TEAB), Triton X-
100, 2-(N-Morpholino)ethanesulfonic acid hemisodium salt (MES), NaCl, EGTA, 
glucose, MgCl2, NaBH4, BSA, Anti-BAX and anti-beta-actin primary antibody, (H+L) 
HRP conjugate, Alexa 647-phalloidin, 100 mM Tris pH 8.0, glucose oxidase, catalase, β-
mercaptoethanol were purchased from Sigma (St. Louis, MO). Urea were from Shanghai 
Sangon Biotech (Shanghai, China). BCA protein assay kit was from Beyotime Institute of 
Biotechnology (Shanghai, China). HPLC-grade acetonitrile (ACN) was from Merck 
(Darmstadt, Germany). Fused silica capillaries with dimensions of 75 and 200 μm i.d. 
were obtained from Yongnian Optical Fiber Factory (Hebei, China). C18 AQ beads (3 
and 5 μm, 120 Å) were purchased from Daiso (Osaka, Japan). Anti-ZO-2 (Cell Signaling 
Technology) and Anti-N-Cadherin (ABclonal) Alexa Fluor-568 conjugated anti-rabbit 
IgG (H+L) (Abcam), goat anti-rabbit IgG Antibody. All the water used in experiments 
was purified with a Milli-Q system from Millipore (Milford, MA).  
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Instrumentation. AuNRs were imaged using a JEOL 100CX-2 transmission 
electron microscope (TEM) microscope, with their average size being measured by 
ImageJ software (NIH). UV−vis spectra were obtained by an Ocean Optics HR4000CG 
UV-NIR spectrometer.  A Nikon Eclipse 80i upright microscope and a back-illuminated 
scientific complementary metal oxide semiconductor (sCOMS) camera (Dhyana 400BSI, 
Tucsen) were used to record high magnification (up to 200 ×) differential interference 
contrast (DIC) images. Phosphoproteomics analysis was performed on a hybrid dual-cell 
quadrupole linear ion trap − Orbitrap mass spectrometer LTQ Orbitrap Elite (Thermo 
Fisher) with XCalibur 3.0.63 software. An 808 nm cw laser (0.7 W/cm2) was used for 
PPTT. STORM imaging was conducted on modified Zeiss Axiovert 100 TV microscope 
equipping with a high sensitive back-illuminated sCOMS camera (Dhyana 95, Tucsen). 
Synthesis, Conjugation and Characterization of AuNRs. AuNRs with an 
average size of 25  6 nm (length  width) were synthesized using a seedless growth 
method according to our previous reports [10, 228].  Briefly, 5 ml of 1.0 mM HAuCl4 was 
added to a solution of 5 mL of 0.2 M cetyltrimethylammonium bromide (CTAB), 250 μL 
of 4.0 mM AgNO3, and 8 μL of 37% HCl. Then, 70 μL of 78.8 mM ascorbic acid was 
added, followed by immediate injection of 15 μL of 0.01M of ice-cold NaBH4. The 
solution was left undisturbed for 12 hours. To remove extra cytotoxic CTAB, the AuNRs 
were centrifuged at 21000 g for 1 hour and dispersed in DI water, followed by a second 
centrifugation at 19000 g for 40 min. The sizes and homogeneity of the AuNRs were 
measured by TEM. AuNRs were then conjugated with surface ligands PEG and RGD. 
For first-step preparation of AuNRs@PEG, mPEG-SH (1 mM in H2O) was added to the 
nanoparticles overnight to achieve about 1000 ligands per AuNR. Then, RGD (1 mM) 
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was added to achieve 10000 molar excess per AuNR. The solution was allowed to shake 
overnight at room temperature. Excess of ligands were removed by centrifugation. UV-
vis spectrometer and zetasizer were used to test the successful conjugation of the ligands.  
Cell Culture, AuNRs Treatments, and PPTT. HeLa and MCF-7 cells were 
grown in Dulbecco’s modified Eagles’ medium DMEM containing 10% (v/v) fetal 
bovine serum and 1% antibiotic solution at 37 oC in a humidified incubator under 5% 
CO2. Cells were cultured for 24 hours followed by incubation with AuNRs (5 nM) for 24 
hours. Then, a cw 808 nm laser (0.75 W/cm2) was applied to the cells for 2 minute. The 
temperature range of  the photothermal effect mediated by AuNRs is 42 ±1 oC. 
Toxicity and uptake of AuNRs to Cancer Cells. In order to examine the 
nanoparticle cytotoxicity in cells, XTT assay was performed. The uptake of AuNRs to 
HeLa and MCF-7 cells was visualized under a DIC microscope. Plasmonic AuNRs can 
be easily discerned from the cellular features as they appeared with high DIC contrast 
at/near SPR wavelength. 
Measuring Cell Migration Speed upon AuNRs Treatment. The 2D scratch 
assay was performed according to previous report [291]. For measuring cell migration rate, 
a scratch assay will be used where cells will be cultured in a 6 well plate to form a 
confluent monolayer. A p200 pipet tip will be used to scrape the cell monolayer in a 
straight line to create an empty gap. Then the cells will be allowed for migration into the 
gap and imaged to track their migration rates. The cells were imaged on an inverted 
Nikon Eclipse Ti-E microscope using bright field microscopy. A Nikon Plan Fluor 10 × 
objective (Numerical aperture: 0.30, working distance: 16.0 mm) and a 12 V/100 W 
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halogen lamp as light source was used. The output power of the light source was kept 
constant for all the imaging experiments and the exposure time of 30 ms was used to 
provide optimal contrast and brightness. Images were then recorded by a sCOMS camera 
(Dhyana 400BSI, Tucsen). 
Super-resolution imaging setup: The STORM imaging system was integrated 
into an inverted microscope (Zeiss Axiovert 100 TV, Jena, Germany). 405 nm and 660 
nm lasers (Newport Excelsior one 405 nm, 200 mW, Irvine, CA; Laser Quantum Gem 
660, 200 mW, Stockport, Cheshire, England) were collimated into a single light path 
after the beam expander (Thorlabs BE03M-A, Newton, NJ) with 3 × magnification. 
Collimation of multicolor lasers was done by using a dichroic mirror (Thorlabs, 
DMLP425T), thus allowing simultaneous illumination of the sample at multi-
wavelengths. Uniblitz mechanical shutters (Vincent Associates, LS2Z2, Rochester, NY) 
in front of each laser were used to control the illumination conditions, either pulsed or 
continuous illumination profiles. The collimated light was expanded by a telescope of a 
pair of achromatic lenses (Thorlabs, AC127–025-A & AC254–150-A) and then focused 
at the back focal plane of a high refractive index oil immersion objective (Olympus, 60X 
Oil, N.A. 1.49) using another achromatic lens (Thorlabs, AC508–300-A). The incident 
angle of illumination light is controlled by the lateral shift of the light path, through a 
three-dimensional stage (Sigma KOKI, SGSP-20-20, Tokyo, Japan), before entering the 
objective. A multi-edge beam splitter (Semrock, DC-405-388-543-635, Rochester, NY) 
was used to reflect the light into the working objective to excite the sample. The emission 
light is collected by the same objective. After the tube lens, provided with the microscope, 
a pair of relay lenses (Thorlabs, AC127–125-A & AC127–150-A) was used to focus 
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emission light onto an sCMOS chip (Tucsen, Dhyana 95) enabling a pixel size of ~110 
nm. A combination of filters (Semrock, 664 nm RazorEdge long-pass edge filter (LP02-
664RU-25), 658 nm StopLine single-notch filter (NF03-658E-25), 708/75 nm BrightLine 
single-band bandpass filter (FF01-708/75-25)) were inserted in front of the camera to 
reduce the background noise. Both epi-fluorescence images and STORM images were 
performed using the customized system.  
Briefly, cells were cultured in an 8-well glass chamber (ibidi) and washed once 
with pre-warmed PBS buffer (Invitrogen). Cells were then fixed and permeabilized with 
0.3% glutaraldehyde (Sigma) and 0.25% Triton X-100 (Sigma) in a cytoskeleton buffer 
containing 10 mM MES pH 6.1 (Sigma), 150 mM NaCl (Sigma), 5 mM EGTA (Sigma), 
5 mM glucose (Sigma), and 5 mM MgCl2 (Sigma). Freshly prepared 0.1% NaBH4 
(Sigma) in a PBS buffer was used to reduce the autofluorescence background generated 
during the cell fixation. The cells were then washed with a PBS buffer three times 
followed by applying a blocking buffer (3% BSA (Sigma) + 0.2% Triton-X100 in PBS 
buffer) for 60 min. The cells were first incubated with beta-catenin primary antibody in 
blocking buffer over 1 h, washed three times with PBS buffer, incubated in Alexa Fluor-
568 conjugated goat anti-mouse IgG (H+L) (Invitrogen) at 2 µg mL-1 in blocking buffer 
over 60 min and washed three times with PBS buffer again. To label the actin, cells were 
stained with 0.5 µM Alexa 647-phalloidin (Invitrogen) in a PBS buffer, wrapped with 
aluminum foil to protect from light and incubated at 4o C overnight. Remove the staining 
solution and briefly wash once with a PBS buffer. Immediately mount the sample for 
STORM imaging in an imaging buffer containing 100 mM Tris pH 8.0 (Invitrogen), 10 
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mM NaCl (Sigma), 0.5mg/mL glucose oxidase (Sigma), 40µg/mL catalase (Sigma), 10% 
(w/v) glucose (Sigma) and 1% (v/v) β-mercaptoethanol (Sigma) for STORM imaging. 
STORM imaging data processing. In our experiments, an imaging sequence of 
30,000–40,000 frames recorded at 60 Hz was used to reconstruct a high resolution 
STORM image. In each frame, individual molecules were identified and fit by an 
elliptical Gaussian function to determine their centroid positions, widths, intensities and 
ellipticities. Molecules that were too dim, too wide or too elliptical to yield high 
localization accuracy were eliminated in order to generate high resolution images. 
Furthermore, positions for those molecules that were appealing continuously in several 
imaging frames were determined using the weighted centroid positions in all consecutive 
frames. To generate the super-resolution images, molecular positions were assigned as 
one point and their sizes were rendered as a normalized 2D Gaussian distribution. The 
width of 2D rendered spot depends the localization accuracy calculated from the number 
of photons detected for that localization event. The reconstructed STORM images have a 
pixel size of 10 nm. 
Sample Preparation for Phosphoproteomics Experiment. Cells were cultured 
in 100 mm dishes (Corning). The cells were then harvested for MS analysis, with a final 
confluence about 80-90%. After AuNRs treatment for 30 min, cells were washed twice 
with PBS before directly adding the lysis buffer (50 mM HEPES (pH =7.4), 150 mM 
NaCl, 0.1% SDC, 10 units/ mL benzonase, protease inhibitor cocktail and phosphatase 
inhibitors) to the cells followed by scraping and collecting the cell lysate on ice. Lysates 
were vortexed and sonicated on ice, followed by centrifugation at 18000 g for 20 min at 4 
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oC to remove cell debris. The proteins in the supernatant were precipitated by adding 4  
excess volumes of ice-cold precipitation solvents (acetone: ethanol: acetic acid=50:50:0.1) 
and kept at -20 oC for overnight. The proteins were obtained after centrifugation, and 
were re-dissolved in 8 M urea and 50 mM HEPES (pH=8). The protein concentration was 
determined by Bradford assay. For mass spectrometry analysis, the disulfide bonds of 
proteins were firstly reduced by 1 mM dithiothreitol (DTT), followed by alkylation with 
5.5 mM iodoacetamide. Then, trypsin (1:50 w/w) was used for protein digestion 
overnight [337].  
Stable-isotope dimethyl labeling was performed according to previous reports [404]. 
Briefly, for light, intermediate and heavy dimethyl labeling, 4 L of CH2O (4%, v/v), 
CD2O (4%, v/v) or 
13CD2O (4%, v/v) was added into 100 g cell protein digest, 
respectively. Then 4 L of freshly prepared NaBH3CN (0.6 M), NaBH3CN (0.6 M), and 
NaBD3CN (0.6 M) was added. The mixtures were then incubated for 1 h at room 
temperature for labeling reaction. For quenching the reaction, 16 μL of ammonia (1%, 
v/v) and 8 μL formic acid (5% v/v) were successively added.  
Phosphorylation enrichment was conducted according to  previous reports by 
using Ti4+-IMAC microspheres after dimethyl labeling [336]. Briefly, the microspheres 
were suspended in the sample loading buffer containing 80% (vol/vol) ACN and 6% (v/v) 
TFA, and mixed with protein digest with a ratio of 10:1 (w/w), followed by violent 
vibration for 30 min. After removing the supernatant by centrifugation, the microspheres 
were washed with washing buffer 1 (50% (v/v) ACN, 6% (v/v) TFA containing 200 mM 
NaCl) and washing buffer 2 (30% (v/v) ACN and 0.1% (v/v) TFA) for 20 min, 
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respectively. Finally, the phosphopeptides were eluted by adding 10% (v/v) ammonia-
water and lyophilized to powder for following analysis. 
RPLC-MS/MS Analysis for Quantitative Phosphoproteomics. LTQ-Orbitrap 
Elite (Thermo Scientific) coupled with Dionex UltiMate 3000 RSLCnano system 
(Thermo Scientific) was used for all proteomic analyses. The lyophilized phosphopeptide 
samples were re-dissolved in aqueous solution with 1% FA and loaded onto a 4 cm × 200 
µm i.d. C18 trap column packed with C18 AQ beads (5 µm, 120 Å) and separated by a 
50 cm × 75 µm i.d C18 (5 µm, 120 Å) capillary column kept in 50℃ with a flow rate 300 
nL/min. Aqueous solution with 0.1% FA (solvent A) and 80% ACN with 0.1% FA 
(solvent B) were used for the reversed phase (RP) binary gradient separation, and the RP 
binary gradient was set as: from 0-3% solvent B in 3 min, from 3-30% solvent B in 135 
min, from 30-45% solvent B in 15 min, from 45%-100% solvent B in 2 min, after flush 
with 100% solvent B for 11 min the whole system was equilibrated by using solvent A 
for 13 min. The MS full scan was acquired from m/z 350 to 1650 in an LTQ-Orbitrap 
Elite with a mass resolution of 60 000 at m/z 400, and the MS/MS scan was acquired in 
ion trap. All MS and MS/MS spectra were acquired in the data dependent analysis (DDA) 
mode, in which the 20 most intense ions in the MS scan were selected for MS/MS scan 
by collision induced dissociation (CID) with the normalized collision energy at 35%. The 
dynamic exclusion function was: repeat count 1, repeat duration 30 s, and exclusion 
duration 90 s. 
Phosphoproteomics data processing. MS data were processed using MaxQuant 
(version 1.5.3.30, http://www.maxquant.org/) using Andromeda as search engine against 
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the Uniprot human protein database (69712 sequences, downloaded from 
http://www.uniprot.org/) with precursor mass tolerance of 4.5 ppm and fragment mass 
deviation of 0.5 Da. Variable modifications consisted of methionine oxidation, 
acetylation of protein N-term and phosphorylation (STY). Fixed modification contained 
cysteine carbamidomethylation. Trypsin was set as specific proteolytic enzyme. Peptides 
with a minimum of six amino acids and a maximum of two missed cleavages were 
allowed for the analysis. For peptide and protein identification, the false discovery rate 
(FDR) cutoffs were both set to 0.01. Triplets were selected as the quantification mode 
with the dimethyl Lys 0 and N-term 0 as light labels, dimethyl Lys 4 and N-term 4 as 
median labels and dimethyl Lys 8 and N-term 8 as heavy labels. All other parameters are 
the default setting in MaxQuant.  
Bioinformatics analysis. Bioinformatics analysis of phosphoproteomics study 
was performed. Three biological replications for each condition (control, AuNRs@RGD, 
AuNRs@RGD+NIR) in MCF7 and HeLa cells were conducted. Raw data from 
phosphoproteomics was normalized using supervised normalization of the microarray 
(SNM) [405]. In the SNM procedure, variance due to biological replicates was adjusted by 
setting them as variables in the model. Variance explained by different experimental 
treatments (control, AuNRs@RGD, and AuNRs@RGD+NIR) was fitted as a biological 
variable in the model. Hierarchical clustering was done with statistical software R. 
Phosphoproteomics data were log2-transformed before analysis of variance (ANOVA), 
which was used to detect differential phosphorylated proteins between two treatment 
groups (e.g., AuNRs@RGD vs. AuNRs@RGD+NIR), with treatment conditions set as 
fixed effects. P value threshold at 0.1 was set to select differential phosphorylated 
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proteins. The proteins identified as being affected were subjected to pathway analysis 
using the MetaCore pathway analysis software (“MetaCore from Thomson Reuters”). 
Western-blot Analysis. Cells were lysed in RIPA buffer (20 mM Tris pH 7.4, 
150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.1% sodium deoxycholate, 1% Triton X-
100, 0.1% SDS) supplemented with protease inhibitors (Sigma-Aldrich) and phosphatase 
inhibitors (25 mM sodium fluoride, 10 mM sodium pyrophosphate, 50 mM β-
glycerophosphate, 1 mM sodium orthovanadate). Protein concentrations were measured 
by BCA assay (Pierce), and equal amounts of protein were loaded on a SDS-PAGE gel. 
After SDS-PAGE, the resulting gels were transferred to PVDF membranes (Millipore) by 
Bio-Rad trans blot turbo (Bio-Rad). Afterwards, the membranes were treated with 
blocking buffer (5% BSA in TBS (20 mM Tris, 150 mM NaCl)). The primary antibodies 
p120 catenin (pS268), GSK3 (pY216), N-Cadherin, and BAX  were incubated with the 
membranes for different sets of experiments overnight in 4° C with shaking, followed by 
adding the secondary antibodies (Goat Anti-Rabbit IgG Antibody, (H+L) HRP conjugate, 
purchased from Millipore Sigma). Blots were washed three times for 10 m in TBS after 
primary and secondary antibodies.  
Immunofluorescence Labeling and Confocal Microscopy.  Cells were cultured 
on 8 well µ-Slide with glass bottom (Ibidi). After treatment, cells were fixed in 3% 
Paraformaldehyde/0.1% Glutaraldehyde for 7 min at room temperature, followed by 
treated with 0.1 % (m/v) NaBH4 for 7 min and the wash three times with PBS. Cells were 
then blocked with 3% (w/v) BSA and 0.5% (v/v) Triton-X100 in PBS for 30 minutes at 
room temperature with mild shaking. Primary antibody was diluted to a working 
concentration in a blocking solution, and incubated at 4 oC overnight. After three times 
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washing with PBS, secondary antibody (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 568) 
from abcam) was added for 1 h, followed by wash 3 X with PBS before mounting with 
Prolong Gold (Invitrogen). Images were taken with a Zeiss LSM 700–405 confocal 
microscopes. 
Statistical information. For the other experiments in this study if not mentioned, 
two-tailed t-tests were performed and the differences between data sets were considered 




1.13.4 Conclusion.  
In this study, we investigated the mechanism of integrin-targeted AuNRs and 
PPTT in inhibiting collective cancer cell migration. Our phosphoproteomics results 
revealed the phosphorylation changes to many cytoskeletal and cell junction proteins, 
setting the foundation for current and future studies of the underlying mechanism at the 
molecular level. Using super-resolution fluorescence microscopy and Western blotting, 
we verified the changes to selected key proteins related to the actin cytoskeleton and cell 
junctions. The morphological changes of actin filaments and extensive phosphorylation 
changes to actin-associated proteins, such as filamin, paxillin, vinculin, zyxin, PAK, 
MLCP, MyHC, et al., upon integrin-targeted AuNRs and PPTT treatment also indicated 
weakened cell adhesion and stress fiber generation. Furthermore, in HeLa cells, we found 
a significantly lower expression level of N-cadherin, as well as the phosphorylation 
changes to -, - and p120-catenin that connect N-cadherin to the actin cytoskeleton, 
while in MCF-7 cells, a discontinuation and altered morphology of the tight junction 
protein ZO-2.  All of the current experimental evidence has led to a proposed mechanism 
that the interactions between the integrin-targeted AuNRs and cells could trigger the 
phosphorylation changes of essential components associated with cytoskeleton filaments 
and cell-cell junctions, and cause their morphological or expression level changes, 
therefore inhibiting cancer collective migration. Further studies of the perturbations to 
individual related proteins will be carried out to provide a more complete understanding 
of the inhibition effect.  
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GOLD NANOPARTICLES AND PLASMONIC PHOTOTHERMAL 
EFFECT ON ANIMALS IN INHIBITING METASTASIS 
After studying the AuNPs impact in viro (on cells) in Chapter 3 and 4, the 
purpose of Chapter 5 is to check the feasibility of applying the AuNPs treatments on 
animals for inhibiting cancer metastasis. We have applied the AuNRs based photothermal 
therapy on animals (dogs and cats with spontaneous breast cancer), and observed that the 
treatments could significantly affect blood vessels inside the tumor, which might lead to 
decrease of cancer metastasis. In addition, our proteomics study on cat tumor samples 
showed a broad regulation of cytoskeleton and cell adhesion proteins, indicating an 
impeded function in cancer metastasis. 
1.14 Gold Nanorod-assisted Photothermal Therapy Decreases Bleeding During 
Breast Cancer Surgery on Dogs and Cats  
Summary. Cancer is the second leading cause of death in the world. Gold 
nanorods-assisted plasmonic photothermal therapy (AuNRs-PPTT) is a potentially more 
effective and efficient alternative to replace traditional surgery for localized tumors in 
which AuNRs absorb near-infrared (NIR) light and convert to heat in order to destruct 
cancer cells. However, for large tumors (volume ≥ 20 cm3), PPTT could be ineffective 
due to an uneven distribution of injected AuNRs, which might cause possible 
inhomogeneity of the heat distribution inside the tumor. However, surgery is frequently 
recommended for removing large tumors with a high risk of cancer recurrence and 
metastasis. Here, we applied PPTT before surgery, which showed improved treatment for 
large tumors. We divided the animals (2 cats and 6 dogs with 21 tumors total) into two 
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different groups: Group I (control group), where three cases were solely treated with 
surgery, laser, or AuNRs alone; and Group II, where animals were treated with PPTT 
(AuNRs and Laser together) before surgery. The animals were monitored for 1-2 years 
after treatments. Group I had recurrence and metastasis, and all the patients died within a 
few months. In Group II, 4 out of the 5 cases had tumor recession without any recurrence 
or metastasis. Interestingly, we observed that applying PPTT before surgery did not show 
any bleeding during tumor removal in all cases. Our histopathology results supported this 
observation with the presence of altered blood vessels after PPTT. In conclusion, our 
study showed that applying AuNRs-PPTT before tumor excision could significantly 
affect blood vessels inside the tumor, leading to a decreased amount of bleeding during 
surgery. In summary, our study suggests that the presence of AuNRs-PPTT before 
surgery potentially avoids the risk of blood loss during surgery, proving it to be beneficial 
for use prior to any surgical operation. 
1.14.1 Introduction.  
Gold nanorods (AuNRs)-based plasmonic photothermal therapy (PPTT) is a 
cancer therapy in which AuNRs are injected into the tumor before exposure to the near-
infrared (NIR) light[20, 406]. The NIR light capable of deeply penetrating the tissue is 
transiently applied to the tumor, producing localized heat that could lead to tumor 
necrosis and apoptosis[407]. PPTT modulation to induce cell apoptosis might be a more 
favorable way than necrosis, as during necrosis, the broken plasma membrane leads to 
the leaking of cytoplasmic components and inflammation, which could further induce 
cancer growth and metastasis [9, 223, 408]. The high efficiency of PPTT in getting rid of 
cancer cells by inducing apoptosis has been demonstrated in vitro and in vivo[40, 407]. We 
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have shown the efficacy of this treatment in tumor-bearing mice [40, 409] and recently 
demonstrated the treatment of mammary carcinoma in dogs and cats, where the 
malignant mammary tumors of volume ≤20 cm3 could be treated by intratumor 
inoculation of AuNRs, followed by PPTT[9]. During these studies, we observed that 
animals with induced or spontaneous tumors have noteworthy regression without 
recurrence nor metastasis. Our recent studies also shown the ability of gold nanorod-
assisted plasmonic photothermal therapy (AuNRs-PPTT) in vitro to inhibit cancer cell 
migration[10, 410]. In addition, the toxicity of this treatment has been examined in mice, 
dogs, and cats, which indicates that there is no toxicity effect on the animals for a long 
period[9, 40]. Therefore, PPTT is believed to be a favorable alternative for treating solid 
tumors with relatively small sizes and preventing metastasis[44].  
For large tumors (volume ≥20 cm3), PPTT could be hard to achieve due to an 
uneven distribution of injected AuNRs that causes inhomogeneity of the heat in the tumor. 
In these cases, surgery is usually recommended to remove primary solid tumors. 
However, the surgical resection of primary breast tumors commonly has a risk for 
metastatic recurrence[411]. It has been recognized that the tumors contain large amounts of 
blood vessels that provide nutrients to support tumor growth[412]. Blood vessels are also 
critical for metastasis as extensive and highly permeable blood vessels provide ways for 
cancer cells to exit primary tumor sites and go to the blood stream. Surgery usually 
disrupts the blood and lymphatic vessels, releasing cancer cells in the vasculature that, in 
turn, promotes the process of metastasis[413]. Therefore, the development of novel 
therapies that aid in the surgical process to prevent blood loss, tumor recurrences, and 
metastasis are of great importance.  
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In this study, we are focusing on introducing a new treatment regime featuring the 
combination of PPTT and surgery in dogs and cats with large tumors as well as 
examining the efficacy of this new regime. Interestingly, we observed that applying 
AuNRs-PPTT before surgery could significantly decrease the bleeding, which could 
potentially avoid the risk of metastasis caused by surgery.  
1.14.2 Methods.  
Synthesis and surface modification of AuNRs. AuNRs were prepared according 
to the seedless method [7]. Briefly, 5 mL of 1 mM HAuCl4 (Sigma-Aldrich, St. Louis, MO, 
USA) were mixed with 5 mL of 0.20 M cetyltrimethylammonium bromide (CTAB; 
Sigma-Aldrich), followed by adding 250 μL of 4 mM AgNO3 (Sigma-Aldrich) and 
adjusting the pH of the solution to be 1–1.15 by 37% HCl. Then, 70 μL of 78.8 mM 
ascorbic acid (Sigma-Aldrich) were added to the solution until the solution became clear. 
15 μL of 0.01 M ice-cold NaBH4 (Sigma-Aldrich) were injected into the growth solution 
immediately, and the solution was left unstirred for 6 hours. To remove the extra CTAB 
and prepare for surface modification, the AuNRs were centrifuged at 19,000 rcf for 1 h, 
and the pellet was redispersed in deionized water and centrifuged at 14,000 rcf for 15 
minutes. The AuNRs were rinsed with water, then conjugated with different surface 
ligands (PEG and RGD). For surface modification, methoxy polyethylene glycol (PEG) 
thiol (m-PEG-Th, PEG; Laysan Bio, Arab, AL, USA) was added to AuNRs and stirred 
overnight to achieve a concentration of around 1000 PEG molecules per AuNR. For 
preparation of the AuNRs@RGD, the PEGylated nanoparticles (1 nM) were treated with 
RGD (1 mM) to achieve 10,000 ligands on each AuNR. Afterwards, the solution was 
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kept for overnight to be shaken at normal temperature, and the extra ligands were 
removed by centrifugation. UV-vis spectrometer was used to confirm the conjugation.  
Characterization of AuNRs: A JEOL 100 CX transmission electron microscope 
(TEM) (JEOL Ltd., Tokyo, Japan) was used to measure the size and homogeneity of the 
samples. A Cary 500 UV–Vis Spectrometer (Agilent Technologies, Santa Clara, CA, 
USA) was used for measuring the absorbance of the AuNRs. To characterize the surface 
conjugation with PEG, a ZetaSizer 3000 HAS (Malvern Instruments, Worcestershire, UK) 
was used for measuring the surface Zeta potentials. In addition, Ellman’s reagents 
(Sigma-Aldrich), which react with free -SH groups (calorimetrically measured at 412 nm), 
were used to quantify the number of PEG molecules bound to the surface of the AuNRs.  
Animal diagnosis, and X-ray examination: All animals were handled in 
accordance with Association for Assessment and Accreditation of Laboratory Animal 
Care and Office of Laboratory Animal Welfare guidelines under the direction of the 
Institutional Animal Care and Use Committee (IACUC) at Cairo University. The pet 
animals were admitted to the Department of Surgery Clinic of the Faculty of Veterinary 
Medicine at Cairo University.  All pets’ owners claimed that their animals did not receive 
any treatment before their arrival at the university. Written informed consent was provided 
by the owners of the pets for the treatments. 8 female animals were treated in this study, 
including 2 canines and 6 felines, with a total of 21 tumors with varied grades (I to III). 
The tumor dimensions were measured using calipers. Histopathology tests were used to 
diagnose the tumors types/grades. At the tumor site, the animal’s hair was shaved, and 
subsequently, radiographic recordings were taken with an X-ray machine (Fischer, Berlin, 
Germany). The radiographic setting factors were 58 to 70 kVp, 10 mAs, and a 90 cm 
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focal spot–film distance. The radiographic exposures were conducted dorsoventrally and 
right laterally. The blood loss was quantified by measuring the blood volume and 
weighing surgical sponges used for blood collection before and after the surgery.  
General anesthesia was applied for animals during surgical mastectomy and 
postsurgical application of PPTT. Under general injectable anesthesia, each animal was 
pre-medicated with atropine sulphate (1%®, 0.05–0.1 mg/kg b.wt.; AdwiaCo. S.A.E., 
Egypt) and xylazine (Xyla-Ject 2%®, 1 mg/kg b.wt.; Adwia Co. S.A.E.), and then 
anesthesia was induced using ketamine HCl (Ketalar®, 10–15 mg/kg b.wt.; Sigma-Tec, 
Egypt) and maintained by ketamine HCl [414], [415].  
Performing PPTT in animals: Each animal was subjected to three sessions of 
PPTT treatment in 2-week intervals using an 808 nm diode laser with a power of 0.5 
W/cm2 and a spot size of around 5.6 mm2. An effective dose of AuNRs solution (7.5 nM 
AuNRs) for each 100 cm3 was used for 2 minutes, and the amount used was scaled up 
based on the volume of the tumor and then injected directly into the tumor. Five minutes 
after injection, the entirety of the tumor was irradiated with the laser. The AuNRs 
concentration was decreased by 50% for each subsequent treatment. The temperature 
increase of a tumor during the laser irradiation was measured by placing a 33-gauge 
hypodermic thermocouple (OMEGA Engineering, Inc., Stamford, CT, USA) needle 
directly inside the tumor (42°C–44°C).  
Histopathology evaluation of the animal tumors: The detailed pathologic 
evaluation of tumors was conducted by members of the pathology department of the 
Faculty of Veterinary Medicine at Cairo University. Histopathological analysis was 
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performed on 5 µm sections from tumor tissue that were fixed in 10% buffered formalin. 
The samples were stained with hematoxylin and eosin to assess pathology.  
1.14.3 Results and Discussion.  
1.14.3.1 Preparation and Characterization of AuNRs 
AuNRs with an average size of 27±5 × 6 ±1 nm (length × width) were used in this 
study, as they showed enhanced efficacy of PPTT [416].  AuNRs were synthesized using 
our reported method [7], and these AuNRs are shown in the TEM image (Figure 5.1 A). 
AuNRs have a surface plasmon resonance wavelength of around 800 nm (Figure 5.1 B). 
After synthesis, AuNRs were successfully coated with mPEG-SH and RGD as evidenced 
by the red-shift of the surface plasmon peak (Figure 5.1 B). The average number of 
ligands on each particle is quantified to be 1,000 mPEG-SH and 10,000 RGD on each 
particle. 

























FIGURE 5.1. Characterization of Gold nanorods (Length 27±5, width 6±1 nm). (A) 
TEM image with 100 nm scale bar. (B) UV-Vis absorbance spectra showing the 
surface plasmon resonance peaks of AuNRs after synthesis (AuNRs@CTAB), then 
 
 227 
after conjugation with PEG (AuNRs@PEG), then after conjugation with RGD 
(AuNRs@PEG@RGD). 
1.14.3.2 PPTT Decreases Bleeding During Surgery 
In our earlier studies, we optimized the PPTT conditions for treating dogs and cats, 
including the AuNRs dosage and the laser conditions (7.5 nM of AuNRs irradiated by 
NIR laser with 0.5 W/cm2 intensity for 2 minutes). The optimized conditions were 
conducted multiple times (2 weeks apart) until complete regression via apoptosis was 
shown and that proved to be better than necrosis[9]. Herein, we devised a new treatment 
regime for treating animals with tumor volumes ≥20 cm3 by combining surgery with 
PPTT.  
Before treatment, all animal tumors showed variant growth, as shown in Tables 5. 
1& 5.2. In control group (I), 3 cases with 10 tumors were solely treated by mastectomy, 
laser, or AuNRs treatment alone. As shown in Figure 5.2 A and B, photographic images 
of case 1 (GI-1) reveal 3 large tumors located at cranioabdominal and inguinal lymph 
nodes. All the three tumors connect to form one chain. Figure 5.2 C is a picture of tumor 
during surgery with obvious bleeding (over 100 gram). Figure 5.2 D is a histopathology 




FIGURE 5.2. (A) Photographic image of control case 1 (GI-1) treated with surgery. 
(B) A magnified figure of A for the tumor area. C) Photo of case during surgery 
with high amount of bleeding. (D) Photo-micrograph of tumor tissue showing ductal 
carcinoma in situ grade II (H&E X100). 
In Group (II), 5 cases with 11 tumors were treated with 3 sessions of PPTT (in 2 
week intervals) and followed by surgery after the last PPTT session.  Figure 5.3 A and B 
show case 1 (GI-1) that treated animals with surgery only, and Figure 5.3 C and D show 
one case with surgery after PPTT. Interestingly, we observed that when applying PPTT 
before surgery, almost no bleeding during the surgery was observed for any of the treated 
tumors in Group II when compared to Group I (Figure 5.3A and C and Videos S1 
(surgery only), S2, (surgery after PPTT)).  
The decrease of the bleeding might be explained by the histopathology of the 
tumor bed vasculature (Figure 5.3 B and D). With surgery only, the blood vessels are 
normal and intact (Figure 5.3 B) while after PPTT, tumor bed vasculature shows 
swelling and sloughing of endothelial lining and destruction of blood vessel wall (H&E 











































FIGURE 5.3. Left side (A, B) shows case 1 in GI (surgery only). Right side (C, D) 
shows one case in GII (treated with PPTT for three sessions (2-weeks intervals) 
before the surgery). (A and C) Photographic images taken from the videos (Movies 
S1 and S2), indicating decrease of bleeding after PPTT (C), compared with control 
(A). (B and D) Photo-micrograph of tumor bed vasculature showing (B) normal 
intact blood vessels with surgery only and (D) swelling and sloughing of endothelial 
lining and destruction of blood vessel wall (arrow) after PPTT (H&E X400). 
In addition, the regime of PPTT before surgery has shown to be effective for 
achieving complete tumor recession shown in Table 5.2. For example, in one case from 
group 2, a 9-year-old mixed breed cat suffered from mammary neoplasms as shown in 
Figure 5.4 A.  The site of 2 tumors located at her left axillary lymph node (black arrow) 
and left cranial thoracic (blue arrow) is demonstrated in Figure 5.4 B. After PPTT, 
followed by surgical excision of the tumors (Figure 5.4 C), tumor recession was 
achieved. The histopathology showed that after PPTT, well-developed granulation tissues 
were observed, indicating tumor recovery (Figure 5.4 D).  After 12 months, this case 
showed complete recovery from the surgery (Figure 5.4 E) without evidence of 











FIGURE 5.4. (A) A 9-year-old mixed breed cat suffered from mammary neoplasm. 
(B) the sites of tumors at left axillary lymph node (black arrow) and left cranial 
thoracic (blue arrow) (C) after surgical excision and (D) Subcutaneous layer 
showing well developed granulation tissue at the site of suture (arrow) (H&E x100). 
(E) the case after 12 months showed complete recovery from the surgery without 
any evidence of recurrence. (F) X-ray shows no metastasis in the chest. 
Three cases among the five in Group II died a few months after PPTT and surgery 
treatment due to lung failure, but evidence of tumor reoccurrence or metastasis was not 
observed. Earlie, we have shown in our study on mice that there is no toxicity after 15 
month of AuNRs injection, whose bio-distribution mainly locates at liver and spleen [40], 
proving that the lung failure might not related to PPTT. However, we do find that other 
types of nanoparticles, such as TiO2, iron, Cr
3+ -doped zinc gallate, silver, could 
accumulate in the lung and might cause toxicity [417], while AuNPs has better 
biocompatibility than these nanoparticles. To the best of our knowledge, there is no much 
systematic studies for discussing the blood circulating (not airborne) AuNRs and their 
relation with the lung failure so far.  
In this report, we observed that PPTT has affected the tumor blood vessels that, in 
turn, decrease the blood flow inside tumor. The reason is still not fully understood. 
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Previous reports have shown that AuNPs could affect blood vessels and tumor 
angiogenesis [81, 418]. In addition, the temperature increase will cause the destruction of 
blood vessels. For instance, it has been reported that photothermal ablation of breast 
cancer in mice models using doxorubicin-loaded DNA-wrapped AuNRs could disturb the 
blood vessels [95].   Furthermore, It is reported that AuNPs with sizes around 30 nm could 
induce tumor endothelial leakiness [419]. The abnormal vascular nature of the tumor 
tissues allows them to uptake more AuNRs [420], which might explain why the AuNRs-
PPTT is more effective on the tumor blood vessels. The importance of applying the 
AuNRs-PPTT before surgery could be very important in decreasing blood loss, especially 
for the patients who have injury-healing problems, including chronic diseases such as 
diabetes, and need tumor surgery. 
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Species& age Site of tumors Size of tumors cm Grade  Therapy  
GI/1 
1a 
Dog Mixed Boxer 14 
years 
1-R caudoabdominal ulcerated (8x5) 
II Only Mastectomy  1b 2-R cranioabdominal (18x4) 
1c 
3-R inguinal LN. All the three connected to 
form one chain 
 
GI/2 2 Dog Griffon 7 years 1-R Cranioinquinal (4.1x 2.9) II Laser only followed by mastectomy 
GI/3 
3a 




 1+2+3 tumors form chain Laser only 
followed by mastectomy 
3b abdominal 
3c 2-R inguinal LN  (3 x2.1). 
3d 3-L cranioabdominal  (5x2) 
3e 4-R inguinal  (1x2) 
I 
4+5+6 tumors treated by AuNRs only 
followed by mastectomy 
3f 5-L inguinal  (1x1) 
 6-L caudothoracic  (1x1) 
GII/1 
4a 
Cat 9 years 
L caudothoracic (4.5x4) 
III 
Three sessions of PPTT followed by 
surgery 4b R caudothoracic (4 x4) 
GII/2 5 Dog Griffon 10 years R Caudoquinal (3.1 x 3.6) III 




Dog Griffon 11 years 
1-L inguinal (5 x5) 
II 
Three session of PPTT followed by 
surgery  
6b 2-L inguinal   (2 x 1.5) PPTT only 
6c 3 small tumor (1.5 x1) PPTT only 
GII/4 7a Dog Griffon 5 years 1-R caudo  thoracic     (3x2.5) II 
Three sessions of PPTT followed by 
surgery   
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Table 5.1. continued 
 
Notes: The control group, GI, included 3 cases (2 dogs and 1 cat with 10 tumors) treated with either surgery only, laser only, or 
AuNRs only. All cases developed metastasis and died after treatment. Group II (GII) included 5 cases (4 dogs and 1 cat with 11 
tumors) treated with PPTT (AuNRs and laser together) for 3 sessions followed by surgery. All were cured from tumor; 1 case had 
metastasis then died. Abbreviations: L, left; LN, lymph node; R, right; PPTT, plasmonic photothermal therapy.  
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Table 5.2. Survival, bleeding loss and met astasis for both GI and GII  
No. # 




GI-1 >100 + 1 month  +(CS, LN) 3 DOD  
GI-2 66.5 -   +(CS, LN) 1 DOC 
GI-3 47.5 - +(LN) 1 DOC 
GII-1 <1 - - 24 ADF 
GII-2 <1 - - 48 ADF 
GII-3 <1 - - 3 
DOC 
(pneumonia) 
GII-4 <1 - +(LN,CS) 1 DOD 
GII-5 <1 - - 6 DOC(pneumonia) 
Notes: Group I (GI) were solely treated with surgery, laser, or AuNrs alone. Group II 
(GII) were treated with PPTT (AuNrs and laser together) before surgery. Estimate blood 
loss significant test P-value and statistical significance: The two-tailed P-value = 0.0010. 
By conventional criteria; this difference is considered to be very statistically significant. 
Abbreviations: ADF, alive disease free; Cs, clinical stage; DM, distant metastases; DOC, 
dead of other cause; DOD, dead of disease; EBL, estimated blood loss; LN, lymph node; 
LR, local recurrence.  
Estimate blood loss significant test  
P value and statistical significance: The two-tailed P value equals 0.0010. By 
conventional criteria; this difference is considered to be very statistically significant.  
 
1.14.4 Conclusion.  
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Surgery is often used for tumor removal; however, it might trigger metastasis [421]. 
PPTT could be a better alter- native to replace traditional chemotherapy and radio- 
therapy for localized tumors, especially for tumors with a volume ≤20 cm3 [9]. Therefore, 
for effective treatment of large tumors (volume ≥20 cm3), we applied PPTT before 
surgical resection to naturally occurring tumors in the mammary glands of dogs and cats. 
Five cases were treated with this regime and showed complete remission without any 
recurrence after therapy. Three cases died in the few months following treatment, but in 
two cases from three, there was no evidence of any tumors upon examination (died due to 
other reasons, such as pneumonia). Histopathology results showed a decrease in cancer 
grades compared before (variant grades from 1 to 4) and after 2 weeks of treatment via 
PPTT and surgery (grade 0). X-ray diffraction revealed an absence of metastasis 1–2 
years after treatment. In conclusion, our study demonstrates the feasibility of applying 
PPTT before surgery to large tumors in dogs and cats. Applying AuNRs-PPTT before 
surgery in treating large tumors could significantly affect blood vessels inside the tumor 
and potentially avoid the risk of bleeding during surgery. PPTT could be incorporated 
before the surgery to decrease the bleeding and potentially avoid the risk of bleeding 
during surgery that could lead to excessive blood loss and metastasis.  
1.15 A Mechanistic Analysis of Gold Nanorod-assisted Photothermal Therapy on a 
Cat with Contentious Mammary Gland Tumor. 
Summary. To understand the mechanism of PPTT in spontaneous breast cancer 
in animals, we conducted comprehensive proteomics analysis on cat tumor before and 
after the treatment, which showed a broad regulation of signaling pathways related to 1) 
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blood circulation system; 2) the cytoskeleton and cell mobility, and 3) immmune 
response, indicating an impeded function in cancer metastasis. 
1.15.1 Methods.  
Synthesis Proteomics sample preparation: The tumor sample collected from a 
cat case (before treatment (A1 and A2), 1st section of PPTT (B1 and B2), and 2 nd 
section of PPTT (C1 and C2)) was immediately frozen in liquid N2 and stored at -80 
oC 
for proteomics study. The samples were homogenized in lysis buffer (8 M urea, 50 mM 
HEPES, pH 8, 100 mM sodium chloride, 25 mM sodium fluoride, 10 mM sodium 
pyrophosphate, 50 mM β-glycerophosphate, 1 mM sodium orthovanadate, EDTA free 
protease inhibitor cocktail (Roche) 1 pill per 10 ml of lysis buffer) followed by ultrasonic 
tissue ablation on ice (10 s x 4 cycles). The cell debris was discarded by centrifugation 
17000 x g for 16 min at at 4 oC the supernatant that contains proteins was kept. The 
disulfide bonds of the proteins were reduced by adding DTT to the supernatant to reach a 
final concentration of 10 mM (incubate in 65 oC for 25 min), and subsequently alkylated 
by adding IAA to a final concentration of 14 mM (in dark for 30 min at room 
temperature). The proteins were precipitated in 4 folds’ sample volume of CH3OH, 1-fold 
sample volumn of CHCl3 and 3 folds’ sample volume of H2O. After precipitation, the 
samples were dried in N2 gas flow and weighted, followed by digestion by trypsin (1: 50) 
in buffer (1.6 M Urea, 50 mM HEPEs, 5 % ACN, pH 8, 6) in 37 oC overnight. The 
lyophilized peptides were labeled with 6-plex TMT reagents (Thermo) following the 
manufacturer’s protocol. Briefly, peptides were dissolved in 100 μL triethylammonium 
bicarbonate buffer (100 mM, pH 8.5). Each channel of the TMT reagents was dissolved 
in 41 μL of anhydrous ACN and mixed with the peptides. The reaction was kept for 1 h at 
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room temperature, and was then quenched by adding 8 μL of 5% hydroxylamine. We 
used 100 ug for each group for TMT labeling (A1, A2, B1, B2, C1, C2), corresponding to 
ion (126,127,128,129,130,131). Peptides from all six tubes with different TMT labels 
were mixed, desalted again using a tC18 SepPak cartridge, and lyophilized overnight. 
Then the TMT-labeled peptides were fractionated by high-pH reversed-phase high 
performance liquid chromatography (HPLC) into 15 fractions using a 4.6×250 mm 5μm 
particle reversed phase column (Waters) with a 40-min gradient of 5-55% ACN in 10 
mM ammonium formate (pH=10). The collected fractions were further purified by the 
Stage Tip method. 
LC-MS/MS Analysis: Each dried peptide sample was suspended in a solvent of 
5% ACN and 4% formic acid (FA), and 2 µl was loaded onto a microcapillary column 
packed with C18 beads (Magic C18AQ, 5 μm, 200 Å, 75 μm x 16 cm) by a Dionex WPS-
3000TPLRS autosampler (UltiMate 3000 Thermostatted Pulled Loop Rapid Separation 
Wellplate Sampler). Peptides were separated by reversed-phase HPLC using an UltiMate 
3000 binary pump with three 112-minute gradients of 4-17%, 8-24%, or 10-28% ACN 
(0.125% FA) for different fractions of the TMT labeled samples. The full MS and MS2 
were detected in a hybrid dual-cell quadrupole linear ion trap – Orbitrap mass 
spectrometer (LTQ Orbitrap Elite, Thermo Scientific, with Xcalibur 3.0.63 software) 
using a data-dependent Top15 method[422]. Each cycle has one full MS scan (resolution: 
60,000) in the Orbitrap at the AGC target of 106, followed by up to 15 MS/MS for the 
most intense ions. The selected ions were excluded from further analysis for 90 s. Ions 
with a single or unassigned charge were not sequenced. MS/MS scan was activated by 
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HCD at 40.0% normalized collision energy with 1.2 m/z isolation width. Fragments were 
detected in the Orbitrap cell with high resolution and high mass accuracy. 
Database search, data filter and protein quantification: Raw data files 
recorded from the mass spectrometer were first converted into the mzXML format. All 
MS/MS spectra were searched using the SEQUEST algorithm (version 28) [423] and 
matched against a database encompassing sequences of all proteins downloaded from the 
Uniprot cat (Felis catus) database. Each protein sequence was listed in both forward and 
reversed orientations to estimate false discovery rate (FDR) of peptide and protein 
identifications. Database search was performed by using the following parameters: 10 
ppm precursor mass tolerance; 0.025 Da product ion mass tolerance; fully digested with 
trypsin; up to three missed cleavages; variable modifications: oxidation of methionine 
(+15.9949); fixed modifications: carbamidomethylation of cysteine (+57.0214) and TMT 
modification of lysine and N-termini (+229.1630). 
The target-decoy method was employed to evaluate and control FDRs of peptide 
and protein identifications [424]. Linear discriminant analysis (LDA) was used to 
distinguish correct and incorrect peptide identifications using numerous parameters such 
as XCorr, ΔCn, and precursor mass error[425]. After scoring, peptides fewer than seven 
amino acids in length were discarded and peptide spectral match was filtered to a less 
than 1% FDR based on the number of decoy sequences in the final data set. The TMT 
reporter ion intensities in the MS/MS spectra were used to quantify peptides. The isotopic 
information provided by Thermo was utilized to calibrate the ion intensities. 
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For proteomics analysis: Proteomics data was log2 transformed before analysis 
of variance (ANOVA) which was used to detect differential levels of proteins between 
control (CTRL) and treatment groups (S1, S2) using the Bioconductor LIMMA package 
[426]. We set false discovery rate (FDR) threshold at 0.05 to select differential proteins. 
Hierarchical clustering was performed with statistical software R [340]. Proteins identified 
as being affected were subjected to pathway analysis using the MetaCore from Thomson 
Reuters. 
1.15.2 Results and discussions.  
Six breast tumor samples from a cat case was collected and subjected to mass 
spectrometry analysis: they are Ctrl_B1 and Ctrl_B2 (tumor samples before treatment, 
two biological replications from different locations of the tumor); S1_B1 and S1_B2 
(tumor samples after first PPTT treatment, two biological replications from different 
locations of the tumor); and S2_B1 and S2_B1 (tumor samples after second PPTT 
treatment, two biological replications from different locations of the tumor).  The samples 
are labeled isotopically by TMT reagents and the relative protein concentrations are 
determined quantitatively. Figure 5.5 A shows the protein expression heat map of 1598 
proteins quantifies in the samples. The clustering analysis in Figure 5.5 B shows that the 
control and experimental groups were separately clustered with good reproducibility. A 
first level clustering of Ctrl_B1 with Ctrl_B2, S1_B1 with S1_B2, and S2_B1 with 
S2_B1 was first observed. The PPTT treated samples are then clustered in the next level, 





FIGURE 5.5. (A) The heatmap of the quantified proteins in different samples. (B) 
The clustering analysis of the samples. Ctrl_B1 and Ctrl_B2 (tumor samples before 
treatment, two biological replications from different locations of the tumor); S1_B1 
and S1_B2 (tumor samples after first PPTT treatment, two biological replications 
from different locations of the tumor); and S2_B1 and S2_B1 (tumor samples after 
second PPTT treatment, two biological replications from different locations of the 
tumor).   
For proteomics analysis, we set [-1, 1] as a threshold for fold change (log 2) 
detection (Figure 5.6 A). Following the first PPTT treatment, 444 proteins were 
decreased and 127 proteins were increased. In addition, second PPTT treatment led to 
down-regulation of 324 and up-regulation of 122 proteins (Figure 5.6 B). Overlap in 



































FIGURE 5.6. (A) Distribution of log2 (fold changes) in proteins perturbed by the 
first and second PPTT treatments compared with control group. (C) Bar graph 
showing numbers of proteins unregulated, upregulated, and downregulated in each 
group. (D) Venn diagram showing the common and unique differentially expressed 
proteins that identified in the first and second PPTT treatments. 
To understand the biological process of PPTT in cat, we performed pathway 
analysis (Figure 5.7), which revealed significant perturbations to the signaling pathways 
related to 1) blood circulation system; 2) the cytoskeleton and cell mobility, and 3) 




FIGURE 5.7. Pathway analysis showing the top most significant pathways. Orange 




FIGURE 5.8. A simple scheme showing the three main pathways of PPTT in cat. 
1.15.3 Conclusion.  
We conducted a comprehensive proteomics analysis on a cat case before and after 
first and second the PPTT treatments, which showed a broad regulation of signaling 
pathways related to 1) blood circulation system; 2) the cytoskeleton and cell mobility, 
and 3) immmune response, indicating the mechanism of PPTT in real animal patients for 
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